var title_f14_20_14656="Brain MRI of PML in HIV infection";
var content_f14_20_14656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain MRI of progressive multifocal leukoencephalopathy (PML) in a patient with HIV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sharply demarcated hyperintense lesion without mass effect is seen in this T2-weighted image in the subcortical right frontal white matter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14656=[""].join("\n");
var outline_f14_20_14656=null;
var title_f14_20_14657="Measles, mumps, rubella, and varicella virus vaccine: Patient drug information";
var content_f14_20_14657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Measles, mumps, rubella, and varicella virus vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29334?source=see_link\">",
"     see \"Measles, mumps, rubella, and varicella virus vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/23/14710?source=see_link\">",
"     see \"Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1433435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ProQuad&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10407944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Priorix-Tetra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10256346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2770181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_mmrv.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11230 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-1401E7A8BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14657=[""].join("\n");
var outline_f14_20_14657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1433435\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10407944\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10256346\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29334?source=related_link\">",
"      Measles, mumps, rubella, and varicella virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/23/14710?source=related_link\">",
"      Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14658="Saber sheath CXR";
var content_f14_20_14658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saber sheath trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 586px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJKATADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDg9K0GW7iTzNe1pXIBLC8fA/Wrh8J3Kt/yH9XZex+2Sf41d0+V/LjwoC7RwPpWvbxM2DyTQBgf8IrKoGda1lvpfSf40+Pwwv8Ay01jXR/2+yf4110NoWxgVaWxPegDkI/ClrIMDXtcVve+k/xqyPAvf+2dbZfVb+T/ABrqW01T1OPpU1tZXMLZhYlfSgDlYfBNuf8AWavr2f8Ar/k/xqSXwBGwzBrWun2N/J/jXeQCN+JkCP69qsi12dBwaAPLZPBW0lTq+uqw9b6T/GsS+8OXFtMyf2xrXH/T7J/jXubWaTphgM9jisHXtAaePci4kTofUUAePjRbg5/4nGtf+Bsn+NWbfw/MJovtOr62InOP+P2T/Guyj0x95RkK4PPHWm3cQe4EYxhOOKAEsPAdnMis+s69z6ahJ/jWn/wrSx4I1jxBz/1EJP8AGtfQmBgQd14NdNajdHzyQaAOB/4VrY/9BnxB/wCDCT/GnRfDTT2YBtY8Qf8Agwk/xr0MwjOKFiIII9aAOJX4W6Ucf8TjxD/4MZP8aif4X6aJdo1jxDjP/QQk/wAa9IjXIxjH1pQilz3NAHn/APwqnS9gb+2PEPT/AKCMn+NRH4VadvG3WPEBQ/8AURkz/OvTQnyEnv0qsY2FwcHCgAg0AedzfCvTVA26x4h986jJ/jTh8KtM2AnWPEOf+wjJ/jXpW3IwRkVG6fLwOAKAPM5fhfpq9NY8Q/8Agwk/xqMfDDTz/wAxjxB/4MJP8a9JeLpkULHjtgUAecj4X6d31jxD/wCDCT/GquofDawt490eseIM++oSf416ayE5I4qneLvUAjNAHjV94MWDaU1jXME97+T/ABptl4NFxJt/tnXMd/8ATpP8a9QvNKWcccUWmmiNhHEv1NAHF2fw2hlYlta10xj0v5P8aSX4dwK21dX1/P8A1/yf416esKQxhF6D071C5UZ4496APLLnwJbQIWbWdez/ANf8n+NUk8GxMuf7Z13/AMD5P8a9E1N4ZG25K474yKz4bZGcYkRwfQ4NAHDv4RiXP/E5136fb5P8agbwmNhYazrf/gdJ/jXo93ouxVYSDae/pWe9ku8jcFUcUAcNF4UMjHbrGt4HX/TpP8atL4NUgD+2dc3H/p+k/wAa7OK3jK7IsDpj3qLVSYB5ScM3U0AcJf8AhpISFi1jXGIPJ+3yf41zniqwudM0G7vLbWdY82IAruvZCPvAevvXoTxsxxXK/ESMReEdSUdCi8/8DWgDsdGsrcxQjK52jr9K6O30xMcIMeqmsPTYSIYv9wfyrpNN8xDlTx3BoAkOmfLmM5/nTVgdWIK+3NdBbYkXcgwR1FSTWay/NjafWgDBjgBbDYArRggj5CcD3qdNPIbBYVr2thCkfmSk4/nQBkC0Enysm7PpUlraCL5JpRs7DqRV64k2qxjGAOgHFZXmMzUAaywwRngFvrUhRZlK7QPTiobJt4Abr2NaCptPSgDldW0dkLyj/WEfKe1cW1k8LkSLg/zr2EoHUq4DKexrKvtCjnXgZX9RQBw2lExzAEcNXZ6fGfK5FQw+H44mBGSRzzW1HBtjAxjFAFVoxT4074qwYcgmogjI3qKAHqg9OtSBFGTjk0+EBhyOakMYY47UAVbtiIwc4FVFmJIw1Xr0AnYAMCs0QfMD0oA1LdgyZxSSnPQYpbPaqbfWpXXJ6YoAqlcjmmFeKuCId6aYsmgCkU4qrJCx5AyK1xBx2potST0wBQBjLAzNtAqcQrAmByx6mtXyVUEY/Gqk0JJzQBnsMnpWffNtXavU1qzAIpA61lzqSeaAMG7hyrGsWZCjgjIPbFdPOmQc1mXFsDmgCtZ6pLERHPmSE8FT/SrksQK+ZGdyNyDWZNCQfatPSfmjeBj1+ZaAIoUKyBugHJPtVHUyZrlpDyCeK0bxSmQDjjBqgBlgrdM4oApugUBsda4z4mr/AMUhqJHI2L/6Gtd5dRbcqemeK4r4lrjwZqoxxsX/ANDWgDvNI2+XCCMjYP5V0cMKbf3fTFc1pIJjiA4+Rf5V0tipAFAGjp2Y5VPbvWlJ88hH8PaqcKZzxzVqMHIBoAdDEAQW7c4pstyxfCn6mrUybLbPcjFZ6RkE5oAdIxKH34qmkfz9O9XuMYpscWXFAE9ugAFX1PZqhjjx9atiMkigByrVhE9aSJAgJPQVHLdqTtix9aAJZFjHLYBqncXCR9i30qreXDKMckmqEl2EUkigDSS8hkyOhpww3K1ib0lPBweuR1q3ZlkcDfkUAbESZPpUxQ4OOtNiyMdqsr0BoAybxJUyduSfWs+OSQy4ZSK3r9SyZrCKnzQM45oA17eIAA57VKybsmnWcZ8n61Y2hFJPQUAUZnW3UlzWJe6rKZNsIq5fOpZnkYn0Wub1C6aQFIhtX2oA1o9TZCPOYZ9AavRasCBnkVwp+aXkndmrVq0gIO47SM4oA9AgnhuRlCM+lNuEKjgZrkrXUdsirHyB1YVt22qDO2Rtw9aAEnizk96zbhCc1vsqypuQ1RuIc545oA5yZOaqyRcGti4h546VRlXGaAMeaADOOajsGMV3Gf8Aa5rRmUHpVQRkTKR0zQBLqKhmJA+uKzGHPP51p3jbUHNZoly+CM89aAFlj3qPYVw/xPXb4J1UDk7Fyf8Aga12WpzkQhY/lB9K8/8AiQ7HwfqYLHGxf/Q1oA9O0iHEMJ9VX+VdFaR4IxzWXp0WLaHPXYv8hWxasEZRjjNAGjEMDFTxj5gaFQBQR0p8ZHmDufSgCe+OIIR61SbrxV2+U5h9ADVcJk5NACJFntzU0EXzcDpSr0qe2U9+9AE8MWTmrGAD6AUsa7R/OszV70QKVU80ALqF4MFVOFFZS3QV+Dz61n3N0WyS2KzZr6OJsZzmgDoL2cMu786y5pRJwrfSoE1EOjBgB3HvWfPLMLjdtzEec0AbsCEqCeoq9ZNtlw3TPFYlrdnCjOB71uWWJCCBkjrQBuwOQqg1bDYHXiqcAyAD2q2V+SgBsw3ofSsfYPtGOpzWy4/dnHaqVvGHuQfU0AakKhIkHtVPUJ/k2rVy4bYuBWVd5K5zQBh6lLxsHU1mPFuUtjtzVi7dmZioz71TUjDbnwKAI3jihjMsrD6Vm3N0ZA3l/KmOAKS9b7TKAucDgCo47UxLvI5Pb0oAuae7BiT071ZuZyCGQ7cDiq9vLkEEA+tR3pwieXkkdRQBr6PrbQyqknK9xXVgx3UIkiOQRXmqgE89c9a6PQNRkglCOcqePrQBs3EGc8c1kXUQB4rp5QJE3pyDyKyryAMCw69xQBzsqhTxUCr86/7wrRnTrmqiKfNGfUUAVNUGBxWTGp3E1tampIxjms1RsVmboOaAMrU5AZAv90VxHxFYHwfqeP7i/wDoa11V45eRmPrXHfEJseEtSX/YX/0NaAPZLS5VbeEA7m2L/Kr8MrNjsPauf0sZihJ/urx+FbsBxjFAHQxndaoc9RT7b/WD0zUNm26yU+5FWrZcsDQBbveTH9KhBx9KmuuSg7AVEF4yaAHIu7itK3j6EjpVa1jyc1pDEcZY9AKAK97OtvF7muH1W8zIzOeewra1O7LSkn1wBXI3yFZGL5J657UAVbm5eXdnp1rPJJcZYsPSpJixYlDxVGacJ85IyDzjtQBqQyFsFeMCrUdwGX0Nc/DqUUhK7vmHPFXbG5hMw3AnI5oA6OIRtGu4DkYNaWmq0b/ISR6VzlncpIgG7GD3ra0i/UTmB+PQ0AdfbsGQHODVvOAADWfCgKcHPerqA7AG60AMvHIhYjvTNMQlwc5xRqAHlouOvNWdLQBcmgB10ayL9ikTkdMVs3KjvWHrUix2chb8aAOeuHRASW59Ky5pshyRwKpajqXOVGQM9azmvS6MmThufegDRE4LAD5fQjtVqEGQEjls81x8t5IkhGSAOta2ja4lvcRrcEFGGCRQBtSw46HkDrWHdTywTNyxHb1roJZopnHluoBHHNYmqgDMowQG60AVYbppRhyVf26Vr6bcusqh65xTvTODvJzitvR5QWVbngr92gD0jTpwyKpOeBU9xEMZArm7C6ZJAe1dTAyzW4Yc4oA529i2scCqIj+f8a3L+PGTis0qN44oAydQHNZN6dtm/qcCt29TLH2rG1RcRge9AHM3QxniuL+IX/Iq6j/uL/6GtdzeLtU1wnxCyfCuof7q/wDoYoA9Z007YYc/3V/lWzDyRjnNYlkf9Hi/3F/lW5p3P4UAb1jxa8/3qvWw+cVUshi3I/2s1etfvjigCWYbpMelAHGBQeZD9anhTcw4oAtWqYHT2qHWJvLjEeccZJrRhjwAOwrk/E12fMkVepNAGRez5lY561mXM6pH+/6dhUVzd/ZgTwzdlPasO9ujLuZ+D60AF7dguwj+VG4K1iyqzSdwGxUrs27BXPcYokGUzztPUDtQBVggVJSGyQP1q2GMcnyggEAjmo0ZQvPTsT2qxCMzfO4O44GaANO3K5jYeoyK0IWK3XyZznI9axJw8Mip/d9KvQufOTbwpAIJoA9Q0uTfAgzzgc1p8ngcmuQ8OTnjLE9K7GM/dPTNAFW+z5iDnpWlYptjAqCZd0wArQhXaAPagCrdKdjVwnjq4ZLAxoSPnwTXos8QeM9q888eaddLYFox5iKd3A6UAcCJlYYkGcjiq9zvQqeMdj7VA5U5BfHqKo3N0m7EjH5eAKALGoyAMzgB+PyrNhV5WRiSPep5JkJRhkqRjpU9xFix2x4Dtxk0AZ1xc3EUzsJjgHsegpYdTuZVUFsKD0Pc+tRTRbFCnkgZJqMDbCxbueKAOjtbzzlzGAOORVu3mxJk1yEU7oy7G2qO9dDpsyzKAThh39aAO00e5BQLIfoa7DRbgmQRt0bivNtOkEcgDEk5xXcaJIZChB5XHNAG9fQZVhWIY/mNdNKfNjyO9YlxHsZjQBjXS/OfSsXUUzt49TW/crk1maggJAHpQByl/DuB471wPxFi2eE9R/3F/wDQ1r0q9jIBrgviamPB+pk/3F/9DWgD0OxOIIv9wfyrodLU7ckda5/TF3ww/wC6v8q6qwi2oo9BQBr2QyjLVyAYaqlmMH8K0I1xzQAKPnNX7RO9VVX5vrWlbpgCgB93IILZm7npXAa/IGYyZ+b09TXXa/OFQIT0GTXB6k5JZmGT2HpQBztyG3M8gySOlZsimQkjp6VrzckySnavc1jXt0o+WIYQ9D3NAFaWSOL7rfP6VnyakdxATAxzUskSyoWQlW6kHvVEwOZOVOB3NAEsMwm3Kx69Ks27lX8vGQpGGqBbUKdwOSOTir9qVEiyAYOOR2NAFqOTzpGCsSwOPqK1FYxRxO3zbQeKzbUJE5ZFwSep962rvTzJbpNFI6J0wDxSba2Kgk3aTsdP4UvIGuBEzRiXAJUnGM13KKG2n0ryCy8OT6rewyGeSGJEA3Bsufp6V6XoenDTLVgtxcy8Y/evurOEpttNaHZiKGHhCMqdS8mtVb9TYhTdKT6U+7v7WxTfdzxxL23Hk/QVE9qt7aNE0ssYbq0TbW/OuJ1P4f3C6nb31lfzXBikDmKd/m4P8LdjRUlOPwq5OEo0KrtWqcvy/XoeiscrWfqEAnhZD3qvFo8iXCSf2nqDqrBtjS5Bweh46VpOgIrRNvc5pxjH4Xc8A8c6X/Zes/J8qSrvUdhzyK5aQozZ6hjgE16z8XIYh9jcj5gGzXl8KwzyGMJnacjB9KZA+KPzXii2gEDJyeKi1WZWRljJ+TnAq/MiKrlMhyDg+grl7x5NxkB7AcUAOW7lY8D92vXNPlnjlIVTtY8AHtVC4mYQ7Qcf3sd6gTl12c5xmgDYWB0cBu/GK1I0fBEI6YqlYy+XIftPKr09RWmpV1DwNvTPBFAG7ozB9gmID4/Oux0ufymULxiuDtfmO48Ed66jRrjzMRufnA496APRrJxLbBh0qnepnnHBpfDsm+GSNuwzVm7j+Q+1AHO3CVm3afvGrauFwxFZ1xHk5NAHP3cWSRivP/inEB4K1Q+iL/6Gtem3UeCa89+LCbfA2r/7i/8Aoa0AdtokZaODj+Bf5V1lrGcD0rhvC1+WEG45G0fyr0O02vErDoRQBZtV5q8BwKggXvVk9qAJIxk9K04lxiqNsvNaQ+VC3oKAOW8TyESSY+9muKvDjLu2AvOD3rsNdImZiTgjnNef6w8kjsqg4HSgDJ1O7eUnd90fdA7VltEW6njtV54nJwep7mn/AGbJXcMd89qAMwAoxByR0HrU8arIjAcvTL26t43IILOKzrq/ZWBiyoPGRQBqxW4WUB3VQ3Y96ltoIhIVMigY71naY6Tyv9qY7duQSasSIYlJY7lPQj0oA1Ra74SoIwADuzWrGWNmYDIpXAI571j2ZZUCuGYsOntWwlnJNFmDDFRwRx+FAHXeFrfZGHyTgDHoa61lIQDHWsbwnayQ2ECSj59v5V0E2F2igCa2GExU2DioLduMVZoAjxUdwyxrlqkckCsbWpZBCwHXBNAHmnxP1CO4uXjLcRj171wGjBPtbPuUpW9rVldX01wZQQWJ5PasIWcltZFlQ7icHFAE15cDdIAwJxgAe9Y08SfIvOc9KfJFJ5DzHg9cHvVO0knEhOCwxk5oAZeWweTA6LwT60+1sPIRpXIB/hBrTs0RRvuBtwcj3q29t58TSEgKeR9KAOelZgu0ZJPJrS0qRrcgg9TyCeDUf2fZlhg/SmRwMX+QkDPSgDrLYpcLut+w5HvW1p4KOpbgg8Edq5rRJHgkD4GDwRXY2kKz4eMgjv7UAdp4df5d56kYNbFwuVb1xXOaPKIZFU/cPFdLKPl59KAMC8UbzWfKK1r5evtWZKuBQBmXi1558W0x4B1kn/nmv/oxa9HuFzXn3xfX/i3+s/8AXNf/AEYtAFHw1qQV4FOduBk/hXsvh+QT2WQQQMV896DcZEQxxgD9K9u+HcrPp84bOFZQPyoA7CIY+tTgbmFQCrMHJzQBdt1qa5bZaSH2wKbAOOO9GoAfZWz060AcRrsxOYw2D1Y1zUy7gQOe3NbGpFpJmOM85rB1KdLdSEOZOo9qAKF6FtkO8jOOB1Nc3fXM0khyWQdhnirs8k00hYde5PeoWjhIzM29vQdKAKMY+1MQ/wB/1HQ05bddxXggjGG4q6PKGxYowoHcVIkSSPllOM43UAJHoyMU8qUl8cr6V1+j6SrosZiRjtwSx6Vl28MUKNJFcA98j+RrrLCbTDAJAzLMDzg8CgDH1HTViuo2QbQODitXQoHd0UD5Qealup7WRlCTK5Y4/Guj0GwECrkAjqaANy2hEcYIGDiopzum45Aq27YUVWCZegCSH7wxVsciqyrtOasRGgBriszUI8r9a1HqncAORQBwOqafv3r3J61ymqWT22xVYZYYNekavCFORgZ5rBns7e6gBY/OhLH6UAcLc2ltLMsLKBgAMR+tZn9j7fNe2OEHXPpXRXln5V+ZwuLdBukz2NT27wz+b5afKVxzQBwVzl1Vix3EYOemKpyTOgCQSHGfmqfUImjkeNZDtU5Iqptj3AICCM8nuaALdrLC7BS21u57VtR2sKgSclj0IHBrmYkcMFLAsewrc027aBcSHcAfu+lAGlHbEqpxxW9pMrWuD1jPBFULQpcRKwJHGStWIsqwxkAHpQB19q4kCvGcg12SnzLaNu5UV57okhMgjxhG7elegWpxGE9BQBn3y8msmUZUity+XPNYkowxFAFCcZFee/GIAfD7Wf8Armv/AKMWvQpzjNee/GL/AJJ9rP8A1zX/ANGLQBw/h8E+QB/EBXvXgWHydJA7s2f0rw/wnDueAnooH8q968LLjT4x7mgDoCeKt2/AFVccCrluvSgDRgHAFQaw+2JUz1qzEMHNZ2tN+8yT8qrQBx2u4tYyYwCzfpXBXhyzGTgn867XUrgSysWGSe3tXM39oZGZwOOpz2FAHOPI+WXkpxSFUC7jjB9aLqcJIyoM+prLlkleQlj8hP4UAaS3KgMY1zjuf6UNdHK+ZkjqE6VmiTEX7vI56U8Mdm8gnA4oAvrMySsgPyP0FdBo6uoUHLA8HPQisDSrOe9YIqnPGGx09a9AtrHZ5ahMBBj6UARaJAr3ce4EqrZ5r0HTEO7IYkelcno1i0V1J5nJJBA9q7nTISEBNAFlunNNQYOamkXPSosc0AP7VJHTAKkQZoASTGTmqcgGc5q5MmRVGTcnSgDnfE5YRZ5281y4jlMEjs/lo2AD/Suq8SXAgtS+wtnjAGa5iW4N24SVdioMgfzoAzZrr7LbkYDLkth+dxrkpdZMFzcOiFIzz9K62+jjeJgBkdB65rmdW0lDbOu0+bJz9AKAOfhZbkPI7DJzgDqTTk06bccjGec9qzDG8EhRiUYfeHetK1vplARmyh4we9ABLZIijacEDlhUkNsRA8jNuAwOe9aaRW/zCQlSBwp7/SmzIGYZygGAAKAIbG5aNsCTJ7Y7V0enzpdrtJw45571z4tWLg42j19av2UMkLocfNnINAHaaJCY5wzZIHrXc2TiVNy9Rwa4zSrlJoApPzgcj1rp9Cc+ayHoRxQBbuedwrEuhhjW7OPmPvWHfAjNAGVPyTXnnxi/5J/rP/XNP/Ri16JKOa89+MZ/4t9rI/6Zr/6MWgDD8IQYSDI64Ne1eG+LVR715P4Si+SA9sD+Ves6DwAKAOhQZxV2IYqpFzir8C5IoAuxjoKxfFb+XCFXq3U1vxDpmua8Qyho5SeXGdooA4i8kjiUtI21scDua5vU72VzycJ2A6Vc1R2mlLOfmzWLIzHIweO5oApyMspw3Udx/WqjRsMgFXU9quLBlueMkH2qZbdUyeueaAK1pp4cO7rhVGSM9a6PSNOtTbHykLB+Crc/rWQyhULbtmRjmuj0JUCRGHc6Y+btg+lAHRaNpKQ7lVFjZRn1NXrqEuoVThuhIqlNcTIEMbAAj8asWcrGNvMyAO/vQBoaRalAzN1yBn2rprNhs21zdtcqp2qTk44robJCEUn0zQBbfABquSMnmp5BkCoFXLUASD61NFTABipIxQA5hxUEkQPJq0elVrhtq8UAcP46keK3PlMAyjd+VYvhSS3m3zXLq3mjGCehrf8AFkX2qIlPvjr715LcX8+i6gVKERknGOKAO6urJYboqmfK/hwKxtbiitIfNmcsD90Crfh/xAl9DtkO5TyCwqz4mtIrnTTNCFYrxtzQBw+oW1vqNsso2JIeFI6kVkx2jWhyv7w9M+lPljmRiCNoXI57VFbvIBhifxoAUTOX/fHf2HtVyyuWA/eHzF9PSohaMyb1BUA/nTY1LyCOBNpPU+tAHRWnlTKNmN3XB61cCEDgZyea5+JpLfoQGHp1ra0++E3yT4ye4oA0LWRoJkaPgg8iu70N1kkikQ5UiuGMOzBHf0rrfCJwHTt1H1oA6WdQQT3FYV+v3q339PWsW9Xg5FAGHIvOa87+Mox4A1n/AK5r/wCjFr0iYc8V518Zv+Sfaz/1zX/0YtADvCUX7iA/7I/lXpWijaFzXB+E4ttrD/uj+Veg6am1Qe9AG9b8kVqWoG4VlWla9vwB6mgCwXCLk1werXLSXMg7ZNdjqD7cJntzXE6gh+0Njjk5oA5u/svMZiD8x5IrIktHkysgx79K6yeRIgTIevp1Nc/qMouZNqllGOCP60AYrqYcoRkZ7cmq6M4GDlOepq2YwuZA3zL+ophuozkSJvY9SO1AEIieUkA5Hr712PgW3DTGCRs7u/pXJKiyldjMOefSui0QXENygt5Aq5oA7rVNMUIixDOOtY8ymyQl5Pm7D1rejd54trSfvWHy81zN2jG8aNsvIg5z2oAn8PMZNUDStln7V6Jb/NwOABXnvheBWvZ5VbLbto9q9Dg+RcY60APdcU0LyMU9sZpB7UALinpxSYp6igB38NVLz/VEirRPFVrjBXBoA5y4tmbcDzmuO8TeH0vEYBQ8o5FehzQg5I+lZtxaZVs/h60AeNWWnXdrJKpRliU8AelbD3EqWq+WSYsZYda7+TShKpkAGT2rjtZs5bG5bYhMTjken0oA5e8tvPlEp6Hk4p9tDHFv3xF1xwexNWZW2o0f3gehHY1mXV5PEqRk70XuOxoA0reZXX5o1PqgqnfwKr7oAV96pQ3EscwMmTz19a1YZI7zKq21s9DQBlBZVfLFcD+L1qWKZQVXgfjViSEHKhSWzwKRLIE8KTmgDX0i+CsI5TmMnGfSu80ofZlVl6k5rz+ztGhwzrkdc11uh3wnHksfmX7v0oA7qTBjV16EZrI1AYJrUtm32MfqOKo6gvy59qAMCYcE15v8aTj4f6wP+maf+jFr0qbgV5l8am/4oLVx/sL/AOjFoA6XwvFi1gyP4B/Ku0tBwK5fQFAtYcf3F/lXU2uNooA2LLoMVtwKM5PQVk6cmXQfjWnM/l2srZxxigDMvZTJOzZ+WuX8QzbZP3XO4fe9K0b263/KnAH61k6kBNDgH5qAOWuXdi3mZI9c8mqYDc4PHc1pS25kxwS2cUsOnkLhSAB1B70AY8xzhAMHpxSxaQxbfkhDzW+tnBGhfGW96QTRg4c/JnhVoAxvs/k4VVyTXRaJphWyae53I2eMntU2mxQ3Fwm1B757UuoyvdO9vAGWIHkg9RQBo6Zdxwzpvf5fug56VjeIrlFvZoEmILfMzj19Kvw2kFrGQW3Ockn0ArKvIo7q8jlCn5yNw96AOo8K2nkWsOU5PzE+tdrHyoOK5/SiFjRT0Arobc5XAxQA7bk04LjilxzRQAmOacKAKcBQA1ulVZSMHNWpB8tUZepoAYRnj1qpdREMPm7VYfmmsNyg5oAropWMcZJqhc6etyWVvyNagPGMdBUTu2d3c0AeZ+JtCNnJJc25Y45K9q5ZLiBi24HJ9u9ez6nZLeWjBuleaa3oK2kxmjQsCcsB/OgDn5wfLG1CzHnHpWdK7pJhSd24cCtd4jFIX3sUJyBjr7U/7PbTsHDAHPKn1oArWeoSbxG43hu/cV0lqEeLghmPAFY0lotu+ExuI4pUlMbjPGPSgDedMLhe/Wm2Za3uUkXhg3A9agtdQDDEoyvZh1rRjhJkV8BgeQaAPQdJkElqrDo3P0pL5eBVHw5LmDyiec5FaV6v7sH0oA5i8wpb2ryv4ynPgbV/9xf/AENa9V1RcM2K8p+Mh/4oTVv9xf8A0NaAO90ND9mg/wBxf5V01ouSorA0D/j0gz/cX+VdFZD5s+lAHRacmF3d+lV/EVz5dsI1PfmrlpiKM7uiLk1ymsXD3LvtPAOaAM15svjJOamjTPEowM1DBGd3TJ9aumI4xuB9KAK81oMs0ODuqvcLHDHhwNwHI9as3F4tspROTj8qyRI1w+0KSOhNAFa4dpn/AHanngClgscYMxALc4PetsrDHbBkwCB196yplYxPPI+0L0Hc0AXoJVto3ihKLwSW79Kq2Um/e24nb29frVG3V2LO33Dx71p6XEGjeLBB3ZzQBLcktblk6niq1oFiZAQXKkcVbuSLeJlCkg1FEh8tpc7Rkcn0oA63TgcgjBB6VvW5KgZ61iaIAQO+Oa3ok6UATgZpcU0UoNADgKUCminZoAjmPy1TfqatzjIFVnXINAEDDIxUYBBI7Gp2U44qInaaAGBDuJxjioptrHB4PSrsZBRietVZI1LMR1NAFIzquVJ+WszVrdHgdwARjH4VcvIWBLCqysWjOeg6igDzfULdoJGK/cPas8xZKy9FONwrrfENouxirfJnJrnpbu3EKxiImQYOfWgBinz02Pglejd6p3BU4D5Rh696uiFWYyxZwRnjtVV0MvytgkcfWgBLfIfcDz2FdLpTskeSTtPY1zIhaDkck9a0YZ5Sg3HAXsO9AHd2ExhMbpzjBNdRPiSLI5DDIrzrR7/5/LlPB9e1d9p8okswM/MnFAHPavxXkvxk/wCRE1b/AHF/9DWvYNaj5cdga8f+M/HgbVf9xf8A0NaAPQNBkP2OEk/wL/IV1WlrvkjB/wB41xfh6XdawDvtX+QrvNEj3F29ABQBe1GcQWHJ5kOK5qE+a7AjrWh4nmxLHGDgKoP4muYk1ACVhF370AX3nWL5cDd/Kqd3dSAH5uT39KqGV3cNkFj29Kik2klmOce/FAEhdiF2nkjLE9qlhdtj/NtjPc9/pVMzJIo6qqHO71p63CzOAWCpjgetAFxnwEVfuYzzQlsJEDSH5e4psU+9PLijLnrlRVpLW8mG3yiqn9KAGeSjOqRfKMAk1bjuYIInLOAWHTvUc1jfNbp5KbG6Z74qWy8NzSxkzZJLZGT2oAxL/UpFk2x9ORzVT7RJKjxbicqMAdCa7ceE7dwhm7dhV218O2EMgbyNzDoT0oAf4Shl+yxu+QWUV1SrgVUsUWMAKoAAxgVbJxQAuOaSkyc0negBR1p2DTV608dKAI5R0qtI2CRVqQ1Sn+/QAhIwMdKY43dgaafumkUkdaAHxKQrfSqzH5uateYMj071BMmSSDQBVnPUHpisyQqrcnrWjNnDVj3HGd3SgCjqlp5ikqeMVyV3pgWUOB8rdcV15uwincQVHBFZ+qbQAEIxjOR70Acy2yGQD5kRSKdIkD/vEfr09qo61OIY3RnyHbj1FZtjcTArnlCetAG9bxHdtK5XFSXUCxgFOV/kadZzxeUqt8sjE/Q1PKAysM9aAM6OcxtuJPFd74R1H7TFsY/NjB9684u1KuQCcCtbwxfm01CFiflJ+b6UAd/rK5QNjrwa8W+NDY8Faqp/uL/6Gte3agBLbsAc5G4GvDfjYf8Aij9T91X/ANDWgDsvD7fuoPTYv8q9M0nCWqjueTXmXhoeZ9lQdwo/SvR7aYRW879lXj60Acx4vvibhkVuo+Y/0rmVuFQ/OTt7VY1yUyu3PIPPNYsvnTMI7VDLJnAwOlAF6bVVhwx49h3qp/aElxcAxRu47KozW9ovgua6ZXv34/uCvQtH8P2dhGFigQY6nFAHCaToWr6igaWNYFYYG/rj6V01j4OtLcq0+6Z155PGfpXYrGiEFAPpSADdkigCjbadGqYSJVHsKs/ZVwowBVsdKXBPFAFf7NGCOOlSFABwKlI5pGHSgCErkke1MCc4qxjmkIwaAFhXaBU3ao1Oak7UAGaM000UAPBp4qEdacM0AEo4qlOPmz2q5Ifl5qpKy9CwoArFqYzgd6s7YzxkGkMKE9KAKbSjk96hE7Ed81peRGucgVGTAhxQBmSSkj7pyaoXAEowyMCOOlb7ywhckDFV2uICeMcUAcHqCPvKqCOeeKp3IfyzubAI4NehD7LKD+7BxTTY2cy7WhQj3FAHgmpGe3vJUlOVPK+9JazZXaeB6ivYtX8IaZfxFGhCt2ZeorjtT8AMq5srgow/hYcGgDAWcqgHUj9auQ6iGTkDd0FUL7SNV0tlWaAyQjq6DNYl7dssqtC4IQYI6Y5oA6uf94qsncfMDVWAtBNljkfwmqGm3/mkK5x7/wBKvyAY8tjg56+hoA9M0u7+0aFbSHlgu0/hXj3x0+XwvqYHQqpH/fa16X4ZcrpLRN1XnFeY/HRs+FLw+qqP/HxQB23hAjzLQ+iD89tdhezmPSZivqK+dvD3h6CV4g9/qQzErfJdMOSBXVxeD7KSPEmoaxtPUfbm5oA6tLSS8uWC/cbqwrrPD2jxWigBPf615hD4G0tQAL7WFHtetVlfBViOmo62P+396APcbZNpBxxVwuScYrwM+D7QdNT1we3296IfCFs8uP7U1vaOv+nvQB78Mk9DUgU55BrxPT/ANnOWL6pr20cDGoPWlF8ONNJGdU8Qf+DF6APXwp9DTwD6V5MfhppX/QT8Q/8AgyegfDXS+f8AiaeIf/Bk9AHrQU+hoKn0NeS/8K10z/oKeIf/AAZPR/wrbS/+gp4h/wDBk9AHrDA+lMYHPQ15V/wrXS/+gp4h/wDBk9IfhrpX/QT8Qf8AgyegD1eMHHQ1JhsfdP5V5EPhnpS526n4g/8ABlJT/wDhXOmgf8hXxD/4MnoA9ZO70P5UgBz0P5V5N/wrrTef+Jr4h/8ABk9J/wAK503/AKCviH/wZPQB66AfQ/lSliB0NeQ/8K503/oKeIf/AAZPR/wrfTMc6p4h/wDBk9AHrUhJQ8dqw7h2MzgZ61wP/CttLP8AzFPEH/gyeo/+FY6Qeuo6+T/2EXoA9FtxIRyDVuMso6GvMh8MtJx/yEtf/wDBk9L/AMKz0n/oJeIP/Bk9AHpdxITHtIOTWY5duNp4rhm+GWk/9BLXz/3Enph+GWk9tR1//wAGL0AduRIMjacVBIpALYxXGH4Z6T/0Ede/8GL0w/DPSO+oa9/4MXoA6szurEqp21Gl9KrnaDXJt8MdH/5/9c/8GD1C3wy0hR/x/a5/4MHoA9Itblpog235sVJKhdSSOfSvLJfh3p0Y/d6hrg9v7QeszUfBVvHCzQanre73vnNAHqtxFkEMK43xF4VtL4PJDH5cuOq8ZrybWtFuLeMtDqurfjdsa4bVpdXgV/J1bUOORmdjQB6zJoF1YSPIQzW46Zq1BP8AaimfvL196+cJfEGsMCr6neEdMGU1XXVtRU5W+uQfUSGgD7R8OktZSNzkLg15d8c3I8MXK+oH/oYrwePxFrMSkR6peqD1xK1VbzVb+8j23d5cTKeoeQkUAe6+FrotJHhBgQr/ACFdpbzbl9K4Dwud00fGD5S9+vArubaM7Rjp6UAa0UhAHNTrPjvVWPOMYFStkCgCfzg4IJwav2NsxCqoO5utZdpA9zdRxhW25yT7V3Gl2nlIGcAnt7UAS21uIIljByR1PvWlbRbRk96IYRkMcZ7CrIAA/nQAwjmlA9qfgU4AUARFck0m2psGk20ARbeOlIVqYjimkc0ARbaaV9qmwaa1AEOOaXbT8UAigBu2kxUmKTjNADMY5pCMVKMUnXPFADFBFPwMUoAFOI9KAI8CmlalxzS7cn2oArlMUwpmrRXNMZRQBUZeKgdcVddahkTNAGdKvFZl9DlTx9a2pU6jtVOaPg0Aec63Zq5dSODxXmOt2ISV0I46V7brlrg7hXAeJNPDoZFX5h1oA8B8Q2RstQdcfK/INZVej+MtL+06cZkX95F834elec0AJTlid0kKjIjXc3sMgfzIpO9SwT+VFdKV3edGEB/u/OrZ/wDHcfjQB6toGoQw3MJe5Ufuhz6cCu907xFp8SgPMZGPoK8FsJmEkZyen9K6O1u5MDEhFAHt8fia0wPLgY47miXxMhB2xBceteSRXsmADI2c+tPa5mmZYlkfc7BQc9c0Ae9+FJ5LiITsB8/P4dq7O3Ej454rgvCgkito41YkIAK9I0lWaMM3SgCzBGQNzde1TxqGzT8g5yOKegwooAbsxil2inmgigCPFGKkxSYoAjxSFakpjCgBuBTSKfg59qa+cHAoAifC4NVWl5NSzhunrVdgKAJ4pNw681IfUVTibnao6ipVfA5JxQBYWjgc96iWYHjHSnbsHJ70AScDk9aA3PtUe+nKMYY9KAFyc81MvI61CTnJpvmEY59qAJ2X0pGUH2qNZgnLmpEkV1yvIoAhkTgioWQ4xVzAPANRsvagDPmQjOKpyqT9a13XI5qlLH3xQBg38PmRkEVxmqWv30YcHmvQrmMEMDXN6vbbgWA5FAHkmpWQWSSJlypB/KvFNdsG0/VJ4CPlDEr9K+j9btVJ3qK8k+JGmgtHdIvONrGgDzsUh6UrDk9qRulAGzZN+8j9hW3buBjI4rn7RuV7YFa0EuMDNAG5HIMDOc1q+Hk+0a1AOqod+K52ObpXafDe0a71Pfg8kD8B1oA9x8KWp8qPK9RmvQrWMR26oOtYXh21ENurkdsCt9BxQA9RlgO1TY7URJhfc0poATvTqYWx0o3ZFADj7UjD8qUHFKcUAMxSHgU4sBUbsBkmgBhJ54xSfU1G8nWo/MyRzwaACYBs81SmcAHHWp5TgetZdzIpfr74oAnabYA3YHmnO/3hnjrxWXNPiJsdOODUxuA8EMmeWG0+1AEj3BjkUk8Zq9FcCRTkgGsOQb0IX5nzn6VHHK0LM7sevSgDpoiGPPQd6nd+x9OKyrO8Vtq5AXH61oNkrnoB3oAdu44pD1zVYygDg06Bt456evpQA2XLNz0qe0O1W9M0j7WACHOP50DCrigC8vzLnHNO2gjmqiS8AA1aHA69aAIJVAb0qvKnUjpV1+pBqsV5oAyriPGfWse+hDA810V1Hjkc1k3SAg8UAcBqsG0upHWvPPGViJrGZMds/QivWdcgALHFcJ4ggDRtx1zQB87ahCYZ24wD0qo3Suu8U6dsnkAGOSRXJN06UAW7d8MPYCtGKU8VmwHGOO1Xoxgc9O9AF+KYkhVySeK95+EulCBIQ3+ulxwf4VryrwNoxurhLmVNwBGxT396+lvA2jfY7L7QyZlkGEHp6mgDtLYKqrGpGF61oQjcfasyGLaoGeT1NatouyMtz7ZoAs4xxUTECkdyoqtLOqfe60ASE5NSx8rk1mS38UQy7Af1qGLUvP3AHA7UAbJdc4B5pA+elZi3AVgTmrMM4cjFAFljkVTuZPmABxVosDkCs26DGUnIC0AIZMA1WkkPGDwakbkD5uahljAPLHFACvKdhBOc1RmUSNjvjtU6bWO3v1qJJFEuXXB6AUAUTGVLb/uA8j3p9sUZJIyeQc1JcSgjhOF6mktMPdN5IGGTvQAkXyRuqg59axLvVbaR7lVfJicxhU5LsAOB+fWrGqNqD2zW1jhZJFy8rfwL7e9Y+l+H10yQTG6aRz95QODW0IQ5XKb16IpJW1NfRriUbnuFVM8qoOSo9/euttbnz7fdnkjmuKlYpjYQC/OK6HRLlDbMMjcrYP0rJu7JLyR537zgdzTDOXIVDiMdT6068kUhQOi87f8AGqTNuPPbgAUgNMSjYNoOaQSbzkc+vtVWAM4yxx6CrKLglVHFACPK0eAOpq5Yzlyysdy1Umh3Ln0PNOtB5fCnpk0AarA9uRUezIJHakt5Ny4NWI2Q5AHWgClMuVKH6ism4QA5/Ctq5BB/qKy7kAk4oA5/VoA8Lccj+Veea5CVDg/jXqN1HvUgjrXCeI7cgs2PY0AeNeKrXd8wXkZzXmmpQ+VM3oa9n8Q2+5ZFx9K8t8RwbEZsdCKAMuDr+FaNqvmyxx9MkA1m2x5/Ct7w/B9o1OGNQScgYoA9v+Fmi/a5oflxGmOcV75aRxxII0GFUYGK4zwDpkelaPAgGJnGW9RXawDJHFAFmGPJAq8RhQB2qO3UKvFLNJj5R170AV7qXaDisO9nIJY9PT1q7qdx5YK9sc1ztxcbgQ3TsaAG3cgaQkkuccD0qDTr7yNQSJsCOTKj2NQznBBBIB4zWRfy7Crq2GQ9RQB3yykHG4Fe/tUiS7HAHIBz9awLLUo5Y4mUFg6hs1opPvXGMMDkE9xQBsJcbwrVFMclvSqiyHyUCjGKnVmZDkA0AKPu4xmq1y5Gcjgc0SO+dqnFZ1zckK0Wck8GgCXJWRX6K3IqO/3ebvQ5VearJIJJ441cA9AmeferU6s5G09OKAKjSmTIGBuGTU2nsY2YnuMH2qJYiXAAyCcH3qeOJlkUE/KCDmgCnLPtkY54Y4HtWcJitw2Mk/pWneQFZmUISQ3BqobOc+YEj+UnGTxigCvLGk8odWIVV9KveHm3tIq9XQhR7jpVmPT2iEKmTkjJCd/ar1kotJYgkSph857470ASW8bxws05BYjdg9qbEyjkfNjke9T3BxL5eMrk7iagjT5hvO1VJ/GgCaHcxLPkLnpj+VSGXIIHAHb/ABqCe7QBlQ5PTNZ/nO7cHPOMCgDXW43r5ajk96nJWFNp5I5NVbbCjeME9acwMi7ifwoAninVQGY7RngVpRujxK0fKn0rm7pwJAByAKuaPKyRSA9jkCgDXlB2kdQOazZoQxz0rRWXf8wPbkVHNFkAqODQBiXcZj4I6jIrl9ftt6uRyrj9a7a+QGBc9QcVzWpxZQp2PNAHj+uwY3gjkda8s8ZwGO1kOBjI/nXtviazI3NjPrXknj2EppExPZl/mKAOEt8Y6fLivTfhJpaPcyapdj5EYLCpH3j6155pNuJ5V3nCDqa9Y8G3qGe1gQKsSsAqigD6A0ZyUiyctgV1luAMVyGgPFJNGFYYFdjAg+Xkc0AXVYKm4/hVaaQLukcjAGSaSeTLBR0FcV4t14pI1pbMDtHzkHv6UAWtYv1kBYOOe3tWDLesOIwOPXrXPzX0pkILnJ5BNSG7Uoru2HzgsvpQBalnm7OTxyM8VCJd8TeZyG4+lR7o5WxHL17Yq1Fau8UuzYV46mgCbw9d7c27gFozke4NdZE2QnHuK42GBoriKYFFdCFIHda7ewjR2BViRQBZmyChH3SM81ZtXG/aR2oMUZYcdDnmlRwJMgCgChq9zDZASXUgQHoO59hXCeIodSvLyGWx+0QpO+1Vc4PTrjsMfzr0u5giuQsrxqzRZ2sw6f5xVJf3kmMc9vpWtOoqbuldjTsYmi6SmlxqPmlnkGJJGOSfpWy1uyzEcccCnOAsiDsKfId0mcYOM1nKTk7sTdyKO2KydcY5qzHChlG/5gTg+1IM+W2MnmnA/L8xwaQDrmFfNUoBiqkoLE7/AMhWjPjaCMYYVFGkancxy3U56CgCK2tiGRm/hBNRpGHDvIQcngelSSXJkk2pwmCOO9EKhMKegOaAJLhAS0oHBAxnvxWFeyOHLF/biuglR51TaMjbgZ6VTmsYgMy/O46AdKAMm3PnSMIhlU6t2q7bRIgORnjmkFu8bjaMD0HSrscUcYJZgQOpoASNC8QWNcAck04FEwCeB3qK5uVU7YicY6nvVPzGdW5yaAJr3CkYA579qW1Yx25Lty/9KgjRrhgrHCDkn+lJcSFpgqr8uOwoA2bS6UEA81sErJbrtGGx0rkbadEnUyPgA/dP9a6qL5hG6kEMMjFAGffDMLDHPFYd4mUOR9K39TQtCccEGsaYHBBFAHD+I7ZWQ4HB7V4r8SoTHol3nsy/+hCvftet/wB2SBXivxcgCeHbuQD+JOf+BigDzSxjCQxoBjIBOK7/AMA2Lz6jFsXLDn6CuFsACsfrgV7Z8LLEx2DXBXLzNtXjsKAPTvCdnhGkHQcA+prr4wVXOeQM1Q0uIRQoqjGBV2dtsEjA4OKAOa8R6rJp2mXE8ch83BC89DXi1zqF7hpDcOzE/Nnqc16H46lL2aR84ZucV5xM0cQcHkHjFAEKajfkEmbcAOmM06LUbw+YfNBGOARUIGZCg+TdwvoagZigKyEKRQBorqt6p3LMCucHHUVqw63fJEpRl3DPHc1zcckQlU5289fWtKFonfcp5HFAHVWmtmXyy8bB88getej+ENQgvLFt4KSISD9K8htUnUpIgUp39a7DwjPO11LFwA0Zbg96APRiw835HBGfWmyFUOMgc8GsiBGZNw3Bxww9amR2AUONy9M96ANaGcbtrkbc4NV5MC8VR91mxu7CoGj+QsjArnj1q2gE1uUxgp1NAEOrhbaZG3ZHtUUlyOcjpSahIIynmDOUwaps5dFbacH+I9zQBdjmkZSqDr19qQMxdyG4H61WhaVyew9qtWoV5sA7mxyKALsW14Gx/CKhO6RtiA5Pc9KuQldjJgCiNUwZGyVAwBQBDZ2hVNz8nPAFWXREJBIJxzTFuz5mwJ26VV88bWzjceOtAFtXPkqA2O2BTRGrFQTwKrQyHKr1Oegqw+TAwBxjuOpoAgkYNJtXPv7VTubpD8sfzbTgfWiSTyy2GzkYIqGBIw2cEkjGBQBBktKCR0HOalRBIxwSAP4jVuGzUvucEf7IqeS3RQBuyeuBQBTMchl2INiL3/rTpCsD5jySF5Y9qsBti8gAnjk1FO6yJIQVVVXn3oA5e6nfzCACzE8mux0C7P8AZsKyHocVxtwzNIQMKOord05jFDHG7bT1bP8AKgDrrhTJBkjkdaoSwhoXAAyOa1bNPO04MhyelVXj2buc5UjNAHG6rGSjA14z8aotnhG9YAAbo/8A0Na9w1CPdnPWvIvjnDt8Cag+P4ov/Ri0AeKaSm94VHOQBX0X8PYDFaW8ZHyIMj8a+f8AwxF5l1bDHUgCvpnwpD5Nqg288UAdrbHI47cE1JfMBaEHvxUdqVAA796h1GQEHJ+UDNAHnvjwqqxh24UHBrzjUDhsL6Z5rrPHmsI4cRkFVOK84vdTaWR8cIemaAJ5J2VgzScg9u1Rz3HntiMnPUsR/KssSK7Y+Y45x2zV60kdJQNgKnrnoKAJoIWkl4BIHJzW5ZWkisMKctxx0x9aqWTPEQETOeQcZrdtftBiUg5XPCgdKANO0hdYdjEY6gV0PhplF3jiMYwCep9qzLCKSQAjqecAVvaVZuJw7ooIGRmgDo4JHUsEkBIpRcky4k496W1VI5UdyAM9u5qeaCCR3miA54xmgByhShdZQCzYK+1X0Ro3G4FePmrJ5Ea+WO9X7a4dwBM5OOOfSgCDWEcwK8a5QfnWfOZDAiAtg4HIropISwGzkNx7U8WvCsyjC89O9AHOfPGFiw27HJqTSY5oZNzZbJx+Fb7xKfvgVHJ5Ns0RD7t3O0DpQBGkEqksFPzMOfakmMqbm6Ivb1NbdoyPb9gx5A9KxvEYlWDMX3vagDMN04VmJIJzVGKfzJAHYLznOc1jW4uvkNwz4J+76GpTFMkm2OM7SQQx70AdalzGgGDkj86kR5pYzsGF/U1naZGsKhp3BkwMjOcVqx6gQ2EVdn5ZoArGD/nrwepAqeJkjGFRff1pjr5rF8hcnoaoXE4Rsg5IP50AbEkoMe/AHtVG4uV2FlYD5c/Sq8lywttzkHOePSsRnkllPmHC4Oee1AFpr3dI2STjkZ9Ka90si5B+U9RVFmRSQSSvQY61Ygg3KpVSWwMZ6CgCNV8tzLMo/wBhf6mrFizXMu5mIjB5b1NOlgRnJwWKgE59ax769aB2VGxjstAHqGm3Gy1wOAMcVLcn7xH3SMj61zfgK9ku7S4+0fNjG0/jXRzYZHQcAA80Ac7dAHj8K8o+PMYX4damRz80P/o1a9amhZR8wyB3ryz4/KB8NtTI/vQ/+jVoA8i+G1ib3xDYxYyqr5jfQCvpTRISACOAT+leR/s/aWr2up6vOoO0JbQk+uMsf5V7lYINoJAGBQBcgXq3euY8W6ibDSriUsM7SBXX265U+uDXk/xRuC1iVRsjeEHP4mgDyjXL83BHmMcs3Jz0rIVN0hDggdqfqEi+aVTBINVkMjsFycH+dAGrbQxEExZlYdsVpWti8o/efLk8IOtUdKcB3GQg2kHHU1uaI5e62xqePzoA1LG08lE3YUEfiDXQWIWLYBGG3DkmoDFDvVWPJ647VZDRxsGBOT6UAa9jJHHLs+72Fa8EiEkt+YrnrQliHx8p6E+tbcCqEX5/r2oAv7gjqOvfHqKnET7kZSdpOFqH5EjBUA+9WFvG+wyAoSExhqAJY/uMjfLtPrU0EqQHcTx0xWOLiRpBhflPJzViSRmCkcKOQfWgDo9Pk3hmzkdge1X7eZSCjNk549q5aMyqRycHkkVesRIXDnJI4xQBp38Lr82dwPpWTG7PcKFBYDtit+NQ0bK4IJ/SqbwrbljjaOuaABbhluVjOORktVm9dEETEZ3etZyGOQrtbDk/pWjqEafZ4lY/dHB9KAOW1thbsDEh+boTwFrHj1BWLxS4dl+cYPH510GrCOe0aPcpU8YJ5rh79hp0yuoDR4IUA5IoA2be5Q3G8sQDz8xrb+1Q+VG6sN5HArzJb9pWVFDNyfm711emPGkEbyEk4PXtQBuvO0skaxMdx7mq5Bjfc7bzmoI5yyMI1II6Gp4bd5VDNxjpQBNCN5+fJB9PX0p0umvJL8w8qEdSx61o6dCsMaZJ9cdTmpLyVWJ+bqTxQBm/ZLWLIRSxPc9KbvCSAjGB2FQ3d3EnBk5PG0VjXF4skoRSeOgU96ANLUpS9kwgIUHqehJrmLgfPlmDMeNorRkvG8l1lwqDjaO5qnAjPMuxQAAOQOnt9aAOt8KlrWyO7guentXX2haaFjjoprgIrqTzo1yRsOAB6V6BpS+XAswYlX4I9M0AVo4i8hVuQwKnNeP/ALQClfhjqwPUPD/6NSvaWUrISOK8b/aGGfhprJ9Hh/8ARyUAM+FFrFp3gXSbSVWWWZPPYj1bnmvTLRMwFh3IArhfC6Aadpa44W2Qf+Oiu5tCRarj+90oAuSMIrOd+4XA+teG/Ep5ZpdicCJs/U17VqbBNNc5xj5s/SvEvGEyS2j95HbIz6CgDyu4ULJnknd81SjaJfYCppY0HmM/3i3b0pk7QwzEjcwA6L3oAuWSEDKZwOtdD4XX/T5drb22Z46Vy9tqEkqsAFjAGMDvW54Se4/tFynKhMnP1oA7FWVlw5O4dhVu2iE6oDuVN340luy5BZcvnINakSMxBG0Me3pQBpW1tFGTEg3pwdwNX4oFV8ldw6deKpQIwVARux3rQt4W2nIOR0oAsBUXJC/L2UmkMrREoEALHp2pwjOQT83t6VbktTDLhyDuAYd8UAZ6ozMS6kZrQS18zZ82MAYqQOo4IBx6VIt6kRwAMnpQBZgtXDBn5Qc49TV6ECI5XHriqcd+8nyqBilS43SAdzwKANJG38Ac1FqS/uXUkAY4zVuAIIw38XvWdrkhEGNucnH0oAo27LGVPynB5NM1HUGurWRISQwFUoS0cbq568Amp7C0aVnCsDvG7AoA5+8lxEuc7ielYGrOrRqiMPLHU+9dDrkDQzlZFwBxkGucuLYNJ+6BXBwS1AFaC2WT5YVbzCM57V1ukaVM1pN5mCwAAz0NU9DtgkiFCHbHOegrqhMwiyVBx6cUAVrWw8rAGCB+VaEflxMoIDP6Gs/+0TGrbsdyaoXWooI94G6fp16UAaAvv34XcfvYIHSs/U7qQvwQseOnc1JpqtLGJWQFwegqDUkZGOAMkc/4UAc/fXDAuFG75sbjVOC4Cybo2+cd605NPkvC+5hGmOo6inQ2MNs+IwWzwWI5oAr28Tq3mTZdid231+tW5Zliiz93jgKKuQ221M4BU9SaxNWnWPeM4wOKANjR9RRrgCVEKjuOtd7ot0s9tPs+7tDY9K8c0FpXu9+Ds4HPvXqPhyQRWZcHO9dh+uc0Ab+/KsW7LmvIP2hEx8LdZOP44P8A0cletDLW+5u4wa8r/aJjZPhTrJPQtBg/9tkoAueG49thZEg8W8YH/fIrsoI/3UIOfWsPQkxYWYVQMQR/+giuoiXiPjtQBm+LZDForcY+UnNeD+IZwZGzyVGPavbfiQ23Ro17sSMfQV8/eJ2ZEm3cBmGKAOavORlzjnAHas9mLvkc8VPKHA2ZDMDkCo1ibzCP5dqAJbQ4kXcc57Cu18Mbvt5VVIwmDge9crp1ozMpztJPTFej+FbYxXBYLj5QOepHrQB0mnWapCXdD5zNwewFalpYuHDOQ2as2ZRosEDJ9BWpaQRtIu5j9PSgCOGNIwileB2FXoUV8HAGOlQOQkhBXGDwaUsqZJPFAFgghQARu7VFMwHzO/TjFQvOBjaGJb9Kr6judk2g4FAD5rgBCQ2AOCKrXNzgqEGSaZHG5YhUJJOAT3qxBp0pkBnwEx0HWgB9lPIZBhiRXSWFqSVmYglv0rLtYo4yQpUY7d60YJxHEGzj1xQBqElcdz7Ujwi4UhscmoBK0tvmFdhfgE/zqWMx2qgSHe/rQBUv9OMSKWHyjnNJZoIpUCYAyKdPrEc9y0S/NGPlbPUVBJhG37wVz8pzQBX1+G3NwzyjIbjjtXK3yWwmGxwC3GT0rotRvEMjK4+ZuvHGK4vVLcfbkedmFrnjb1NAF3Tr2C2LISm7PT1qy+sxylo3YqqjjaOpri5mL3TqqMI2bjPU1q21rcyowKY2jaD04oA1pA1yjvHIVyOcVHb2klyqx/dwclj296XTrZbRGEsvmSsfuDoKvQSBEkeRflU4Cj+tAGrpSwxxGMOX2DAI78Ulx5X/ACyZGY/eL81j28wklGxsDdyBTJnjJZlc8cjPSgCzczFy8alI1Hf1rOaUxkbnP1AqpdzfJIY/mZfXoeaxbiaSR28whPQZ4H4UAdQNWRI2QFCwHHoKwNSMc8oIwGY8Y5qkEjRlfz92Vywp4TzpSqfKjfxE9KANLSEO4IrjDMB+Ir0GyVLcG3Ei7iQzY/vCuO0e0FuofKvI2BnOa7W3tknhjm581CN+KAOkji3WP1NeX/tGKP8AhTmtZ6iS3x/3+SvVoyBaqi9MV5R+0idnwj1pPWS3/wDRyUAdB4fkWTTbJlXafJQEf8BFdMFBdR0wAK5fw6hTTLMd/JQn/vkV0qsGuAOcjH8qAOT+JUpZrW3HPyljXhviiNZZRkHcW4HrivZfiA3/ABNJjnJWJVA+teS6nGJLhN5+VBkCgDh2hYuxIPBPNXdOgyd0ing4J9a0pYEeViAQM8Y7mtGws2b5WXGaAI7Gz8mfAAbnhvY12ehoY+WzgfLxzVHTbVTtVEO7GA1dHYKLdAWUA56UAbmnxsIeAAc1oRoNxbd07CsSEzTOGD7Fzz7Vt20Cu4KsTmgB253UqSKckKlQSDg9QavR2QRdpYEk556j6VYMEUeQdzduKAM0lI8BFLcelTQW0jhZAuF7g1eYQxgCKPDDoT1NMeSZoU+QhyaAGlEtXCYHTcSOc+9VJJWLnyHOP1NSNZzO7H7vbnvU1vZeQpklILdF+tACR2iw24mYfO/Xmrq+S8C7R2wQO1I8QKKHchRyAO9Oe4hhRmVQB056UASGZU2cYUcDdWW95I8szORtTo1QajeRgeY0ucfwjsK4nxbq9zJpkiWbeUhIJI6kdxQBox6tHaSOJJFZyScA5rS0K+lvY5o5eEjG9Sa8TsZLgXSOGbYDk5Neq+EZpLsNIq7VVOh70AbVzfRRP8+GI7E/rWFqEqyTr5hBVjlM9CKz5POnv2dxjDlcH0re0mxe4ZV2blXPUUAZdnbSLM8lzxDGcjjv2qQXVzKd2VSInHufaun1eFfswiKblPHHrXJAsszo/wAgWgDSt1XcN4QMeD6/jUl0CwCLKuc9u5rAvL3Y7SFlyDng96x5tRPnxN55xnJC+lAHVz3sWnEogaVthzjpk1kXlx54JJZfQVJb3aiUvMxctnI7NTbm5hIJNpvJ7r0FAGTIZpJSFLe/NMnDyiMopdwfmwK1oY7Z1O3Ic84PSrMEDxlMAhicDsBQBlWenMw3MDuPb0qzLCkQCKckc46ZNdLJbxpbb5G2nPX/AArBvYmRwdykHoAck0AXvD0paUlkGO2egrttNuRbtIgGY3IX8+9cVYwskBeYkBcHA7CulikEjweSco4BOPbigDuVykag9TXlf7Soz8LdZIPGbf8A9HJXrEqboo/90V5R+0khHwn1k9Rutx/5GSgDrNDizp1kV+75EfH/AAEVuRR/6QTjArI8PknS7MZPEEf/AKCK24RmQ55oA4Tx/Gq6gSfvOgIIHTFeWavbCOYse65+tet+OULztJ/cjNea6nbtLfoE+5gUAYMdk0ioyL8442jrj1rW0+yk+8xAwO57VHDbuzOWJGOMiti3gEaxogPPLZoAs2yEkCCPAJ+ma2LK3y4DZmY8BQOlRWERxu25Ge9dFpsJWTKgZ6nigBsdmUIUgA9SOwrZtI4/Iwo2t2PqKZHCZGZm6tzgVdit+OTtAoAh2bn/AHYOemTUyQlMY6Z5q3GqxhivPbNO2Agf3aAKsuAVZQN2OKjlSZoS27nPGKtEKuARkZpjFW4DY9vWgCvEgkmCyM2BzUc+558yEFV+6O1STSBIZNnDOflFZ13OI4Bnj29TQAahqRh2qMEEYyKxru9ldG83hM/KKcY3lcyMMKAWAPY1kahdNMvlhsbR8zUARTzFl+V8l+pqhcxedayoByFJz9KlhhlfZtUbX+UVppFDb2km8/IAdxPVz6CgDi7PSGnfzceXCG4/2vWu60NI9PtjcyMQrEKq9KzoW82IhE6sNigdMmneLLryYLayR0EuzezL0HsfegBviSU29+q2oJBkDhx0IPUVvaXfCGBFLqr55U+lcdp1/wDaLJra5OdhJQjrmotJv5jcXC3Cfv1y0b9jQB6Hqd5FFC2xiWPCj0NcNq169xAqbQkisQzjqalhvmKIHJZ2OSCapXEzJI5dQSD3oAyLhwiCN1O4HduNYupSTBQyMuG4+ldPKqXu4hfl6g1lJYwzXe2ZSQp5K9KAJNNmnmsYA3zOuevcdq1bcTKhKtsHQ80sdtOsebUKI8cD2pZfPiUSnjJwwYcCgCyJ0yolIOOM4xipJdSSNo1T7gGMnvWDc3pdxtPzZ5xTIpS/Ep4JoA6WXUTPGoUkRgEkVnRzxh9y5LN2qAyGNV3AqnaprWWB58Y+90KjnPr9KAOg05y9rN8jSHADD2zXV+G7WPC4LKiNuXNZ/hu0FswlnIkjf5WWuitbYm92xjbED19qAOqAHl7ieAK8k/aO5+EGun/bt/8A0eleszNiIgdcV5J+0g+PhFrK/wB54M/9/koA6jw/ITYWYHUQR8+vyiuktyGYmua8Nr/oVkAc/uI//QRXRxEDcehoA57xZCsgnPXoOK4WOzQyEkkN/td67rxFdLE8qkZ3c1xlqWkkYkcg4xQBU/sgrd84C9cA8Vo2Wju05JbC9R9KvRxCTGOh71p20TY2/qKAGWunBcLmtqytURWHIwPSi2hWMZH3verUa/IxJ5xigBYwi49vSnD5mpq8YwOKep+YelAFmOWJUwRggc571FLICOOgqNioGT0zSb2xggbT2oAYWGCCcU1FLqzKOB3pdnOcfKaS4kEcO1TkY5xQBVvpE8wbGDHv9axrpTM0Zfg7iD7CrswZ5BgY9xTL9C0IhPDk8nuaAMPULovJ5duCuzv/AHqzJIG3FpjknnjvW5LAEZcYwOmaz7s7SBt+Y8Z9B60ARtOlvbgEBCRx7ViaxffZ7FnLDJP3j6e1UNb1eNbh/nDKg59Fri9S1Q6hL5MbltgyST97PNAHaaR4i+xmOeRCYVGWJ6msHUvF32meQrGpmupiSp6r6Vz0925tVLbmRGwR+PT8aztBHm6xIbshFVSxx1B7UAddZaqzzCNMoC21mUdc9c11elvBLdMsm/eg2AeuRXC6cIvtIWHJUc47muz0PN06MT5WF5Y9SRQAl1IINVji2NhumO1X7yBI5GfGc468inapEMHzXViDzt6nNJAxa38uT/VNwrehHY0AZkp2733fIOgHAq5HbO6AW6qoxnnue9ULlI1glWXICHofSs621OWIqoLKpPynNAHQtO8BCqdrDqvUVTm1Cdwd22RQfuD0qnqN5cCQSMAUccYPPvVNLtE27DjPXIzQBsGAXeWgiUMoyRjFRi1RGVlQvn0ORVRiZGDo+Ebrg449K29JRNpQdBnBzmgDGmeV5irjjoAP0ra8O2cstwpKboycHjtViPS91xubDhuje1dJpFqsUihmAA4OOgoA2NLtwLOEP99G6du9bmlTiafYcF19K5mO6byJUQ4dFH1PNb3hKI73c+negDec/NivJP2jTu+FWtkdN8A/8jJXrcq8lh0HNeQftEf8ko1n/fg/9HJQB2Hhc4srYEniCM5/4CK6QbSpbqG6VyXhuYf2fZOp48iNT/3yK6KCU7/KPbmgDH8WwOxV1UlcYyK5vTc+U6lec5rs9Xy0RX0HIrBsrYeYeM89qAHWsBJBxgDkYrXtowoxnr1p6Q7Y+OOOlSxRfNyDg0APQBT6+9TbsocdxUMisW+TgU4qyIQe9AEnAXkjNKoJX1z0FRRqTyfrUvCj3PegAIO3nGKcANpJ6elMPO7nimnJjUDOeaAGs5fjO0VXkzkqo6dc1YK/JyPmNRuoKqPwNAEccY2lsfP0X0qvLGAhDNl/X0q4xAGFPArNupVjTLHkngDvQBm3uVR2U8Lya4rxDqy6fCdzbpXGSc/dHpXTa1dBYZCxIhjG5sfxH0rxXxXqDzSyMN2G5xQBka5qz3s7RRLshPBC9Wb1pLYKu2JeZCASPQVnWsjeazHp/CMd6mhf7KJLibPmOcKDQBf1q+X7P9mgwEDZYj1HSs20BUgK2WP3j7Uy4zLfMCMqQCMdOKsWZJupAByARzQB0fhyTM5II4IAyK6zw5eGK8ZJl3qkhDA+hNczoGwyFjkOV+WPHU10Bljt4nlwFdh84PBAx1oA2L6BZFEkEm/eSCPQ1X0zUQPOsrkHdkFD2JrOsrwzSPbq2GH3W9/WqeorIN5O5pgeCPSgC5qztd3nkyH90OQ3tSPbpvVLdd0ac7T1Iq5psYntQjfNKFDNJjIHtUxtvMmXzYygJ6oM4FAEVzpTvaM6IQMZUH/PSslLNicOoUjj6V3elxbVaF5d4XknFLe6fbxMHLLjrjFAHO2FjudRwQB90jitmKKC2ChPmJ4O3pSCCNt7RnAwcc1Rm1FINqr8w25bHrQBqNPHAM7jjPAXrVzRrh55p0jA3bCVLdm7Vy1pqXmS8+XGWxgHtXWWdsIzBPE3ztzketAFaC5u1ucyJyDt/wAa9P8ACuGsDKVKs3Y1ytvZJJcNKeuc7O2a7TSF2WoOMYFAE8nEcv0rx/8AaJ/5JPrP+9B/6OSvWbqTEbYPXivI/wBodh/wqnWR33Qf+jkoA1PC0nlafZ5yVMaEj/gIrpkk3TFx3Oa5fw8p/s2zxjiBD/46K3rYujgNQBoXTBipJ5PWnWka5yqgZPYVCAWcH8CK0LSDBzuoAUpz04p4jIQbfyqy0XHFG0KPWgCCFcZ4z6U8xBupqTbnntUgXj8aAK/2dgBg0x4yD83PsK0VjzR9nzz0oAy/LJUYU+1KIZOMKc1rCEccUuwd/wAqAMiaBwo4qAjHIHI6Vsyx7lwOKozwPjAxQBlXUwihPHz55rElVmbc5Izk5PYV0FxZTNk7dymuZ19LqEMpjcZ7gcYoA47xfqBdJEhyFX7oH8X1rxzWbmSSXBPIPPua7rxPfF5jbRMuS2JJCensK5G4t1ErMqh/Rj3oAzbZdke9kA+UkfWq9xIZxvkOW6Kvp71PfSgzbcHCDCjtUCjyvM8xQJCMgelAFksI7LdHhpOhNPt7jfe+ewyzYJ7CsyCfEbhujDApbVi5Ck/d9KAOqhuvKuYmiJOfmyOg/GtG9uDcokru3ztggdMVkaZHJNGISoUc4B4zWq4jhtUExGc4Cjn2oAXT5T9rVR9zoWz0q/q8sltcgK3mkAEjsBWbHEyXCIpHJ3Ma2RZebbyzztiUHgH0xQB1HgiVJoGSHany8EjJNbWo2lxZQh43AV+WAHBIrl/DqyWkMZRcPgkEeldK8xm0/MpOc7evU0AU4bpftEbMg2PkHacEVHcajDFP5bMzI3QdazNR8+Gc4xsH3c9vbNR6rLGbSOaKAqcAFwefegC5NIisUY7UY8EHt61maq7yj9xGC/dlHardgbe7tgjKxK8ZY9KWCFhO3lv+6zgqew9KAM7w/pazzmZg/PVDzz616P4esxBo9v5jZeIliT2+Y1j6UsUSyuqhRGpY7fStWK6JRUjyyOpBA9zmgDa0eQXUhCKVAJOfWuytyEtlUcVyWiALLGoGD0rr5FCgKO1AFC6649K8k/aIyPhfqw9Wh/8ARyV6xPySa8h/aKk/4tzqiDpuhH/kVaAOh8PA/wBnWfp5Cf8AoIrfjwxXsRXPeGpFbTrQH/nimP8AvkV0KggqetAGhHGG5B96tRhgQe1UYHwfatKA5/GgCzE3GaeVDZpETA46Gpo0oAbHFUwjFPQDFPznigBu3FOox1pfrQAcUjL3p1I1AFdjzUJXnJq1JtTk9aqu3OT+VACZAPNUb6UbTGqhi3ByM4FW3c4+UZNMS3Y8kYY80Achc+C9M1M7prVFIJOcd65PxZ8NbaLTpDp8bKy8lkP6V7Cluwzxz70S2jmFwoBJHT1oA+Q7vwfdKskglJCHqwrmb+x1BJWMqF3HUj07V9ReJfDsoVytuQpOTtHFcfPocJ80SKo3rg8ZzQB8+rHKpUsj8N0xUsHySkbtpznFezSeFoTEoWIBt2eBVi48IWtyjFrdPMUDJ29TigDzO3mb77nLADHvW95SywCQkIyMDg9s10Mnw/hkRWgLpKvzYHQ02bwpqcEcjRKsyMPm9aAMqNRFFhUzvxz3rSmmaWwjQqMbsMc881lXhmsJQlzG6MRhcjpUcF45REhUy4OWPZqAOrt5Y4bYhVcKjDa2f0pkmpvNbTRR5LqwYepqquoIiAOpBZhlSMgcVd07ylctNsIC4xjr6UAEV4ZIzBcqeVHJ9c1PaWiyRAb98fQqD1qGYgTRsyrtZdoIOK0dPtoLWcTySMikjKdeKAGWNgIHWIouC2QT7U9o33Mqja2eSe9XdYljSI+WyxMD8ue9Y0T5mDSysc9CegNAG/otq7LcqBuDJgr7VoaeFX5Rxg4IPWpdNXy0gk5DyDGVqUbZr3f5YDk9u9AHSeHYQ0+4jjrW/OcEn0HFVNFhVLfcv41YuOQRnpQBnzNhTXi/7Qcm/wABapz/ABw/+jFr2W8O2Nj6V4f8e5N3gXUwP70X/oxaAOl8LziXSrF433I8CFWHf5RXZ2jeZCM/eArxX4I6wbzQX06Rsz2OGXPdD/8AXr2XT5Bkeh4oAujII/WtKyyeW/Cs5Mk7fWtWEYwB2oAuK4UcnmpEcHtVGVtrZJpyS4xQBpr0yOlKG46c1DbyBuM1LigCQMKcKhHvTlOBQBITnpSUo5o4oArsjOTmlEI7ipiR0pufegBPLUelKeuaYz4qMv8AlQBMXA6mgTLVZuaAMCgCd5EyQec+1Z15pOnXmfNgj3H+JeDVk4NAUdutAHP3PhGFtrWszDaeFaqJ0W6t5HLRhg3HFdnH3yal4I55FAHEpZeWAGTbznOKf5UeHXAzjNdZJbo4xj86pXOlo4OF2s3cUAef6nolvfO3mRBgB1I5rmZPBYgkaW1Hl8ZKHlTXrMukyKv7v5s9QetI1g4x5kZGAO1AHhOrWbwzBZIJbcr1I+ZG989qzbUyNKxjcuyHI2ntXv11pFpPxLEMnrxXK6z8PNLunMlv5lvL/fjOKAONtytzbq0oAPfP8JFXdNnRGcP+9XHEYGabN4P1vTJGEEwvIH49GFYedQsndLlJIWRvlJHT2oA17wC73oEJbkhS3Kn2pum6fLcAFlYRR8Nu70WCRSzLMCxkOBKB378V0sEMcjxvAxWNhgrQBsWKRvp0EcOVYDA9Tirtla+SV3Alj1qvZhbdVIwdgwpra05Gu5FYZwTn6UAbtgnk2qD2yahnY7T7nNW5SFT0Aqg7ZLE0AUNTbbbmvCfjm4bwXqQ68x/+jVr2zW5tkRA7DNeEfGmTf4Q1MZ6GL/0YtAHnvw11n+xfFGnzs2LecC3m54w3Q/gcV9OabcArtyMg4r45tj+5XBIIUEex9a+kfAeuf2jo9jdFvmaMK/8AvDg0AenxyjzVJ5rVjf5D9K5uGTcoYdjzWzaSZUGgC0f3mOeR1qxEq4xjJpIivoKtIQOwoAWJdvOKkDGjcO/WlBGaAHg+oqRelMBGOlODDtQBIP0pDSA0uaAGkGkK0/NIScUARlM9qQpUhORSA0ARFcUbD6VLmkzQBCUJ7UojwakzS54oAaBz7U8U0U4daAAcdafTe9LQA7A9KMDvTcmjcaAB442HKg/hUZgjz90Yp5bikzQBWksYmbIUZrF1rSIpVYSQJKp9RzXRk1FNgrgigDy+48JWTzq1lI8Eh4ZQeDWzpHh/y7V4nkXduyvrXSzacjyeYpw1V5reVJV2rjHegDnp4JEuQkfz88gV1OjwfZ4iD98jJrPsLTyXZ5PmkJ79q14srH15JoAdO+VHpmqjnOammfnA6VWdsKT7UAc7r82FYDpXh/xcbf4O1U9gYv8A0Ytex+IH/dua8X+KWT4I1Qn+9H/6NWgDxa1uYlUBmxxjmvR/hp4s0/S7W5tr+9jhQSCSMtnBz1FfQ58N6Hn/AJA2m/8AgKn+FH/CN6H/ANAbTf8AwFT/AAoA5DT/AIleFljxJrVspI75/wAK2LH4o+D0AD69aD6k/wCFaw8N6H/0BtN/8BU/wpf+Eb0P/oDab/4Cp/hQBHF8VvBI6+IbMfif8KmPxb8EAYHiGzP4n/Cm/wDCN6H/ANAbTf8AwFT/AAo/4RvQ/wDoDab/AOAqf4UATr8XPAxPzeIrMfif8KmX4t+A+/iSyH4n/CqX/CN6H/0BtN/8BU/wo/4RvQ8/8gbTf/AVP8KANH/hbfgL/oZrL8z/AIUo+LfgIf8AMzWX5n/Cs3/hG9D/AOgNpv8A4Cp/hR/wjeh/9AbTf/AVP8KANQfF3wF/0M1j+Z/wpf8Ahb/gL/oZrH8z/hWT/wAI3oef+QNpv/gKn+FA8N6H/wBAbTf/AAFT/CgDVPxf8B/9DNY/mf8ACk/4W94DP/MzWX5n/Csv/hG9Dz/yBtN/8BU/wpf+Eb0P/oDab/4Cp/hQBp/8Ld8Bf9DNZfmf8KT/AIW74D/6GWy/M/4Vm/8ACN6H/wBAbTf/AAFT/Cj/AIRvQ/8AoDab/wCAqf4UAaR+LvgP/oZbH8z/AIUn/C3fAeP+RlsfzP8AhWd/wjeh/wDQG03/AMBU/wAKP+Eb0P8A6A2m/wDgKn+FAF8/FzwJn/kZbL8z/hSj4u+A/wDoZbL8z/hWf/wjeh/9AbTf/AVP8KP+Eb0P/oDab/4Cp/hQBpf8Ld8B/wDQy2X5n/Cj/hbvgP8A6Gay/M/4Vm/8I3of/QG03/wFT/Ck/wCEb0P/AKA2m9P+fVP8KANQfF7wH/0M1l+Z/wAKX/hb3gL/AKGax/M/4Vlf8I3oeR/xJtN/8BU/wpf+Eb0P/oDab/4Cp/hQBq/8Le8Bf9DNY/mf8KT/AIW74B5/4qay/M/4Vlf8I3oef+QNpv8A4Cp/hS/8I3of/QG03/wFT/CgDTPxd8Bf9DNZfmf8KQ/FzwF/0M1l+Z/wrN/4RvQ/+gNpv/gKn+FA8N6H/wBAbTf/AAFT/CgDR/4W74C/6GWy/M/4VG3xb8CdvEtl+Z/wql/wjeh/9AbTf/AVP8KP+Eb0P/oDab/4Cp/hQBdHxb8CYx/wkll+Z/wpW+LngQjjxJZfmf8ACqA8N6Hkf8SbTen/AD6p/hS/8I3of/QG03/wFT/CgCZ/ix4EJ48R2PP1/wAKQ/FrwOBx4js+OByf8Ki/4RvQ/wDoDab/AOAqf4Uf8I3of/QG03/wFT/CgBJPiv4IPTxFZfmf8Kgufir4KMTBfENmT6ZP+FWP+Eb0P/oDab/4Cp/hQfDeh/8AQG03/wABU/woA4zWviL4VnjYRa3bMfbP+Fea+P8AxLo2oeEdStrPUIpriQx7EXOWxIpP6A177/wjeh/9AbTf/AVP8KP+Eb0P/oDab/4Cp/hQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA chest radiograph from a patient with a typical saber sheath trachea (top) demonstrates severe intrathoracic coronal narrowing (red arrows). Marked intrathoracic sagittal widening is apparent on the lateral view (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14658=[""].join("\n");
var outline_f14_20_14658=null;
var title_f14_20_14659="Fibrinogen concentrate (human): Drug information";
var content_f14_20_14659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fibrinogen concentrate (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6862568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      RiaSTAP&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6864316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6864406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Congenital fibrinogen deficiency:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on laboratory values and condition of patient. Maintain a target fibrinogen level of 100 mg/dL until hemostasis is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     When baseline fibrinogen level is known:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)]",
"     <b>",
"      divided by",
"     </b>",
"     1.7 (mg/dL per mg/kg body weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     When baseline fibrinogen level is not known: 70 mg/kg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6864405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Congenital fibrinogen deficiency:",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6864407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6864450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     RiaSTAP&reg;: 900-1300 mg [contains albumin (human); exact potency labeled on vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6864314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6864446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only; infuse at &le;5 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6864317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6864346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;1%: Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Allergic reactions, anaphylaxis, arterial thrombosis, chills, DVT, dyspnea, MI, nausea, pulmonary embolism, rash, thromboembolism, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6864322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions to fibrinogen concentrate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6864343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions (eg, urticaria, hives, wheezing, hypotension, anaphylaxis) may occur. In the event of hypersensitivity reactions, treatment should be discontinued immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic events: Thrombosis may occur in patients with congenital fibrinogen deficiency with or without fibrinogen replacement therapy. Consider potential risk of thrombosis with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Dysfibrinogenemia: Not for the treatment of dysfibrinogenemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6871911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifibrinolytic Agents: May enhance the adverse/toxic effect of Fibrinogen Concentrate (Human). Specifically, the risk for thrombosis may be increased. Fibrinogen Concentrate (Human) may enhance the adverse/toxic effect of Antifibrinolytic Agents. Specifically, the risk for thrombosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6864318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6864319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Increased pregnancy loss is associated with untreated congenital fibrinogen disorders.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6864321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of fibrinogen concentrate has not been studied in nursing women with congenital fibrinogen deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6864448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypersensitivity, thrombosis; fibrinogen level",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6864445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A target fibrinogen level of 100 mg/dL should be maintained until hemostasis occurs and wound healing is complete.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Normal fibrinogen levels: 200-450 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Haemocomplettan (AT, CH, CZ, DE, FR, GR, HN, NL, PT, TR);",
"     </li>",
"     <li>",
"      Riastap (DK, GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6864443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fibrinogen (coagulation factor I), a protein found in normal plasma, is required to clot blood. Fibrinogen concentrate made from pooled human plasma replaces this protein which is missing or reduced in patients with a congenital fibrinogen deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6864361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 45-60 mL/kg (range 36-68 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 61-97 hours (range 56-117 hours); may be decreased in children &lt;16 years of age",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acharya SS and Dimichele DM, &ldquo;Rare Inherited Disorders of Fibrinogen,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2008, 14(6):1151-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/20/14659/abstract-text/19141154/pubmed\" id=\"19141154\" target=\"_blank\">",
"        19141154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kreuz W, Meili E, Peter-Salonen K, et al. &ldquo;Efficacy and Tolerability of a Pasteurised Human Fibrinogen Concentrate in Patients With Congenital Fibrinogen Deficiency,&rdquo;",
"      <i>",
"       Transfus Apher Sci",
"      </i>",
"      , 2005, 32(3):247-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/20/14659/abstract-text/15919240/pubmed\" id=\"15919240\" target=\"_blank\">",
"        15919240",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9082 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14659=[""].join("\n");
var outline_f14_20_14659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6862568\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864316\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864406\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864405\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864407\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881423\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881424\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864450\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864314\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864446\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864317\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864346\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864322\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864343\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299332\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6871911\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864318\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864319\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864321\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864448\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864445\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992809\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864443\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6864361\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9082|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14660="Asthma and pregnancy";
var content_f14_20_14660=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Asthma and pregnancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/20/14660/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"au6191\">",
"       Steven E Weinberger, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"au5678\">",
"       Michael Schatz, MD, MS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"au1871\">",
"       Mitchell P Dombrowski, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/20/14660/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"se4723\">",
"       Charles J Lockwood, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"se5257\">",
"       Peter J Barnes, DM, DSc, FRCP, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/20/14660/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14660/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/20/14660?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Asthma is the most common condition affecting the lungs during pregnancy. At any given time, up to 8 percent of pregnant women have asthma. Many women worry about how the changes of pregnancy will affect their asthma and if asthma treatments will harm the baby. With appropriate asthma therapy, most women can breathe easily, have a normal pregnancy, and deliver a healthy baby. Overall, the risk of poorly controlled asthma is much greater than the risk of taking medications to control asthma.",
"    </p>",
"    <p>",
"     Asthma therapy during pregnancy is most successful when a woman receives regular medical care and follows her treatment plan closely. Before becoming pregnant, women with asthma should discuss their condition with a healthcare provider. Women who discover that they are pregnant should continue their asthma medications. Suddenly stopping asthma medications could be harmful to you and your baby.",
"    </p>",
"    <p>",
"     Topic reviews about asthma in non-pregnant adults are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"      \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SEVERITY OF ASTHMA DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     The severity of asthma during pregnancy varies from one woman to another. Unfortunately, it is difficult to predict the course that asthma will follow in a woman's first pregnancy. During pregnancy, asthma worsens in about one-third of women, improves in one-third, and remains stable in one-third.",
"    </p>",
"    <p>",
"     Other patterns that have been observed include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Among women whose asthma worsens, an increase in symptoms is often seen between weeks 29 and 36 of pregnancy",
"      </li>",
"      <li>",
"       Asthma is generally less severe during the last month of pregnancy",
"      </li>",
"      <li>",
"       Labor and delivery do not usually worsen asthma",
"      </li>",
"      <li>",
"       Among women whose asthma improves, the improvement typically progresses gradually throughout pregnancy",
"      </li>",
"      <li>",
"       The severity of asthma symptoms during the first pregnancy is often similar in subsequent pregnancies",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Factors affecting risk of attacks",
"     </span>",
"     &nbsp;&mdash;&nbsp;The factors that increase or decrease the risk of asthma attacks during pregnancy are not entirely clear. The likelihood of these attacks is not constant throughout pregnancy; attacks seem to be most likely during weeks 17 through 24 of pregnancy. The cause for this pattern is unknown, although it may be because some women stop using asthma-controlling drugs when they realize they are pregnant, increasing their risk for attacks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      EFFECTS OF ASTHMA ON PREGNANCY AND BABY",
"     </span>",
"    </p>",
"    <p>",
"     Women who have asthma have a small increase in the risk for certain complications of pregnancy, although the reasons for this are unknown. Compared to women who do not have asthma, women with asthma are slightly more likely to have one or more of the following pregnancy complications:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       High blood pressure or preeclampsia (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"        \"Patient information: Preeclampsia (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       A premature delivery (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"        \"Patient information: Preterm labor (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       A cesarean delivery (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"        \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       A baby that is small for its age",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, the vast majority of women with asthma and their babies do NOT have any complications during pregnancy. Good control of asthma during pregnancy reduces the risk of complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CARE BEFORE PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     If you take prescription or non-prescription medications, these should be reviewed with a healthcare provider. Some medications are safe during pregnancy while others are not. In some cases, an alternate medication can be substituted for an unsafe drug.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ASTHMA TREATMENT DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     During pregnancy, care of women with asthma is sometimes shared between an asthma specialist and an obstetrical provider. Visits with an asthma specialist are scheduled based upon the severity of asthma during pregnancy. Asthma treatment in pregnant women is very similar to asthma treatment in those who are not pregnant. Therapy during pregnancy has several key components, which are most successful when used together:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mother's lung function &ndash; Normal lung function is important to a mother's health and to her baby's well-being. Lung function can be monitored in a healthcare provider's office or hospital. Lung function tests, such as spirometry, are useful for distinguishing the shortness of breath associated with a worsening of asthma from the normal shortness of breath that many women experience during pregnancy. &nbsp;",
"      </li>",
"      <li>",
"       Asthma can also be monitored at home by using a simple device called a peak flow meter that assesses airway narrowing due to asthma. Depending on the frequency of asthma symptoms, a healthcare provider may recommend measuring the peak flow rate (PEFR) once or twice per day: once upon awakening and again 12 hours later. Decreasing flow rates usually signal a worsening of asthma and a need for more intensive therapy, even if the patient is feeling well. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"        \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3141525\">",
"     <span class=\"h3\">",
"      Baby's well-being",
"     </span>",
"     &nbsp;&mdash;&nbsp;A baby's well-being is monitored in a variety of ways during regular medical visits throughout pregnancy. These visits are particularly important for women who have asthma. Women should be aware of their baby's movements. If your baby is not moving normally, contact your obstetrical provider immediately. This is especially true for women who are also having asthma symptoms or an asthma attack.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Non-stress testing is sometimes recommended after 32 weeks of pregnancy for women who have frequent asthma symptoms or attacks. The test is performed to assess the baby's condition. It is done by monitoring the baby's heart rate with a small ultrasound device that is placed on the mother's abdomen. The baby's heart rate should increase when it moves. The test is considered reassuring if two or more fetal heart rate increases are seen within a 20 minute period. Further testing may be needed if these increases are not observed after monitoring for 40 minutes.",
"      </li>",
"      <li>",
"       Ultrasound examination to check the baby&rsquo;s growth and activity, and also the amount of amniotic fluid around the baby, is sometimes performed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21146055\">",
"     <span class=\"h2\">",
"      Education",
"     </span>",
"     &nbsp;&mdash;&nbsp;Learning more about asthma may help you manage your symptoms better, prevent attacks, and react quickly when attacks do occur. This education can be particularly reassuring and useful during pregnancy. Asthma education teaches strategies to recognize the signs and symptoms of asthma, avoid factors that trigger attacks, and use asthma-controlling drugs correctly. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Avoiding triggers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several simple steps can help control environmental factors that worsen asthma and trigger attacks. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid exposure to specific allergens that are known to cause your asthma symptoms, especially pet dander (such as fur or feathers), house dust, and nonspecific irritants, such as tobacco smoke, strong perfume, and pollutants",
"      </li>",
"      <li>",
"       Cover mattresses and pillows with special casings to reduce exposure to dust mites. Avoid sleeping on upholstered furniture (eg, couches, recliners).",
"      </li>",
"      <li>",
"       Pregnant women should not smoke or permit smoking in their home.",
"      </li>",
"      <li>",
"       Women who will be pregnant during flu season (the winter months in most areas) should get a flu shot; there are no known risks of the flu shot for a developing fetus. Flu shots are generally given once per year in the fall. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"        \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For more information about trigger avoidance, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;With a few exceptions, the medications used to treat asthma during pregnancy are similar to the medications used to treat asthma at other times during a person's life. The type and dose of asthma medications will depend upon many factors. In general, inhaled drugs are recommended because there are limited body-wide effects in the mother and the baby. It may be necessary to adjust the type or dose of drugs during pregnancy to compensate for changes in the woman's metabolism and changes in the severity of asthma.",
"    </p>",
"    <p>",
"     It is difficult to prove that asthma-controlling drugs are completely safe during pregnancy. However, asthma medications have been used by pregnant women for many years, suggesting that most of them probably carry little or no risk for the mother or baby. Specific guidance about medication safety is discussed in the section below. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'Asthma medications'",
"     </a>",
"     below.)",
"     <br/>",
"     <br/>",
"     It is important to consider the unknown (but likely small) risk of asthma-controlling drugs compared to the potentially serious harm of undertreated asthma. Severe asthma attacks can reduce the oxygen supply to the baby. In most cases, undertreated asthma poses a far greater risk to both the mother and the baby than the use of asthma-controlling drugs. Therefore, it is important to take asthma medications on a regular basis to prevent asthma symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      ASTHMA MEDICATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Short-acting bronchodilators rapidly relieve asthma symptoms by relaxing the airways. They include albuterol (Proventil&reg;, Ventolin&reg;), metaproterenol (Alupent&reg;), terbutaline, and other drugs. Short-acting bronchodilators appear to be safe during pregnancy. Several studies have shown that the babies of women who used these drugs during pregnancy had no increase in health problems when compared to the babies of mothers who did not.",
"    </p>",
"    <p>",
"     Longer-acting bronchodilators, such as salmeterol (Serevent&reg;) and formoterol (Foradil&reg;), are used for long-term control of asthma in combination with an inhaled glucocorticoid (eg, Advair&reg; and Symbicort&reg;), but not for rapid relief of symptoms. Although less safety data is available for long-acting bronchodilators than for other asthma medications, they are often used because of their effectiveness in controlling asthma and chemical similarities to the short-acting bronchodilators mentioned above. Women who take a long-acting bronchodilators should discuss the risks and benefits of use during pregnancy with their healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids are used to treat many conditions in addition to asthma. Experience from their use in pregnant women suggests that these drugs are generally safe for both the mother and the baby. The glucocorticoids include pills such as prednisone and inhaled drugs such as beclomethasone (Qvar&reg;), budesonide (Pulmicort&reg;), and fluticasone (Flovent&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Oral glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some studies have suggested that there may be a very small increased risk of cleft lip or cleft palate in the babies of mothers who took oral glucocorticoid medications during the first 13 weeks of pregnancy. Two studies found a slightly increased risk of premature delivery, and one study found a slightly increased risk of having a low birth weight baby. However, the researchers could not rule out the possibility that these effects were related to the severity of asthma and not to the use of the drug.",
"    </p>",
"    <p>",
"     However, all of the above risks are probably smaller than the risk of not treating severe asthma, which could be life-threatening for the mother and the baby.",
"    </p>",
"    <p>",
"     Women who take glucocorticoid pills during pregnancy may be more likely to develop gestational diabetes and high blood pressure, although these conditions can be detected and managed with regular medical visits. Women who take glucocorticoid pills frequently during pregnancy will need glucocorticoids by IV (into a vein) during labor and delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Inhaled glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;The information about inhaled glucocorticoids is quite reassuring. A variety of inhaled glucocorticoids have been used during pregnancy. Budesonide is thought to be one of the safest inhaled glucocorticoids. Beclomethasone has also been used extensively during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Theophylline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Theophylline (Slo-bid&reg;, Theo-Dur&reg;, and others) has been used for many years during pregnancy without any apparent complications, suggesting that it is safe during pregnancy. However, theophylline is used less often for asthma since the introduction of inhaled glucocorticoids. Inhaled glucocorticoids are more effective and cause fewer side effects than theophylline.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Cromolyn sodium",
"     </span>",
"     &nbsp;&mdash;&nbsp;There was no increase in birth defects or other pregnancy complications in one study of women who took cromolyn sodium during pregnancy. Cromolyn appears to be a safe drug during pregnancy, although it is not as effective as inhaled glucocorticoids in controlling asthma and is now only available in a nebulized form.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Leukotriene modifiers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some drugs help control asthma by blocking the leukotriene pathway, which plays an important role in asthma. These drugs include zafirlukast (Accolate&reg;), montelukast (Singulair&reg;), and zileuton (Zyflo&trade;). Three studies have shown that infants of pregnant women who took a leukotriene modifier had no increase in major birth defects or adverse outcomes.",
"    </p>",
"    <p>",
"     Little is known about the safety of zileuton in pregnant women. If you are taking zileuton and planning to become pregnant, discuss whether to stop zileuton with your doctor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although antihistamines are not used to directly treat asthma, they may be used to treat the allergies that often accompany asthma. These drugs include diphenhydramine (Benadryl&reg;), chlorpheniramine (Chlor-Trimeton&reg; and others), loratadine (Claritin&reg;), fexofenadine (Allegra&reg;), and cetirizine (Zyrtec&reg;).",
"    </p>",
"    <p>",
"     Studies in both animals and humans suggest that antihistamines cause no increase or only a very small increase in the risk for birth defects when taken during pregnancy. Of the currently available preparations, chlorpheniramine (which can be sedating), loratadine, or cetirizine are considered the antihistamines of choice for use during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Decongestants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Decongestants are not used for the treatment of asthma, but may be used to treat the symptoms of upper airway allergies. Pseudoephedrine (Sudafed&reg;) is a decongestant that is commonly available.",
"    </p>",
"    <p>",
"     Most studies examining the safety of decongestants during pregnancy have been small, making it difficult to draw clear-cut conclusions. Until more information is available, it is probably safest to use a nasal spray decongestant (for 3 days in a row) rather than to take an oral decongestant during the first 13 weeks. After the first 13 weeks, the use of pseudoephedrine is thought to be safe in pregnant women who do not have high blood pressure or placental problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Immunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Immunotherapy refers to regular injections (allergy shots) that are given to reduce a person's sensitivity to allergens. This therapy appears to be safe during pregnancy, although it carries a very small risk of a severe allergic reaction (anaphylaxis) in any person, including pregnant women.",
"    </p>",
"    <p>",
"     It is probably safe for women who are already receiving immunotherapy to continue receiving allergy shots during pregnancy. Women who are not using immunotherapy at the time they become pregnant generally should not start immunotherapy until after delivery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"     </span>",
"    </p>",
"    <p>",
"     Pregnant women with asthma should discuss their labor and delivery plans with their healthcare provider. Asthma may affect a provider's choice of medications commonly used during labor, delivery, and the postpartum period.",
"    </p>",
"    <p>",
"     Women with asthma can be treated with the drug oxytocin (Pitocin&reg;) to induce labor and to control bleeding after delivery. During labor and delivery, epidural anesthesia is preferred over general anesthesia for women with asthma because epidural anesthesia reduces the demands on the lungs.",
"    </p>",
"    <p>",
"     If general anesthesia becomes necessary (eg, for emergency cesarean section), a general anesthetic that promotes dilation of airways is recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Breastfeeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Breastfeeding appears to lower the risk that an infant will have recurrent episodes of wheezing during the first two years of life. This is probably due to the fact that infants who breastfeed have a reduced number of respiratory infections during this period. Respiratory infections are a common cause of wheezing in infants.",
"    </p>",
"    <p>",
"     It is less clear if breastfeeding reduces the risk that the infant will later develop asthma. However, women with asthma are encouraged to breastfeed because there are a number of other benefits for both her and her infant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H251\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15453726\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/21/18770?source=see_link\">",
"      Patient information: Asthma and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15453734\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"      Physiology and clinical course of asthma in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=see_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"      www.aaaai.org/patients.stm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg.htm\">",
"      www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/20/14660/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 22, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/20/14660?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14660/abstract/1\">",
"      Dombrowski MP, Schatz M, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol 2008; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14660/abstract/2\">",
"      Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N Engl J Med 2009; 360:1862.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_20_14660=[""].join("\n");
var outline_f14_20_14660=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SEVERITY OF ASTHMA DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           EFFECTS OF ASTHMA ON PREGNANCY AND BABY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CARE BEFORE PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ASTHMA TREATMENT DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           ASTHMA MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           LABOR, DELIVERY, AND THE POSTPARTUM PERIOD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14661="Cisplatin: Patient drug information";
var content_f14_20_14661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cisplatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     see \"Cisplatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"     see \"Cisplatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700695",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney problems in some patients. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3760045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause hearing loss. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may irritate the vein. It may burn the skin if the drug leaks from the vein when it is given. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cisplatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, hearing loss, or poor kidney function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14280458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the belly cavity sometimes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12217 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14661=[""].join("\n");
var outline_f14_20_14661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028585\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028587\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028586\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028591\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028592\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14280458\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028589\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028596\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=related_link\">",
"      Cisplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=related_link\">",
"      Cisplatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14662="Type I atrial flutter";
var content_f14_20_14662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1127px;\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Type I atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 85px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 1:1 AV conduction was induced by quinidine which both slowed the flutter wave and, via its vagolytic effect, enhanced conduction through the AV node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14662=[""].join("\n");
var outline_f14_20_14662=null;
var title_f14_20_14663="Saber sheath CXR";
var content_f14_20_14663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82632%7EPULM%2F68278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82632%7EPULM%2F68278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saber sheath trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA chest radiograph from a patient with a typical saber sheath trachea (top) demonstrates severe intrathoracic coronal narrowing (red arrows). Marked intrathoracic sagittal widening is apparent on the lateral view (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saber sheath trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAcADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKWkpw/WgAAq5pemXWqXS29lCZHIyT/AAqPUnsKfo2lXOr36WtouWILOxztRR1ZvauivL6HT7R9L0VmW33fvrhvledh6/7I7DP1oArX+naXpifZFX7de5G+VmKovqFCnJ+p/Ks02sLkfuAvy9FLce55qaOImRUCHBA6Zyf89a9J8HeAZb4iXUSYoiuQdvzfjQBwWleGZtRnVYbY7CBk5P6c13Gj/CuO4UtdKwVSBkMefXvXqtjpdhpqrDHG3y4yQM5NXS0Y2qMrgHC9vr9aAOEtvhT4dRQLi2d3PT984H6Gro+GPhGNFEmlMxxkuLmXr+DV1TIpO0hguS27OOajkukRfOOVRT065NAHMf8ACs/CLb2XSSQBwv2mXP4fPSL8M/CbIzDR/lHcXM34/wAVbkWqBwZmXCIcj/EU/wC3uqmUk/vGyA56f4UAc/J8NvCIHyaOT6n7TKQP/H6Rfhv4SJLHRsIOObmbr/33W8+qKjL82T046VLpsV7qswt9LiaZzklgpwB7+lAHKy+AfBkIJm0oK2MhftE35ffrofA/wP0HxJdm4utHey0pR1+0S+Y57Yy/T3xXouieC7XTCt3q4F1cnkbuUB+ld54VvRdwzqxRZg/yJkAkAfyoA8b1f4G+CLOc240WVQDxMbuYlh/31ioE+DfgFWCSaMWJOAftk39Hr1TxI14ZvOvHgWKPhkWQEp7Y9fevOtU+LPg7Sbhre5vkkki4ZY8tj2470AU1+DXgNty/2CA/Qf6Zcf8Axynr8FvAip+90LD+n2ycf+z1j3fx/wDC+8GBLtsc58ojPtUFh8X9J1m/WCzuHjc/NiYbR9MnrQBvT/CD4dRsNuh5IGSPtlwR/wCjKRPhB8PjDu/4R/7oyc3lwMj/AL+U3UfGemW1kZ7q8itUzhWd9u4+1cVffG7RrNybWK71BhnAA2KD6knn9KAOwg+EngCSV1GgEhuU/wBLuOP/AB/+dW7b4P8Aw8VJZLjQF8tflGb24HPr/rK8w/4aJuk3rD4dgCk8E3Bz/wCg16B4A+MvhXxLcIniZ49GES5dZ3+Rz7Hv+NAHbWPwJ+GN3aRTp4ZIVxxm+uR+P+sqC3+BPw6N0YpfC5/8Drnj0/5aV1uj/E3wPql4tjpniDTmZAFQeaqg/wC7muyxuVWRgysMhl53UAeWH4BfDPOP+Ea9/wDj+uf/AI5S/wDCgvhnj/kWsf8Ab9c//HK9Q9cngUuPf8qAPLf+FBfDTBP/AAjX/k9c/wDxygfAL4Z7sHw0Ov8Az/3P/wAcr1E9sde1Ude1jTPDumzalrl5DZ2cK5ZpWx+XqfagDxHX/gx4F0fUW8/w0BYyHMcn224wPY/vOtYV94E+ElpMqT21nAchj5t/OAV9P9YPz/nXM/Fr9oabxJps2keHrERWrMd11KCGI/2Rnj618/3Ekkzl55XlfH3nbJ/PNAH07J4V+DxwkVpYszdD/ac3/wAcoHgb4ZlmH9g7gOQUvZzn/wAfr5cwK0tL13U9JcHT76aID+ENlfyPFAH0lH4D+GDYebTYYFxnbLfzKT+clTw/D74WzHCWlnuPOBqE3H/kSvmHVtUvNXuvtGoTNLLjAJ4wPpVHigD7H0r4MfD3U7pYrfTYSGGVZb2Zgfb/AFlS6l8CvB1mDt8NyykDki5nxn2+evknRfEWs6JPHNpOq3lnJEdyeVKwAP06fnXtmn/tS+K4NMtre60zTLq5iGHuWDKZPcqDgH6UAen6d8Gfh7Do93c6l4YlMqD93uu7lcn04kqPR/hB8OZokNz4aYswzkX1xj9JK8wvP2m/Ed9IBcaVYiDP3I2YH8z1q/pP7RMcNzGlxpzi2z1wCU/WgDsPEfwE8MG2kl0DTWa4U5W3a6kO4Y92/rXlt14Q8PWNy0Go6E1vPGdrI80oyf8Avqvpn4feO/DHjaMNpWpQxX23JhZwrg/Q81qeLfAWn+JbRo9SXMhGEuoh84z6+tAHyt/whnha4Cva6ec/xRmeQ4H/AH1Vt/AXheKNZDpm6Nv+m8uR68bqn+IHg7xN8Or83Esct1pIb5LqFSQRn+P0NGk+I4LuIvJny/usjY/OgCSD4e+FJMf8StTnkYuJun/fVQD4f+GG+ZdMG1Gwy/aJSx/8erV0K7UTyWYlJQ5aNu49q01ZTI+Mecg+Zc8kH+f/ANegDCb4deEmi3JpjLnkfv5Sfx+b+Vc94g+Ftp5fnaNG4ToFd2JP5mvRbU/u3RGG1eVGcn6VNFKN4J3Mc5xzQB803ulJZ3TQ3ULQuhwysf0qG3S0gnDTWq3ESt8yl2Uke2DX0J4s8J2evWzN5ax3aAkSbTz9a8P1rS7vS7loLuExsGO3OSD/AJ/z3oAo63oqQ2ialppaXTZTj5jl4G/uvj+dYe3jp+NdTpOoSaO8gaMT2cw2zwykbXGOh9/Q+uKqeJtFSwWG904vLpVzzFIw5Ru8b+jDn60Ac/RTiKbQAUUUtABirWn2k99dwW1pF5s8rBVQd/8AAep7VXAGQTjH1rtdKtk0LQxeSAHVtTiP2cd4IDkF/ZmIOPbPrQAzU5YtGtBo+mSAlSPtdymf3z/3fUBew71m2cb3E2yJHZiw6Dk+2KZ5JBURhmdvk45yc9T7nNe0fDTwYulWaahfxg3Mo3KhGdv196AK3gzwfHblL3U05/ghxwOO/vXctebVVQjLxkAEDFQzbpbpVQ5QE8A4zz1xT40RlcbVJ3BeeooArGV1yoPzZzkHp+FR6jqH2ZEWV1MhxkHqwqa9khsxJJKFbOWwepFeay6pda7ru/eUsU+7jrQB6DZ3Mt5G0r58gnCKTVO+vohKVQ5hhHzKx6motT1iOzto4YNoZUwB7etcPq+sQvmNnbIO75SPmPofWgDeufESyzHYwjt04B9/8KyrjXpr19wDEKQV5Iz7/Ss2CxbUCFjjYbvlKgcH6e9eoaXpPhn4eafBrvxCnWSdh5ljpafNNJ/tEZ4H1wKAL/w6+HOq6+qalqiHT9NHJeUhS69cj0HvW142+L/gnwDYPpnhsJql+uUKWjDYjDgl5MevpmvCfiv8a/EHjtnsoGOl6APlSxgbl17b26n6dK8r6e9AHpfir40eMNfkYC9FjbZ+SKBeg9yetcePFHiAXQuU1zU45xyrx3LqV+mCMfhWGTRQBr3niTXbyRpLvWtSndvvNJdOxP1yayicnJOSeSSabmjNADuMdOaVW2OGQlWByDnpTKMmgCaeeW4IaeV5CBgFmJxUYIHrTc0ooAcrY9qflDnIHXIHp/n61DTgeKAJNqEcjn2Neh/Dz4t+LfAskaadqMl5pgwGsLpjJHj/AGc8p+H615zngU9W24745FAH3P4A+PXhbxRpwbVHGlX4wJImyy5PocdK7O98f+D9OtvMuvEFikajOPMyT+A5r8+9LGIlfCuZWIOatPAJ3MrJkIPmyMn8KAPpPx3+03aW5lsvBWly3E/AW9uhtTHqqdT+OK+evHfjXX/GF6H169keP7yxZIjB+lUjDA6oT+Azms/VIXWJWySqDHToPegDOkYYwBx2qInPNObIPTFMNABRSUUAFFFFAC5opKKAFzSjHOc/lTaKAJYZZIZBJBI8Ui9GRiCPxr1r4YfHnxR4LnSC/nk1rR+htrqTLoPVJDkj6HI+leQU5Tjucd6AP0U8BfETwp8S9Lli0u4jmkaP/SdOukAkUHqCp4Ye4yK8d+LnwRm0gza74Ejd7NFLz6avLL3yh6ke3btxXyzo+qX2i6lBqGkXc1pewMHjmibayn/D26Gvsj4E/Hu28YSwaF4oEdlr23bFcAgRXZHbH8L+3Q9vSgD55sNamhlimV/LkhbaUJ5GOuTXX2msLcX8TxuMkbtxPDZ7V6F+0N8Ici68VeE7c+b9++soxw3TMiDsePmHsDXz1p988c6SxnEwO7PbPcjP40Ae2WqrkPGBsAyFBOeetWGUtgpHyOPauf8ACGtxXyxiV8S/dK5Arp0dZJCucbem09qAFQIuwqByeSfX8qx/FfhqDxBYSL5ai+Q4jlIHFa6RY+fYchshSepNSBZTg78HPODjAoA+cta017C8a3vInSWNmH3eD71L4av0hiu9J1JXfTL1Qrrj/Ut2kX/aBHPrnFez+PfDcetaW81rGv22Abhg/e6/rXhk8Zw7ZHyvtMZB+U9x69s0AZevaVNo2oyWc5DlcMki/dkQ8hl9jWbjjPau8tIB4k0UaXL/AMhKxjZ7Fif9avVoST/477g+tcLIrISjgqykgqeoPfigBlOH0zSU5eCOcCgDe8EaOmteIIIbk7bGLM90/QCNeSPx6fU1r6/fNq+t3F86xqhOyCNekcY4Cgeg7fU1ZsLY6H8PVkZAt9rk25Mj5lt4+nuNzZ+oAzxis21tvNuYogFyWCj05xQB2vwx8PRarqj3lwM2lm2djdGfFexSFCzuYyuegT0xWboFgmh6Bb2ixhWClmYLnJqWWUG2G7jfyAeDQBXi2xjeh4BJB7ipI2ErLLtBKfMW7EUW8TxxBn3BB/CRg1FO4+yGBTuUnPoRQByXii8urrdb2y5HR2x90Vj6No0aW2+EsJCcyFmJHFdt/ZjTBYokGM8t6ZFSDTUsrRwvAydynoaAPP8AxLLKDDGhkEv94D5SPrWRpGh+bfLNcttij+Y7iR+OTXf3mlRzRCWf7iDcQegH9K8h8ZeKHv3axsHC2MbEbl6yfj6UAdxfeNNL8MRCXTIo7vU1X/RSTlI2/vsO+Ow/pXlOuavqGuanNf6vdS3V3KctJI2T9B6D2FZ5ooAKKSigAooooAKKKKACiiigAooooAUdaKKcOh9KAAcgCrFnbSXlzHBApLuccdh3JqID8u57V1ng6yuD5ywwlrq4j+Rschf/AK9AFhYLOyuLVXCNsA78+la+iaE19dysgZYXJwQPlA7irmheH7SxuYpNSmQTEHGcHHsQa6u38RaRprkBRgHgAgc0AZF14HsHuVMdwyYUZIrmvEOkw6LdxwJETG+d+8Z3/U13v/CWaMgikMkatzuX1qfUL/RPEOnPbXSqpZso+RlT9aAPnrUYDa3ksJxgHIx6VUrc8YWcljr08DnKjGxvVe1YlACUUUUAFFFFABRRRQAUUUUAFFFFACinxu0cqyROySKQyspwVI6EGo6WgD7M/Zy+MqeJNNTw/wCKroNq0I2Ryyf8vCY7+pHf865f49/CxdEv21jQYFi0u6bcUiXAhkPJHHQHqK+YrO6nsruK5tJXhuIiGSRDgqa+yPgh8R7L4neFZ/CfiZlOsLCRucDEqjow/wBodaAPGPDMTiHCxuGibOT19P8AGusvpZoQkkZGFOA2exqzfaM/h/XprO6VjcQv5bNjqOze4NaV1pe+3zAcqeQvbGeaAKui6jLeRkq67oyo5IIrWaaOBtrkb3XOO4NYNpC9sJUxt28j0bv9amt99zIElXLsex5HvmgDciljHO5c45ct1ryf4q6Elldx6jZA+VcHDYHyg88fU4/SvT/JVLfIAES4GTyTVbxXYLrHhe8gRVBEe9T3DDkUAfOzPNBeQvGWhkiIKunBDf5zz9Ks+M4Ib61h16Aok00nk3ka8DzcEh1HowBJ9D9ajmRtoe4k3SDKlR368fr+lZeomQWWG4UyDgHrgEZoAyxWh4f0uXWdbsdNt8+ZdTLECBnaCeWx6AZP4Vnr164ru/hhbi2fWfEEoxHplqUiIb/ltLlVx6/Lv/SgCx431CO/8QyRWilLKwRbO2QHO1EAA/PBP/Aqi8LwJPq1gHDEM65A55z/APWrGSWYqZFYEucnPGP8+9dv8PLZZdf0+NhwcycD0I7dqAPY5trKqiQkbc47iqjQGVwTl0VskZ9K0H2gOxAyF79R1rPuZ1awjIYKxyTigCSZmlQODnJwo6HH1p0FntbzpVDY4ChuSe1VrJpJEixt2DgqelaSrhsbgAPXt6UAKrgoxVNkZ/hz09eaztRO5lQLuVQCQeh/HNOu5n8wpjbGBjO3qa5Pxt4mi8MaQZI8tdTHESsM5x3PtQByfxc8WvAp0XTpCrSLm5YHoD0QfhXkNT311Ne3ctzcuZJpW3Mx7mq9ABRRRQAUUUUAFFFFABRRRQAUtJS9qADFFKOTSgUAH4U/aQOMY9c0qfeBxx9cV2ng/wAC6jrEsFzd2zrZyEMiMcNMP5ge9AGT4Y8NXWssJ1hZLCPl5n4DEfwg969f8LXEVrILaSFY5Sm1JPTHQCtLX/Dt2NJgiRo4LaD5BBFhQB+XNUbLS2t41kAG9eEDYyAKAM/xL4UlNxNdidmLjcy56Vx2oac9hbAzBQ0i9c8fr0r2GRluIkM26QsMHj+dc9rGgfaoizEmQAjYOhGenSgDySO1WaYK4JfHGf581ox26NapGzAHePnU1a1DT3069kDnb5XReeh4qjZXDeaI4ApIYlsc4NADvFsCXuh/a+txayBC2eShrhe1d3cW8scEqSOHWYFWAbjB71wrKVYg8EcUANooooAKKKKACiiigAooooAKWkooAKKKKACtLw/rF54f1m01TS5nhu7aQOjKcdOx9jWbTl680AfaHie5s/HvgbSfG2k7WuGRYLxFOQjDsw7EHj6EVh2LTLHGWwF6HA4P5V5H+zt4yTQfFEuhapK39ia6v2WVCflSUkbH9ueCfcZ6V640UulXlxY3ow1u5TLDBAB4P4igC3LbpdxNwFkHAz3Gax57Z7aUGNZCgOWOMfl7VpwzLcsY5QAw6bePxzVnMZCrIQQOSGOcfWgChYXiTo6yhGcEEBD1q3LMFtJwAXldSkcaj7zHgDHpzWTdWz2V80sDKIc855q3HfDy41LAs7YOMA/nQB494n8M3FjdvvUCKfLR5GBnPP41wmtQPDbKJOT5nX8DX01relrqukz2hO92+5J3BH8q+evHlm9lKYJSN6S4+6AT1oA5JTjnkV6bdKuh/CvSNNL/AOmatO9/KncIQFjH5Lu/4FXA6Bpkusa3p+mwZ8y7nSEEdsnGfw616B8Tp7K88USxW0rNbafEtnD7rGNq8/560AcrFEyZxuOMkEd8V6H8NyV8RWRc7SEYema85iXCMDIRE3QHjIre0W9aNw8O8PE4dAT+goA9z1+/e0hcqwLSLtAxisuxSe7tUdoyicZAwfxrL0LVm8QakttOMDbuHPb6V2MqpFZIuRwdigcZA9aAJZNmwR+UNoUZ45pHiEaM5Q7V4U+tSFwY0CbFC4y5/lWdqG8pKhYDI5BPBPtQBSvrgxyMZn/cgFy2eFxXzx4515/EPiG4uyW8hf3cKnso/wAetelfFLXH0nw9FpnnRyX18mJtgwFGPmIHYE9AecV4rQAUlFFABRRRQAUUUUAFFFFABRRRQAtKKQUq0AKAQakQDPJHHrQq5GOpz0rU0HRrzXdSjstPieZvvOUHCr3NAHcfCrwXDqsTa7rClrCGTZbwtwJ3Hc47CvbNKtPKeW4u+HlUEFOiAdAK5Dw5FrDXVrp0NgINKtlARX/XA9fWu3nURholLA56elAFbUZP9FKbuAc5PORUVuqx2gnliARiCATn8aL+MvGwC8E5yD2qYMsiRGI5hUY2nsaAIQqbpJMEt1A459/b8ar3CbifPyqgYyvarfmeWGILF9xGB0qpKyrISTiQnae/NAHO6/pq3IDRQg543MefpXn17prWV0kkKtnJY85x2Oa9muLdntEQqDiTcSDyayLqwhZ3RU+ViQVoA8g1u9hEaxxJuxhQR1//AFVymuRkXKyHGXUE4GOfWuo8f6YNK8RQqMMjL9MVhlRM0QnjXLkgnPRaAMCirmo2bWc2OTE3KN6iqlACUUUUAFFFFABRRRQAtJRRQAUUUUAFLSUUAOUlSGUkMOQR2r6d03WG8Y+CtM1xR/piD7JfqOjSLgBvxAzXzDXsH7OWrsNb1Pw27DydVgJjyfuyoCRj3Iz+VAHosUr2rr5p2hiMFT+n61qgAQgZVUbIZ84Le9c1qUkttcyWuMyCTkuOnatu1Yz28azPkRdwM9aALU0H2jeqEFAuA/pXnfit9S06ZTBIxjjffwPTt616XE2xdzNkHj5eMfWqep2K39uy4BdgVLGgDP8ACuvRapYxCYGGbALIh715T8cFRNViHmbnchsAcDg5rR1GxufD2tLcW7Osavk4Hykelcd8QbqXUb57yb5cuFVPQYPNAGl8O4U0TSdR8UXO0XCo1ppit/FMw+Z/oq8f8C9q52aYyQiRTn5iGOMnJPJ/n+dMGovcWVpE8amO2+WKMEgA8ZJ+p5q86xwufs/zLIpyG/hJ9PpQBXZSttGCF9eDyR/StDTkUsBEQVYDKnsKqLGdwy3AGN3rj/8AVWnp42qdwfcQCCOwoA9I+HNrElxLcxgrkbV4ztrvrhWJjMKgFRghun4VheCrV7bRYd6qGYZJx1rd3Bg3UqMEEUANlYFUxlDn5gR976VnuxzM0zYSPruH6Ci+u5Cyjqyn7xNct481RrLwdfSHcNy+UhzyS3GaAPFfGmrtrfiS8uy2Y93lx/7i8D/H8aw6XtSUAFFFFABRRRQAUUUUAFFFFABRRRQAtPUio6cvUUATpjae7HoK+k/hpoEXh3wTbPNt+23b+bOyjDJn7q/SvA/B1kmo+LNItH/1ctwgP0Byf5V9VzoI3IhG5V+Rlxn8aAI4X3xl8bGzjd2qKRm80Bm9cAryT9aikkwxhfa65wFJ4+tOXynaVVkyQN23POfWgB06sW8kqWBTg9h61h2WsRxapLpPmqkoAz61t282B5kmSCCNp7CvE9Y1B5vGc1yEG5JcLt6lR05oA9sCgEkAhWOA2OpquzA3CLsPmDluOnvWdo+rfarJTIQ8qD5l9PpVppEZ1Y8knLMx5I+lADpiqwbJJGRieEU/rTHZTFF5aksvXPVhVO7lEl597cMFf3YAqzBcN5UAaIl1ypbFAHG+O9KOq5mEKh9mQT1Fed6l4euLcg7GEJQHnnPrXvBtklkLTkEk9D0Ipt9o9tNDsCKq5w2fT2oA8fj0uLVfCF1bfI9xADLbtgAjb1X8RXmh5HTmvoa08NrZR3SQoVkyXUE8GvGPF2jvp1+06Li1nYlcdFPdfwoA56inEU2gAooooAKKKKACiiigAooooAKKKKACr+halNo2tWGpWpImtJ0nXDYyVIOM++MVQooA+s/GE/2lLDW9LQSWWpwLcxuy9Qw5H1rP0jU1nypjWNQMFsdfrWd8JNQfxR8HbnT5mL3Xh24/dqp5NvJkjP0YNUVnM9vfSRPllByoxjaD6etAHYW7BGkX5lUgMuOS9TMA8oLKu7AGztVHTJI7i33K+9l/jHcf5FTu2wNsG9/brjNAGP40sDfaXI0YVZVBJAPUV4P4wihFqsiOTJ521lPbg19HFBKsyMQy7d2H7DFfN3jFFEt0ycr9qIXHTGDQBV0pUaxUFRvZioyParEqFCpxwBuB75/zmrnhrT5L6K0SJlPXCjqT/nFdc/hZdNtJJHeKWZyDtz9zHagDk/IbyogMCPIY5b9KumZJUeYALCi4J6A4pl0kYLoGRnRctjoOazr+R7uNLeEuqcnbjqPp9aAPoDwtdxXnh20lhP7srtIB9Ki1bWLew2xpIC+B8vtXkXg3xXc6Tp91Y3Dv5AG+Pb1B5qG51afUZ1kaU4bILZyVFAHpt7qQchoWD+YBz2rzv4w6ozQ6dpgcdDPKo7Hoo/nXVaDApMUbsWZ8EDsa8q+Idz9q8Y6k27cqP5a4PA2gD+eaAOcpKKKACiiigAooooAKKKKACiiigAooooAKVetJSjigDrfhZ5P/AAn+jG5nEMYmyGJwCcHA/E19H3eoy2Fy8k0EnlBvmABOB718kQyvFIkkTbJI2Dqw6gjoa+nPAnxd0zW9Ngg1dIItTiTbJFKAFmI6up9T6UAa3ihYZ/Bl34o8PyLdLp43XUEZ+ZF7nFcx4H8UJ4ouTbaPZ3Nzd7d7JHGSV+p6CvSPhT8RbLXPH1/4Ph8NQWtrLbO5uk48wADIIxypzwc1Y8ZeMvDPwduYPDPgjw/bHWr8iV7eI7EjU9HdjknpwPbtQBh67a3Ok6RdT6hiLbGcp/EOK8K0e28+6nkUK2SWLOen0Ndz408Rat4huPsl1/rX+eQoMKo9AK89W4uU1KSxijZwrbsxjO4fQUAdBa300YaeNuIlwSB1+tdX4e1OO8ZWw25fu8cYrhLrUw0KwfY57YSJtJkQgn/Cum8EW7RuVlIMwXGCcAAf1oA6+a3BujOFJULj0xT41xIEjDKpG7mnXBG1k8x2GCwU9jUSEq6qshICjHGaALY3SxgqByMN/s1JMWktApAD9M561XCx7MecxLNkHjA+tTMvmW5baSe2Bjj1oAhRN+0O2WBK1xPxB8HG/s3ms8nf820n5Y2H8Q+tdvtXYCAzIemegPtV2H5rcxS7Wh6EDpj0IoA+RrmGSCeSGdSkyNhlYY5qAjmvYfjT4VMUQ1i0QqsGI5QRyyno34dK8gYYoAZRRRQAUUUUAFFFFABRRRQAUUUUAFLSUUAes/s3a8dM8cy6bK4Fpq9u1s6HgFhyv/s3513Pie1NhfyoEYyRyFBg4yo9/wAK8B8Maj/Y/iPTNRyQLW5jlJHoGBP6Zr6c+JVoJ7154Pm+0IssbA9CVHNAHL6JqUltfi2nZkjI3KwOBz2xXaIPPi3ICvow615NqBuYyjXCFZM7grDv7V1Nnrd1HHE+xVVxgqwwen8qAOuvXS10y8muHwUiYtxx09a+Y9buDcWbt/C0+QP++q9I+IPjGW/sG0m1ztmwH2HkDPOa8w1I7bAIWBJlztB6cGgDr/hxcWun2Fxe32MDKRgdenWk1DxFJqEbRxoVhJwzA4bGa53R50jskDoM5O09j7mmSI1zNhCPnOBtPT0oA1bdgoMCBZd4K784wOtR2DpBd7iSAqtgseo9KtpE1tpDu6YmJHl7hg/XFZERAyUIdnGH56HuR6UANldbgTMF65wq9etdF4csSwztHIJXbz09awRFLDGNxI8xhxj8K9G8LQEvGpiIijBLOvvQBq2CpY6dc39zv3QRl244HHArwK6ma5uZp5PvyuXb6k5r3Pxg/wBk8Da2VLYkIjXPcEgV4RQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSUUAOHWpBjoRkVDTsnrQB2fw/8f674E1dNR0OeOQhDG0FwpdCvpjqPwNakviRvE3ie/wDEV++y/mfzJec7RgAbPYYxivOlbnjINSwSMJ1wcFiFOB1BoA9atfEUMM7LcxmZ5CBGRyTk8fjXtPh5/BHwv8Lf8JP4jhX+0tQ5hgKh53x2VT29T0FeE+BNFN/4ksbe6Ybo3DKSMleaqfHzxBJrnxDuoBKXtNMRbOBR91Qo+Yj6mgD1e2/aB8FahqzRax4MePTpmw0xZZHUE/eK/wA8Guj8R+CLN7BvE3gy9hu9CmxJmJ87R3H4fpXyBx0OfrX01+ylq8reDvF2jXMrfZVAkjHXYzKQcZ9cUAW4pJD5LnY2fugmmwpHOMFwHDnBB4NXI4YYreI7Pn7SN1qFIStxujGxmOXD9vegCzuCOkXBBHLKOM05NsasyOzzE4I7EUxYwJGkIG09KsDmJUBLEHORwaAKbxsu1Q2CPvAnAFTW0bbgFHf5kB61GrrLJILkEn7owMEU22/cyl8szfdP9CaALmrwrq+iXenXablkiZApHJBH9DivkzUrR7C+uLSYYlgco3vg19b2snlXKzMrMG4JJ4B/wrwH426H/ZPjJ7lMGC/Xz129AehFAHnZpKc3Wm0AFFFFABRRRQAUUUUAFFFFABRRRQAV9S2moLrPw48O6hIQ9wtssTsPVBjn8RXy3X0B8KLlbn4Xpbb1LW91IuAMkbuf65oAv3ZFw0BZ1aQtgqV5Ixxj9aw9buI4onMCTTE/6vae+avX7/ZLi5eQyFjhBgfMB7Vx8OrTpriwyNHHEjfcA5Jz1/KgCymgpp1lNdXeFuZQWVn5xnPHtXnGplGhJQggyfKO4XnFereI/EemSQvC0jvIVwflxg4rzTxB9iFsBaNufzAeOy4NACabEXs4wG+ctxxnjHSteICONZIIvLniO0Z4yfWnaHos5061u1WQBuhB46Dr+dOvhCxc3SEuGwozgGgCnLfy3ZxfTEnGAMdPw71Db4jzHhSWPX2qXTbQTvLIM+TGMYUc5pZ4ik4cOgQDPC0AadrFFc3ltI0u1eAw6lTXqsEUVnHGls6sJCACRwa8k8M2Ml5qsbOrfZ8b9/Tpk/0r1DRYx5QcsCd/QnOB/SgDF+KzPB4ICsY1M0qgqp685/pXiFezfHRwmi6XCON87SYx6L/9evGKACiiigAooooAKKKKACiiigAooooAKKKWgBKK6zxH4KvND8IaD4hluIJrTVlJRYz80TD+E+vArk6ACiiigBwNLkj6g8UynAUAe8/D2wlfULO/mfbIY436/e4rxzxU2fE+rHB5u5OvX7xr174DXJvFtEn+YQXQg5OTtIyMfSvL/iPbG08ea/ARjZeSAfnmgDnRz0r3n9mxWj0TxRcIDz5ceQenBNeCr1x7V7/+zzhfAHit1G2QTxjzD0xt6UAdhot6NQ0yWCZCtzA5ZCe4z/niokyJ/wB7u3vxlu2ax7fUYrWS1kVkEmTvXOc1vxkXS7uM9SOvPagCUqkcUf8AfBxnHBNT2hE0RaFVBY4IB5HrUEqsLYKzjzEcbjjsaltFVmO0BXwRntn3oAa4SMSbHYSnglutRncQGAWN+p9DT95aeMSsTtPzccZqOYBpdmdrNnbzxQBYIPkjjY2MkIfvVxfxf0T+1/CD3ESM1xYHzQx/iX+IflXZWf7tmZ+CByBzuqyieZEba4izDOpQoOgB/wD10AfHhwR702tzxlpX9ieJ9R01QdkEpVM/3TyP51iGgBtFWY3thYzpJE7XTMhikDYVVGdwI754/Kq1ABRRRQAUUUUAFFLSUAFFFFABXrPwPvpTBrGnBwqYS4HHcZB/pXk1d98Hnddbv+phNoyuB7sMf1oA7vVg5+0X0c5KlsAnkD/Jrzy9lVPMupIzJcK3G3gHnr+les3FujeHfKlQorHAC+mc/wCFeU68YwrRgeXgnDA5PegCxo6aZqN5Lc3RUlsHyh6/5NZvj/S47C4ie2IFu4GxR24NZ8cDxxkkyBAMjHGP8ah1y7nnjRJtpVSNhxzjFAHQ6H4gu30aOwRlXYuFOOeBgD9Kz5Eb7R/pjtkjGOo96q6XDmzSVA6sTgFRnJFXREXt8O5WUDJD9Se5oA7rwxb2t9ZJbwtsOcqVGdv1q54p8NRWtpNfbVfyE3YVcB8f1rivDN++m3gNtInyOAyE8N611OreJ7y70+9t57I7JFwhzwKAOMtdUvLueASxmJFAVQvHBr1XQSVSILhoiOWXsK80sNJuzLHII3aJRk45zkf0r07wzMs0aLEmZFXaRjA/GgDi/j3IzXOjAYEJSRlUfVa8nr1b47KFl0X5VDbZc7enVa8qoASiiigAoopaAEooooAKKKKACilpKAClHXmgUUATy3VxLbxwSTyvBF9yNnJVM+g6Cq9dDr/hLU9C0PRNVvli+x6vEZrYo+44Bxhh2Nc/QAlFFLQAlOHWm0o60AewfAWWWKScp9z7XDg+hz/hXG/FeTzfiT4jcY+a8c10HwKukHiC609mxLcorQg9NyNk/jiuc+JVnd2XjrVk1CMxyyTGUFv4lPQj2oA5cDmvePgHOR8N/GlsnzSSTQbVx9ea8KijeaVY4I3kkbgKgJJ+gFe5/A2aTRdF1u2vLdoJrmRHCyKQQoHofegDcs/CEMlq8hkbz1UshPRT1rZ0LzI7YLOMsmVLDrn196raVNdtLqEtw+1C2IkYcVploVjtRk884B4B70ASTMBC4eMjdySDnn1pbKQyAxu2F7EDPPvSMZNrBlQlclBnqKSyYres0cWzpjA+83egAmkJwrIqxk5Vl9RUNzDskjdOVI4Uc7jVnaSZVkOVXLM2Mhc1GIy0OGfcqcMR6etADYspOrZAjAxwOntU5kCMJVBWTPBLdfpTG8wRlUVBGP4Sc7qWRJGRU2rv5ODjC+1AHjX7QOnrFrmm6jHgi6t9rtj7zKe/515Q3WvePjtbvJ4N02VV+W2uypJ6ruX19MivB2680ANpaSigB8SGR1QEAnuTgU00lLQAlFFFABRS0lABRS0UAJXd/CQH+2rsjJBh2ED3Yf4Vworv/hGwF5qCAAyOqBfzOaAPYNQ8tNJUnzFAUjjvxXjHiBd7eWITGfM3bjyWBzXseqSGGCTcnyY+XPHavI9clW51NTDHjPDOx43dcCgDLjKxqY5HIHfPI/8ArVn666zQLJFGViDhc++D/wDXrutC8Kz6lco8jjMuCYwPzP5Vp/GDR7TSPA1lHawRq5vkDyKOWxHJxQBt/DzwtpVz4LsZ5kZpZV3t9cA1u3XhPRblTALUJOy7QSM7fr+FRfDVo18DaSWO0iMDP/ARXSboYvMlkfcw+UccmgDx3xV4EvNOuv8ARNssTZKlcA/lXKJcXVrqEkfmNu4Dq4zgf0r6HkiiuYJFIVZkIYM4yRggnntXGnTtMXUbm8vVV58HeCuNoz6f560AcB4f1m6tb2VJZY/JcYVD6816N4bljn8zaVj2ruZVHevP7uzW51Uz6egEKsTyR+ldj4aTyoVdo3RjksQcigDlvjozSvpDxtvt1EihiMHccf4V5RXtPxntnk8MWd4V3/6Rgspxsyp614vigBKKWkoAKKKWgBKKKKACiiigAooooAKWkooAsTXdxPDDDNcTSQwjEaO5KoPQDtUFJRQAtJRRQAUopKWgC9o2pXGkara6jZttuLeQSIf6fj0r6Rez0XxxpWnazq+n/aITEPLJJVhk8rkdgc18xDofevoH4ReI21bwjDowCJLpvybXPDKxzmgDt103RdEhMeh6bbWgVdwkVAWOf9o81jT2iTXjysT9zJK87j25p/iOx1K6tWtdMuFgvZDjcBldtXNGMvlNYXNsfMCj99/CxoAroqrOhYO7hN5xxlvWrsIzZghVV3Y5Hf8ACs3Up/s+oBCwU7NhVTnmr1nMkskZYkIRjOf0+tAAEEbuZFYYONrHk/SrKAGZMBlDfeBbqMdB6UlzC8mAPM3jjJ/hHb61KgeHYWmRpF6hh938aAELY2gbu/0PoDTVUzMBuMcQG59x71NPKZLpVjG5FGTtXAB+tMJWRCx37c4YAcgf1oAqxoCwaHcJGOCpbt61NGqncCzM2fuevvT4VUzSeVF8mcDd1B9TT06AKVTaT5jn+lAHn/xvldPBawmRQGuE/d98c814A1e8/HZo18MwQoF3eeG34ySMV4Oe3rQAyilpKACiiigAooooAKKKKACiiigBa9S+CNoA2o3shXyxtjXI53DJ4/OvLa90+EFssHhSKV4mLSyO+GGAecDH5UAdB4tuF+xhwU3jgk85OD27VwunaJJqMhuEYmIc5K+9dd4o3yRCOLEJY5yeprf8L2cVtp42Sefx0YYGfT8KAMnwLcCSW8Jz50Z2Ko5xx2rG+PIYeErUux3m/TIIx/BJXR26xab41uoIz5a3sW9dq87scge+K5D42xtF4WtVEpeJLyNQGYs3Eb4ye/FAHW/DkF/AmknarBYgNuOTwP6V0CzRlirQsqq2wk9+Of8ACuf+G6lfBGlOpLjy1BA4x8oronWRVB2CRwSwUn7rHvQBIF3rIY9yY5GcEEdxXM/Yo9RhuYrhSJ1kDbs4IAznnuDxx0rpYlFvbhpOWc4+9368fjWfaorXN2+Cis+OTk59vagDy69sp9KnuYriFWjZsowzyK7PwBCt47204PKYHPfNaviXRl1OxXdGGli6AHBI9a0fhfbRwaj5bhN6ksAy5IoA5L4m6dJJ4F1OzON9mRNjHYHnH4A187dq+z/idoS6nod9ewwOC8b2115PGwMDg18YlSCQwwRwQaAEopKXNACUUUUAFFLSUAFFFFABRRRQAtJRRQAUUUtACUtJRQAoGaMc9qUU4LnpzQAqZBB4zmvbfgZp0EHhrVtUuWTzbqYW8ZPJG0ZP6mvF4IjI4wM8/SvR/hPBqU99e2llcOliiiSUAZ/eZwMD1x1FAHr+jiW7uzbNJudWCI687s1a8U3GqaPPLY/ZWMpwu4DgD1+teofDnwtHBbQXd3bqCihkJXBZvWu6udPs7ku1xaxOXHJI5NAHyKEk/tCO5yrsPlPbBrp7HfK8JKZO77vQZ7mvQvGnw0g8xr3ScxKp3MpJOa4xrcQA+ZIQ8X3lxg/hQBMD5ckpJHJ+Ytz+VVQkcjTAMREOST1zTdipIWYs8bfcHTFOAhCpKSFmx8uegoAnldd8PlyH5uW2jr9KYEkZJC25Sx5XPQU6Rkjji3g7MYGDzn2qJxJ8nVVY7Rk5P40AJIrRIi79rsMjHJalYS+YGZxzgFccZp6AqxCnc3Q4FZ/ifWLfRNHnu718LGvCL1ZvSgDy746+IFmnt9DtwAqYlnbrlugH4V5EevWr2s6jNquoz3twf3krE47AdhVA9aACikooAWjFJRQAuKSiigBaKSloAKO9JRQA4AkgAcmvpfwtaLp2h6Za79zxQLyei5Hf86+e/DFmuoeIbC2kJCPMN5Az8o5P6CvpJUMalLeMsdqj5hwTigDCv41vdfVWlZ3j52LwoxXZaWqfYkAjChPm4PrXFiGeLU5ZJpto3DftPT2rsLdw4JUk/KpQNwB70AUtTtludShmB+eEbowvALehrhfjgJh4RtPNb5TfIQD1H7uSvUVUI4kK844PTP4V5t8eTjwhaq3Lfb0OcdvLk4oA6D4cSj/hC9HHmbN0QXbjOSAOf0rqEAZt0YUsRkNyOtcx8OwH8DaMu7ZKsYZSDjsOPfg11KW4Rmco+W7K33frQA+SN5E/dgpt/iwCPfiqelpHFkTfM0jkgMKmlHy7I5fmU5OT96pcAoxYJtHQ0AVrlPLjaN2GT8vPb/61J4KlEHia1tbp12SZTIHcmnoizuw2n5TkHcASPSqE8TWmsRSojAeYrjB6cigD33T9Pty9/plygKzptcH+IdBXwB8VPDsvhX4ga1pMyMoinLR5/iRvmBHtzX6ElluLSx1NHRJdgOTzuHpXz/8AtleDftmjaZ4xsYfntcWt6QBny3P7tifZjt/4H7UAfJWKSn44zim0AJS0lFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSU4UAGM81LEhY4XnFNAyPp71et4lVdzEbRzn0oAmt4WJSGJGmnlIRIl5LMfujFfbXwM+GNr4J8M21xrUMTazcgPKGGfLY84+tcF+zD8KZoZo/GfiazRcoH0yCQ5Zc9ZWHYkdM/WvpKZS7q6t8y9ARkfWgBzycooB+bO3jpVG3gVmdnkl89Tggnp71eAP8RzzkcU0IA8jpw79SaACCUbhE7b2wTnHBFea/Efwg4ZtVtP3iJkyLj7nvXophUgiQgndmMIcUsDFpp7adQ0W3GCOxHOaAPm231G385V3Kwk53MPu/Wr4dFjAOJAQQuwdT61zPxHtX8DfEOfTp4v+JZen7TZvjggnlSf9k1qaPqkNy/kySKodchh2PX+VAGiY96OZgu9cEKOSpp1uoKRvKpYuCMA4IqiuqQGSULIAitsLNjj61xPjL4o6fp7PbaT/AKXOnG5eEB+tAHYeI9csfD9gbrUZWjQZAjXkyH0r598ceL5/FF7kIYLJPuQg/qfesrX9c1HXbs3GpXLytn5V/hT2A7VlnI4oACe3amUuaSgAooooAKKKKACiiigAoopaAEpR1pKWgDvfg9pbX3iGa6I+S0jzu7hmPGPwDV7gjSRxvsDOo/jY459TXD/CbTf7O8KCaQeXPfEyjnquML+Hf8a7iUTG2dDGyoecuc55oAyI4lN+xCiR5ByCOG5610qw/uYkEe3AxwcFqwIyIbqCRmXJxuQDHf1rrbnO0IkaeWSGLlsk/SgCujCSNYQhGzu38s15t8ein/CJWgUDJvkJb/tnJXpaO5DCJCx6jsAP8mvNfj0rL4QtQyBf9PT6/wCrkoA6H4dRyN4G0fgFQikbhnHA6V0/yIv7yQpt65GM1T+F3h/Vbr4faHPaWk7pJApV1AwOBWw1rNFK0Fzbt5wyCW4IPvQBAwBRhIEQdh6jpTJ3baqIFEY6jqcVZ8sRSHBCnphxkHmmpFtYE53Hq0S9vcUAVXVNoRnw7HhgMr+J/D86jvoIpbuJ2dy6fwj7rYFXJcKx3oGYcqp+XjPpUF1IwO+FSFB+7jJxQB658OrlNS8Km2kOWgYocnJUHkVrXukQa54avtE1dPMt7mF7WXnllIxkH154rzz4Y6qlrqxiz+6u+HU9mHQivV5soDwSegHrk4oA/Njxz4ZvfB3irUdB1JCJrSUqrlcCVP4ZByeGXB68dOornzX2R+1l8PDr/hpfF+nxk6ppce26RWyHtgSSenVCSe3BbrxXxzjgH1oAbSUtJQAUUUUAFFFFABRRRQAUUUUAFFFLQAUq0g9aevQZ7cmgCWBcuN3TvXrPwB8Ajx146hg1CLfo1goub0Ef6w/wRnp1P6CvL4ECDf1Xtivp79kz7fp2pXmnxRboLhfPunYH5DjCjPrQB9NKqRxrHEqpCgCqijAUDgAUUrdeKQUAB4HQnmmksRgqUHqOaV1DpgkjnII7GnE856UAMVxj5EYZHG4YFDRq2CwywA570rckAEnkE/hTuv1oA8t/aM8HP4p8Cm90+JX1bSH+1QnOCyfxrwOcj+VfNegreQwR3zljEi7tvbbivuYYwQRkHgg85FfO3xd8MT+H9fZ7CADSdQJcbRxE2OVHpQB8watrF/dXF8DcyRQSuf3Q9OwrDbCgDH/166vxXYJDeSPbq6MWw6MeT6HHpXLTJtb09qAIicYIpmee9Kc5pMUAJRS0lABRRRQAUUUUAFFLRQAlFFLQACr2iafJq2r2ljFndPIEJHYdz+Ayfwql0619Nfsw/CgX4TxPrcTfZiAYFbgMPb16c0Adx4U8KPFpSXD2zpYwwBIIyvzOFGAwz9KydcQQO6vCAGyVY17pcTG8v2tkBESDYqgYB968T8cRka/dQAkxoTuLcAGgDjLiL7QjiIFptuRx92uk8NsV0uBJMtcA4J9ar6RBb+Y7iUEKP4RnPvVyO7hhkYRqYlYZZscn6UAaly4hmA5Xec7QOD/jXmH7QGG8IWrmbc51BPkbqB5cldfc6wqKGhjlYf7RzXmnxn1CS98O248sRxi7Q4x1OySgD6o+Bblfg74WbPAslOR9OlZ3xrni0y003VBBuaWQwySBTg55XPv/AIVo/A7j4PeE8/8APkuOKj+N0ay+CrcOwC/bEJB+hoA8xh1mIxo0jxiRh/CT0+hqVrlZCXiuFxt6A8iuabTYZGMkU22McFd/I+lWra02kbFZX75bIUepoA1IA8kn7yWY7eQuDnP+e1SaiFCZYsjtj5gf6VXkllXCtOHwMAKv6iqUvnMWc5KnjAHA9/rQBvWRl8pJIbhVlhY7ZQK910HUF1XRLW7BDO6YkwejDgivm3w7IqwMGkILPkAjrXo/w+146Lqv2S7/AOPG8Iy27Ajfsfp60AetEKytHKA8bgqwI4I9K/Pz45/D+X4f+OrqzSJ10e6Yz6fKehjOCUz6qTt9eh71+gmMP2wcfjXB/Ezwnp3xE8N33h/UcxXaAy2dywBaGUDg/Q9CO4NAH577IgOZDn0AoKxZ4dsfSrmu6Ve6Fq93pWrQvBfWkhikjb+Ej+nOfxrPxQA/bF/fb8qNsWfvn8qjo4oAk2xf32/KjbF2kb/vn/69R0UASbYu8jf980bYv77flUdFAEm2L/no3/fNG2L/AJ6N/wB81HRQBJiP+835UBY/75/Ko/ypcUAOYID8pLD6Yqa2Us/XioVGcY6mr1spVckc4+XjPP0oA9Q+AHw+Xx14vm/tCKRtJ01fOmCcB5P4Uz+FfavhvSLLRtP8qytY7d3OZNoAJPvXm37LeiDRvheCdnn3dy8skirgk8DB9cdK9bU8EE5PU0AIGYseCcU7pn/Gqep6tZaXGr382wt91AMs30FVLbWJtQt2n0yyYxKeHn+XIzzj8KANgAn8KinuIIWVZXAY/jiuM1vxzEtzJbWUYdEJDPk8n61zU/iq5eZ1SKJGIzvyQPpzQB66RwDxg/rR/nmvONC8ezxBba+hWQAjEn3QBXVza80aRyi3R4GGcqck+1AG0Thskjb9Oc0y4ghuoTFeRRzRH+F1zmuej8Z2bzWSvbTpFcSeVuPJRz0z7V0smFYA9WOBQB84ftF/CTTotLm8SeHw1vMXHnW4OY2PqB26V8q3EZwSMBvSv0k8Xad/a3hTVbLaGd4HKDGTuAyPxyK/P3xXp6QzC5gQxQyk+ZFjmNxwfpyKAORAU/fO36CjbHt+82fpTpuWLDBGetRde9ADwsZB+c/lRtix98/981HRQBKVi4/eH8BSbYv77flUdH40AShYj1c/lQVi/v8A6VFxRxQBLsiz/rD+VG2EZ/eE/wDAai4pQMkYNAEoSL/nof8AvmhliUHDEkdOKZgcc5r1j4G/B3UfiJfLfXvmWXhyF/3tyQQ0+Dykfr3BboPrQAfAL4T3nxA16O8v4pIfDdo+6ecjAmYf8s19T6nsK+4ltoLSxi07TvLtYokCpGoxtQe3ak0bTLHQtLttM0e1itbK2QJFDGMAD+p75qSxtWRzLO/mXDcFvbPT8qAM7XbqHQNFur6aYK4Xamepb2r541N5Z5Z52uAzSHJeRuma7r4qeIY9U1hdOgZ2trInOOQ8nc8enIrgLpfnVpQSQoHyjHWgBbYNa2m5QxMhGSc4X6Uk6ISHVnMvTL9h/kVYkErwDf8AKoI2heWpLvzftBjGxcgfvGGT+VAFUswYF5FBz1rg/jIoHhW1JfLm9Xj0+ST+dehG0l8zlBKSOw6ntXnvxogmXw7azSkANdqMAf7D0AfRnwC8T2Fz8O/DmkTsYLqK1VFLfdfAHQ+tb/xmsp7vwLJ5CFmgnWRwB0Hc/rXgHgO+MPg7R1fcFWFMMAeDgHr+VfSvhi+HiTwQkjkSs8LQOTzuZRjP50AfPttAI41RldiU/wBYOc1chjjBYfNnaN289qs2azyBg25ZAdjK5xtI4OP85qcJG5ZPK2yqOHR8kf0NAFNrVVWZ4VGwjbvWoJNPSS3KrLsdTyCep9eK0zbZ3rsCt1yH24471C1o80qqTyoHIbGfoDQBR0yOW0RVu08wBsqwPX9K07mP7TbHcdr445wAfWpVh8ll37hjuMc06aMsh+7Irjhc4z7GgD0b4beKjc28ejazJtvI1CwTOf8AXL6Z9f510fiizk8lry3VjLEMsqnBOO9eISP5aqWQRsvQqcMD2IPrXpfgPx0l+V0vXsRTgbYbh2G2cdMH0b+dAHkHx/8ACNr4v0eTXLGBo/EVmg3r/wA/EIzkYH8Q7H2xXyr/AEr9AvFmmvY6lKDIsVvLzESBjHcZr5e+Knw4mXUZ9R0OJcSEvJbLwSe7L/hQB47SU90ZHKOpV1OCCMEGm0AJRS0lABRRRQAUUUUALSgZHahetSKoI5/nQA6JN3Tt3rtPAvhy913ULW3sLczXV1L5MORlVPd2H90dTVDw14a1LWL22gsrOa7e4ZVhhjXLOfcDoPc4FfaXwj+HWn+BIIbi+SGTxBcJ5bGLlYFPOxfT3PegDs/CGiQeGfDdjo1qyuLWMCRum9zyW/E5rY/SkAG58AZPLYpxoAo6lpdtqNxazXIybckgf3s+tU/Gl+uleFL2ddsaKuwY4Cg8Vs0y4ghuraW2uYlmt5V2OjDgigD55j1GJJ337SSm1eatvcwkg740kwBsOeTXZ+IvhfbPFPLpbxxIBuUPklcds14nNq80E0kH+taKXAcocce9AHZTXEc8AxIApHBbBI9ua9I+D+pLqGiXVtNmV7aTGXAPB9K8l8B6Je+MrvyFgaO0A8x5G+6Of55r6A8K+HrTwzpQsrLksd8kh/jb1oAsLo2nrcCZbdQwbcFzwD64q+xJyepowO9A69OPagBrltoaNgrAgnd0x3r5U+PnhlfD3jCaRrbOg61+9V0UFVl/jX2PcfWvqC8Z5UmtGt22lCd7NjP0rzrxnplpr+k3Ph3xLEXsplE1pcAZaFx0NAHxL4k0eTSboqXEts3+rkBzx6H3FYhFep+IrE+G9WuNH12F5oyp2OBxKnqpxjNYNz4Cvry0mv8Aw4BfWyHJt0bMyj2Xq38/agDiKKe6NHIySKySIcMrDBB9MUFDjPagBlJTttG0igBKSlxRQACl+vFT2lrPdSbbaF5Gzj5RnFe6/BL4caKLyPVPGGy62YaK0zlA2eN2Ov06fWgB3wB+BU/i1rfxB4theDw+fmht2JWS79D6qnv37ccn7CsLS00+whsdMghtrOBQkcMKhURR2AHSuestVvtZikj05Fhgj+T5RgAV0dpbiCFIk5A6nqSe9AEmM8c1xvxE8Trpto2lae5bUbhfm2n/AFa9/wAas+OfGll4Zg+zxsJ9YmUmKFedvu3oK8ZBe4up7mYl72YlnkY9GNAEc2PPESK4I5Ys3OT60+4jcWwUF/m52cYPpSCDdPmeUc4GVGQ1W5mEW0Jsz0+Y/wAvyoAo2CbWdpGcMpz9KmSCP7e8quXOOCwyFqJm33AcSjdt5Ud/wqxJKV+fG1eMk/z/AJ0ADPEkbBpcqOQVHIyee1ee/Gu3km+HcWoGNxF/asMIZh3MMxx+ldhKZ7y5gt7ZWZ3cKvHByauftS6LH4f+Cui2EeC66xE8rgfecwTZNAGH8P1f/hBtJ2u2x4FGMfdO39RXtnwYvxJpd/p5G2WCYSqAuAQRyR+Irxj4cD/iidH3SnJgUgE9OBXX6Nqk2h3y3ljL++UnchPyuvcUAbPxR0VtI1f+17XP2O65ZR/BLnn2wR+tcqhWRBIkeC33mUZyBXuun32meLdBZ1VZbaUFZYnHzI3fivIPGHhS68KymZFmuNObIjmQ8Rj+6w7fWgDJa4CqPNuIlQnAOQGJJwB9T0qJTicy4ndAAoAOaS2kikZTExR/4ldcg+4/z+VWFRS42MjOTgKoK5HpQBJDPKEGVZQOqMM8fWmuGZAyxjeCAFJ7etRPIsAEoRSM42+vYjFPfY6FsBsdgcnJ7YoAc07gBZCgyR8rDj65qjfxRSbY3GSeVKjjPrjPrUrSwpGVXKnnKON201HdqJ0IaR8feUL0X6e1AHRaJ4/nFn/YviaBruAACO64Lr9fWqGvwxsDLZ3JkjHzKp5//VXJ3hmVTEbcsV/jBwMU3TrwrKIiJYsjJO7gigDE8b+DIPFFobm2SK31RB8rhceYPRsdfY14VqFlcafdSW15E8U6HDKwr6fkhllLGCaLPX5xgrWB4g8Nxa3AYtSjjkkGcOoCkH60AfO+DSYru9V+Hd5Ax/s+cXHP3GG0/n0rktR02702cw39u8Mg6bhw30PegCjR3qUxgdGU9uDTSoxnp+NADMUoH0pyK0jqkSl3Y4CqMkn2FdXaeCb1I47jWmXToW+YRSEec49l7fj+VAHNWlvLdS+VbxtLIecKpPHrXrHwt+F+peJrtP7MjSWRSPNu5UPkQ/Q4+Y+wrs/hV8M9PvoEvdVkl03S3wfKLfvrgD+8fT6V73a+ItLs7SPStFthbWFuoRVC4FAEfhPwhonw/tvK0i3judeuEAlu5cb3P17L7Cu3srcogeQK1y4zIy+voK5nSFl1K7ZvKKxj+IDOPxrL+MHxCtvAWg+XY7JtYnxHbwZyUz/GR3+negC18SPiHZeEIWtbZDeay6gx268hM92Pb6d61vh7rF9r/hW3vdWiWK+YkSIBjHPHHbivJ/APhS4gtU1vxS3mapqLbxHLksoPOT7816Ta2UsUEh06XDnBY46+lAHYd8UdR7VFbNKLJHvTGrBfmbPFVotZ0ua8S0iv4HuWyVQN1xQBeK70dWOA6lenrXjs/wALbYalqMRvJnjWPej5AJY9q9kZGHb9aYOGzkgYxigDnvAXh+Lw34fhhGw3EoBkdB19BXRA80ZLfWnBDkA9/egBvJ45FZHi3W08O+HLzUmieWSNP3cS8MzHgVV1fxAsM9xZ23ySx8bgc7j7Vwl19pu79pdQmkPmHaoJOwfh60AVPgl8TLrX7u60TxePJ1EyM9pJJwJV/ucn7wr0XxbosVzZSPHgMEIAPQV5vdeCNK1O2M9oXt7+P5klQ/xA9RU/hr4j3GlXg8NfEBsNKCttqC8B1xwHHr70Ac/4t8Ox69oMtjfWqefEC0D8bkb2OOleE6BLqvhLxMk0AlWaN8bACxfnpgcGve/F+t21jbSW4kFzknYyHqOxzXmGnQtqeqQo0rRyzvwoILKfYmgD1hNL8CfFrS1/4STSl03WigH2qECKbOO5HDfRsivKfHP7NXiXSRLdeE7mHXrD7yx5EVwFxnoTtb8Dk+lepr4UeCCCV4mhu4lyvPL+54rq/BOqajZErLllH3t5OCKAPhXUrC80m+az1ayubG8QAtDcRNG656ZVgD05quI1dgsWXJ4AXqa/SrUtN0PxXpiJqun2WqWTHcq3MKyANjGRkcH3FeYeIf2evCV1K134bD6Net/CGMkR/wCAscjt0P4UAfHFv4Z1CZNzKkSjGdx5A9a6C28GW0Co8t0tzNwfLAwv4969S8aeB9e8FII7y2jls25+3W53KfqD0PtXNWqwuGkJEkR+8wHJP9KAKvhrT9R1Gc29jFbW9kpClhHtP5g817l4N0fyjHFCDNOxC7EUkY9/SvMNEvYre5VZ4/KC42he4969G0/xtcWURi0uIWoKgmZV3M3vQB7bbx2uhaWHvJLe1jAzI2cLn+tcD4n+Jxk8y18MxnPIa8nXA/4AP615pqus3GsyGXULiWU7uskg2r9BmksmM6eZIvmDp07UAWbLTy7yXl5dzT3kxLSSseTz3q3HKJnEcBACcEqM5/Oq17c+QmyNCGfgBjnilgULGm6Zic4BH+frQBOsJE22WViegCjbT3Z3LIkQVh8u9uePXNUERJ7hhHJI7BuwIx71MbeY7IVbBHX5s5oAVYAFDO5LY5AqrdvbRhTI80XTJI6e31p+x1bO4yXDnbHFEclifavT/h/4BazWPUvEaRS3x5S2PKwjtu9TQBD8NPBwDW+s3xfcfmgRv4h2Y+leWfth+J4b3RbPQrQLItrfrNcTA9JPLkG0fgTmvVPif48k022ew8PSIbgjbLcAZCf7K44z1r5l+L9oYvCFvPIxeWW+Qs56n93JQB2Pw+u1j8GaPGcZMC5Ixnp0FdIssLpImXUt8u5gOa5L4fy48F6YVUOY4wM7cEHaD1xzXRRyb3gZyWfccKwoA0vDHiK48L6oLyKbdbOdstuzcMPbnrXu2k6npfifSXa2aO4t5V2ywPjcvsw/rXzjfxvOHQlFIHJGP1FQ6Vf6vp5LaZPNb3AbIdWIGPf/AA5oA9M8TfDe+s5zP4bK3FuefIdsOg9AT1FcTKnL2t7A8U3SSJ4zE6j29+ten+BfiLDqFolt4kdLTUU4MgXEcnv7Hiuuu7TR/E1kY5Db3kfZ42G9PcEcigDwRMzRHdCzqDgEnaB/9eoEBhm8zamzkFm9u9a/j/wxqHhKRrtf9I0YkKLhOsXoJPTnHzVzEdysmQ8qvG6ngnkqehA+tAF5Wd95WVSM8+Xtqs0qg7WkfHUZrMhmK3hifauRlHUYGPQ4p8P+sXLiT5j88jd6AJ7iZDDvS5ExX7xAxj8KyZbuFZxEJ5FckHlNy/Wr8tgC0h3ooHzEsMA1Re38hi4aJmHZl4I9KAO18O6Z/bgMCQHdjmQc5NdnZeC7HaseoXRbBGFQ8+nSmfCa+tCyBAvzDayKc8+tehXWk+TKs1mAH9x1oA5LUfhRYXCFYb+VFA+VGUEfjXOX/wADk1WH7PqlzBJAv3AAflr2OEymMCYL5g64p/50AeF2X7L/AIMiYPf32pzt3SOVUT+RP61qzfs5/D1bZvI026eYdC95Jj8cGvYAK57X9Ruo5vJto3WMdGU8sfxoA8vuvCXhv4dIx0/SIIb4ptSYL5jHPucmvIdS003PiSXWtbSSV42BhLycE+mMdPzr6Gv7OTVIlD5lnQ7RgYI/OvKvinY2HhicNqUitdtzHCcknPfAoAl8O/aNbmSJi5LjG2MgKoNet2fg/wDsqxVpTlSBuPWvC/hd4qWz11JPsxjj6sz8Dr0A7V9I6j4x0ddHlnjuY5JniJWE9ScdKAOdu/FA0eOSCFxuA2xxw8s7HoMCqvh74fRPqQ8VeLE+0a5IP3MMhykHpx615T8K47u0+NTat4lkEFlKsiwLI+UWQ42+2etfTd9bC5zN5xMQXgKePrnvQBhWEbS6jE964uEG7cZFxtHarym3shcXl5LFDYRcq+do+nvVe/n0vR7dru4vgEVCxXdndjtivEvEHiubxfe3EjwSRWEbfuo2OAcd8dKAOi8d+PrrWZzZ6ZiDTwMlycs49TjoK4u0uZdNZHtrqLzt28P1I/GpbaMBWEcZUH0OS1VNS067uShjBVVOSxGTj6UAdT4T+JGqWniiyGs3rS6bcOLZlkI+XPR/zxXvrjaeOc9MV8ka1ZtLpeHkUSKdyO/QMpyD+Yr6r0idrnRtPncqzyQIzHsTgUAZfjrxJF4V8NXGoMoe5b91bR5+/Ieg/qa8G0rxXrlmCzX1xNPOS8hkJIUnqBmu3+Pd0r6noliSSIle4b27A15nOn9oW8Mq7xCpPOSM+9AGpDqeo296tzBcu53hzFKOGPXr2r1bwpc6f4y07z7XdbXsLZmgnP3T3I9q8gjTymVpWJKtgE88YpLi5NpJLLY3E9qz54yRux/SgD1XVPtOnXJSOJkU5YNzgivM/iZBLrkTw26RtcQESA85I7ge9drYeMJ7nw1a2uoMC8fDSOMkqenPrXL3N/bQ6w11a7XCApknOQaAPKrJrpSbdZvNU5Qq7DAH4mmXYliMT24kiuYgfmxwp+taPiTTLibxILzTYXaCR8MOij1zxxVrxAzWqAM24Mmdq88+maAPXPgj8V7XVkh8OeJ9kWpQoBBduuI7hfQnoGHv1r2SLTrS3ld44IwHOcdQSa+JrW3Y6M8V5boxd8xhSQR3HNexfCHx9quhwJYeLLpbjRgojhlJLTWx9GPVl9+ooA98iijhQJDGEQc4HQU/p3P4Uy3ngu7aO6tJUnt5BlZYzuVh+FS7WyeM/SgCvqFnDqdhNZ3QDxSrg8Dr6184/ELwxZaFqDrbukc24na4yCfXFfSrssMMksp2ogJJPAGK+XviXq41DxI4s4zPEpO6Tdk5/wAKAMFFkVU85N0efmaMfp9KvRSiRQkUYXIyAG6L6EVStWlu9s91IRADgqgwV9KuNbSSyqFkkwxBwMLn8aAH29q9zM8iKNkY2ncdq49/WtMSrEEhimVvkyAjng1SM4t0WCFihU4IIBJNW40HlOuY43J67CCfpQBFBA7zs7SPj+JiSc89uemf5VrAsG2xrAsIGAGPI9/1qG3tXADLgleocYLCraDYcF0VQPlyMnFAFJDMys29z1BQY4FamlaTLrF+tjptuzOeHbdgIMdWPbvVvwx4Zvdbk/0N3EQbPnP91ff3r1q3ttM8FeHp58KI413SyYAed/8A6/pQBk2Gj6D8P9MfVNQlDz4CmUrlv92Na5LxN48vtWhkgsreSys2OCCf3kgPcnsPaub8QaxeeJNW+2ahJiNQfJiTOIh6D36ZNU1ZixkQ5A5QjjOfbmgCveb2MaKjHviuB+OjMfCVmh4C3yDH/bOSvQXe53tiTIJ4VR+tee/HIMPCVoCuP9OXndnP7uTtQBs/D6Hf4S0qUSSktAI9gHAx3H5nP0FdKkaoVMuD25XvXnvhubx1o2jW9gfh34lnEIwH+yTr2x08o1qxa345X73wz8St/wBu03/xmgDrpogHZsDGP4VIp0Ow3G1CVGDw3PcVyD6746Ybf+FaeJRjp/o03H/kGkOueOt+5Php4lU4xxbT/wDxmgDuTCJnBO9YnXLkEAE5qOOK7sJll06/eG4U5Dqdpb69iK49fEXjsE5+GPiLB7C1nA/9FUw6543C7U+GHiUAZx/o85I/8g0Ae7+EvHsl0zaV4uijaKZdgu9oCNnja4/rXK+OPBQ8JXRvLG2mudEl5Vlbcbcnop7kHPB/CvM21/xwyMrfDDxEVYYI+zT4J9f9TXVeFvil8QtH0yXTtR+FfiPU7IjbGkkM6Min+HPknIoAga1gugHVT6jt+dH2RkhCqkTtknHHFYOo694rmvXmsvhT4qtoW5ELLM4T2U+QOPaqZ1TxpuLf8Kx8TD/thP8A/GaAOomtS8QJjw5GCpOF/nUaWqmMJMyzHnCqMAe2KwV1vxop3f8ACsPE5b1MM+Py8mmvrnjk4Zfhl4kVh/ELafP/AKKoA6nQpptCujPZNsVTkxsu7Fe5+CfFtjr0HkmXZfAAsjjbn6Zr5gbWPHRk3j4a+J/cG2mI/wDRNMi1PxvFOs8Xw18UxTr0dIJwR/5BoA+yypHB6ew6U0khT/jXzTovxY+KOm24hl+G3iK8AGAZ7ackfiIq2V+NnxBx8/we10kekdyP/aNAHvwB6cn60SxJJGTOqbF53P0Hvmvnu5+NPxIeIrbfCPWoXP8AEbe4f/2lXD+J/FvxM8Syr/afgLxQ1upz5EdtcKn5CLFAHt/xF+Kun+FoXs/DdnHq+rnoiNtijPqz9/oK+bb2213W9bn1rxNcPPqMzbiF4RR2CjsB0x+tPum8duVNv8OvENui9VWxnOfzipYZPHcUpk/4V34jZ8bRus5yF+g8ugCdYLgbHNqUQHmRmAP5VHBqV1a6iZi80sAwAAOPpT4bjxx5/mXHw28STAfdX7JONv8A5CpupT+Oru0WCP4ceIoQO4spz/7ToA9Bu3E8ETxxqy7QQD3z15q5YazqOnWht7e68u2YjcC2R+Feb2V948t4kjk+HXiWQLjH+iTr/wC0qtDV/HA6/DLxJ14xaz//ABmgDtLu9kuEaGad5t56YByK5m8sp9MjeXSI5SgfLxA9apHWPHIkWRfhl4iVwMbvss+cf9+qT+1/G+Ofhn4lGM4Itp8/+iaANzTPFGnXoAEgW4A5i3bWyK1Ybi4mjSRWZYpeXO4Mw9q8b1fw14xu9VlvrL4feJbN5DkgWM7c+ufLFdFoM3jvStOitW+Hniadkz+8NpOCff8A1RoA7fUrfztLKM6vnKgID/XvX0j4Yge28NaRA6urJbIrK3Xp3r5Q0vXfGNpqVndXfwr8SXcdtIJfLaCddxHqfJ/pXo5+N3jUsD/wpnxJxwBmfj/yWoAj+O2rp/wmUlhHKBcJZptAQnqeawJIxHYwxK/KoG+YZVq5nxdrHi/xD4wk14/CzxRBI8YjMJincce/kCov7Y8bh9yfDDxEqldpUW1xgj/v1QB1NvGvlo7RBkJPKnocfWqutXrRG3tLeJBJOcNnBOO+cniuZm1Tx+7Zj+HXiSNCfmVbSfB/8h1UMnjR7t55vhr4kkYtuQG1uPl/8h80Adq6stq0YGDjbtzx/OnW6iG2RFQRNj+I9T61yf8AaHjgsGf4a+JnIGBm1n/pFUrap43xtX4Z+JdvcNbztn/yFQB2u+4ELsWjkVAXbC4xgfrXNaZY2WrQSz3CSfvjwVcrkf7tZc2oeN5IZI1+GvidAylRi3n+XI7fuqxtMj+IWnxRQx+BvEzxJ2exnLH8fLoA7XTNKtLOaaOJi8S9FbIOa07d2eMxi1xuGAHYEH3NcjZ6n45gleST4a+JJi3razj/ANpVPFrPjePcD8MvEpU52j7PP8v0/c0Ad9oGq3/hxD/ZE7wKTl0J3Rn6L0H4VqSfEPxZcNm2eFU/65gD35615M+qePDKjJ8OPEihRgL9knP/ALSqUaz48xh/ht4lZeuDaz8f+QqAPSdZ8W+INXtTFezDyB1Ea4U/WuKNqBMojR5ZJTnKnj6VkTap45mGG+G/ikL/AHVgmA/9E10vhfxj4i0M72+DHiW8m6h5BMAPw+z0AWp9OuIYWlvlMKEDAjArN3GObCvulY4yOf8A9VaOu/EXxpqrOP8AhUPiK3hIwsaRTfL+P2esO31/xNCc/wDCofExbGCwScE/+QKAOjsVEaAXDqZM9do/Q10ujaIb5A7Fio5Rsfd+vrXF2vjTxPb4I+DfiUvjGSs3/wAj1r2fxQ8V2qFV+C/iZiTnJMw/9tqAOoj8NTzXAW2j3ENgMa6/RvAlpEEm1NFMowTH6/XFecRfGXxnCu2L4L+I1Ht5/wD8j0p+NPjfv8GvEn/kf/5HoA94toYoY0t7aNYolGFVRgCvHfibrH9ra99iWRBaWZIVd3O7uay1+NfjhckfBrxLnHH+v4/8l688vPEXja6u5Zz8LfEYMjFjm3nJ59/JoA7HAifMbBFC9F5J561FLN+6LKI9ueF28/WuM/tvxt3+GHiM8Y/49p//AIzQ2ueOSMf8Ky8RAYAH+iTZH/kGgDrFlULgw/KwwQW/lXnvxveBvC1n5KeW5vEyP72EfmtU6146OP8Ai2XiMgZ62s//AMarmvG9l468UWENq/w/8R2wilEgIsJ37EYx5Y9aAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan demonstrates the characteristic narrow coronal and wide sagittal diameter of the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14663=[""].join("\n");
var outline_f14_20_14663=null;
var title_f14_20_14664="Totally dystrophic onychomycosis";
var content_f14_20_14664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52455%7EDERM%2F72013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52455%7EDERM%2F72013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Totally dystrophic onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Total destruction of the nail with a ridged, hyperkeratotic nail bed is present in this patient with totally dystrophic onychomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Distal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail discoloration and subungual hyperkeratosis are present on the nail. The area immediately adjacent to the cuticle is not yet involved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14664=[""].join("\n");
var outline_f14_20_14664=null;
var title_f14_20_14665="Botulinum toxin for cosmetic indications: Treatment of specific sites";
var content_f14_20_14665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Botulinum toxin for cosmetic indications: Treatment of specific sites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Alastair Carruthers, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Jean Carruthers, MD, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14665/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/20/14665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1727983\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin is an injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. As a result of the ability of the toxin to inhibit neurotransmission between peripheral nerves and muscle tissue, botulinum toxin is an effective treatment for aesthetic and medical concerns that are exacerbated by muscle contraction. Although the US Food and Drug Administration&rsquo;s approval for the cosmetic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    remains limited to the treatment of glabellar lines, injectable botulinum toxin is widely used for other cosmetic indications.",
"   </p>",
"   <p>",
"    Examples of aesthetic concerns on the face and neck that can be improved with botulinum toxin will be reviewed here. The mechanism of action, available formulations, general use, and adverse effects of botulinum toxin in cosmetic settings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link\">",
"     \"Overview of botulinum toxin for cosmetic indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1727991\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human face is composed of a complex array of muscles that act in concert to create facial expressions and fulfill vital functions. Clinicians with a thorough understanding of facial anatomy and the functional relationships between muscles in the face and neck can safely use botulinum toxin to selectively weaken specific muscles, resulting in favorable cosmetic results. An illustration of normal facial musculature is provided (",
"    <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Appropriate candidates for botulinum toxin injection are patients with specific cosmetic concerns that can be alleviated by local muscle weakening and who lack contraindications to therapy. Patients between the ages of 30 and 50 years often achieve the most benefit from treatment; a greater proportion of rhytides in older patients may be due to loss of skin elasticity, which is not alleviated by botulinum toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link&amp;anchor=H522661#H522661\">",
"     \"Overview of botulinum toxin for cosmetic indications\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once patients have been determined to be good candidates for botulinum toxin therapy, care must be taken to ensure that the anatomic placement of injections is correct and that the doses used are appropriate based upon the treatment site and patient-specific characteristics (eg, anatomic variation, patient sex, and preferences regarding the magnitude of effect). Conservative treatment is preferred; improper placement of injections or an excessive dose of botulinum toxin can result in cosmetic or functional defects that persist for months.",
"   </p>",
"   <p>",
"    There are seven serotypes of botulinum toxin, two of which are available for clinical use (botulinum toxin type A and botulinum toxin type B). Botulinum toxin type A has been the most extensively studied for cosmetic indications and is the serotype that will be reviewed here. A variety of formulations of botulinum toxin type A are available for clinical use worldwide; the agents most commonly used in North America include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    (Botox, Botox Cosmetic),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    (Xeomin, Bocouture), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    (Dysport).",
"    <strong>",
"     Dosing is not interchangeable among the different formulations of botulinum toxin type A; all examples of doses provided below are specific to the form of botulinum toxin mentioned.",
"    </strong>",
"   </p>",
"   <p>",
"    The general principles of botulinum toxin therapy for cosmetic indications are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link\">",
"     \"Overview of botulinum toxin for cosmetic indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080941\">",
"    <span class=\"h1\">",
"     UPPER FACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles of movement and expression in the upper face include the frontalis, a large quadrilateral muscle that raises the eyebrows and skin over the root of the nose and draws the scalp forward, and the glabellar complex, a group of brow-associated muscles (corrugator supercilii, procerus, depressor supercilii, and orbicularis oculi muscles) used primarily for expression, especially anger, displeasure, or concern (",
"    <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hyperactivity or repetitive use of these muscles over time leads to the formation of skin lines that are exacerbated during muscle contraction (dynamic rhytides). Weakening of the responsible muscles with botulinum toxin can smooth vertical glabellar rhytides (related to the contraction of muscles in the glabellar complex), horizontal forehead rhytides (induced by frontalis muscle contraction), and periorbital lateral canthal rhytides (associated with contraction of the lateral orbicularis oculi muscle).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080948\">",
"    <span class=\"h2\">",
"     Glabellar rhytides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first report of the use of botulinum toxin for a cosmetic purpose focused on the treatment of glabellar rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/3\">",
"     3",
"    </a>",
"    ]. Glabellar rhytides remain the only cosmetic indications for botulinum toxin injections approved by the US Food and Drug Administration.",
"   </p>",
"   <p>",
"    Glabellar lines (",
"    <a class=\"graphic graphic_picture graphicRef71122 \" href=\"UTD.htm?4/3/4149\">",
"     picture 1",
"    </a>",
"    ) are caused by contraction of the corrugator supercilii and orbicularis oculi muscles, which move the brow medially, and the procerus and depressor supercilii muscles, which pull the brow inferiorly. The corrugator supercilii and procerus muscles are typically targeted during treatment. Beneficial effects from injection last for at least three months in most patients (",
"    <a class=\"graphic graphic_picture graphicRef64007 \" href=\"UTD.htm?2/28/2497\">",
"     picture 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the precise placement and number of injections is influenced by anatomical differences among patients, five injection sites are commonly used to weaken the brow depressors in the treatment of glabellar rhytides (",
"    <a class=\"graphic graphic_picture graphicRef65462 \" href=\"UTD.htm?38/39/39551\">",
"     picture 2B",
"    </a>",
"    ). All injections should be placed above the supraorbital rim to reduce the risk of upper eyelid ptosis. We typically inject into the corrugator supercilii muscles above the inner canthi bilaterally (30 percent of total dose per injection) followed by a third medial injection into the procerus (20 percent of total dose). We have found that the fourth and fifth injections are particularly beneficial in patients in whom the brow musculature leads to the appearance of horizontal eyebrows. These injections are placed 1 cm above the supraorbital rim in the mid-pupillary line (10 percent of total dose per injection), but can also be sited above the lateral canthus, above the bony rim.",
"   </p>",
"   <p>",
"    The standard doses recommended by the manufacturers of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA (Botox&reg; Cosmetic),",
"    <strong>",
"     inco",
"    </strong>",
"    botulinumtoxinA (Xeomin), and",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA (Dysport&reg;) are total doses 20 units, 20 units, and 50 units, respectively. However, the doses required to achieve desired results vary among patients due to differences in muscle mass or muscle activity. Males typically have greater muscle mass in the brow than females, and thus require higher doses to achieve satisfactory results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. We found the following results in two randomized dose-finding trials of 80 patients with glabellar rhytides:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A dose of 10 units of",
"      <strong>",
"       ona",
"      </strong>",
"      botulinumtoxinA was significantly less effective than 20, 30, or 40 units for the treatment of glabellar lines in women and was associated with a higher risk of relapse after four months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among male patients, doses of 40, 60, or 80 units of",
"      <strong>",
"       ona",
"      </strong>",
"      botulinumtoxinA were more effective and induced longer lasting benefit than treatment with 20 units [",
"      <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of adverse effects was similar among treatment groups in both trials. Treatment-related adverse effects were transient and mild to moderate, and included symptoms such as headache, symptoms of tension or heaviness in the forehead or brow, ptosis of the brow, and muscle spasms in the forehead.",
"   </p>",
"   <p>",
"    We typically initiate treatment with approximately 30 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA in women and 60 units in men, with subsequent increases in dose up to 50 or 100 units, respectively, based upon response. Lower initial doses (10 to 30 units for women and 20 to 40 units for men) have also been used for glabellar rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/6\">",
"     6",
"    </a>",
"    ]. For treatment with",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA, dose ranges of 30 to 70 units in women and 50 to 80 units in men have been suggested by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We have found that some patients benefit from a total of seven injections, with the additional two injections placed into the lateral orbicularis oculi muscle. These injections are performed above the lateral canthus or into the lateral end of the eyebrow, and can result in further reductions in the glabellar lines and improved positioning of the lateral brow. We typically use 4 to 8 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA in these sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080955\">",
"    <span class=\"h2\">",
"     Horizontal forehead rhytides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraction of the frontalis muscle eventually leads to the formation of horizontal creases in the forehead that are exacerbated during brow elevation (",
"    <a class=\"graphic graphic_picture graphicRef50165 \" href=\"UTD.htm?11/4/11334\">",
"     picture 3A",
"    </a>",
"    ). Botulinum toxin injection can reduce the appearance of these lines both during muscle contraction and at rest (",
"    <a class=\"graphic graphic_picture graphicRef71162 \" href=\"UTD.htm?26/60/27584\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/8\">",
"     8",
"    </a>",
"    ]. In our experience, the beneficial effects of treatment in this area typically last between three and six months.",
"   </p>",
"   <p>",
"    The goal of treatment is to weaken but not completely paralyze the frontalis muscle. Patients with favorable responses have reduced forehead rhytides and remain able to elevate the brows, albeit to a lesser extent. Treatment of the frontalis muscle for horizontal rhytides should always be performed in conjunction with treatment of the brow depressors. Weakening of the frontalis muscle without corresponding inhibition of the brow depressors can result in unopposed action of the depressors and a lowered, angry-looking brow.",
"   </p>",
"   <p>",
"    In a randomized, dose-finding trial that investigated the efficacy of treatment with",
"    <strong>",
"     ona",
"    </strong>",
"    boutlinumtoxinA in 59 women with moderate to severe forehead rhytides, total doses of 16, 32, and 48 units injected into the brow elevators and depressors (frontalis, procerus, and lateral orbicularis oculi muscles) (8, 16, and 24 units injected into the frontalis) all were effective for achieving improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/8\">",
"     8",
"    </a>",
"    ]. Of note, a statistically significant trend towards longer durations of response was observed with increasing doses. Sixteen weeks after treatment, wrinkle severity at maximum muscle contraction and repose had returned to baseline in 75, 58, and 35 percent of patients in the 16, 32, and 48 unit treatment groups, respectively. The number of adverse effects was similar among treatment groups and no serious adverse effects occurred during the course of the trial.",
"   </p>",
"   <p>",
"    As in the glabellar area, patient-specific characteristics influence botulinum toxin administration. We typically perform five injections in patients with broad foreheads (greater than 12 cm between the temporal fusion lines at the mid-brow) and four injections in patients with narrower foreheads, using a slightly lower total dose in the latter (",
"    <a class=\"graphic graphic_picture graphicRef75187 \" href=\"UTD.htm?35/8/35970\">",
"     picture 3B",
"    </a>",
"    ). The total amount of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxin we inject into the frontalis muscle usually ranges between 10 and 15 units. Treatment with 40 units (range 20 to 60 units) of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA in four injection sites has been utilized by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injections into the frontalis muscle must be placed carefully to avoid undesirable cosmetic results. We inject horizontally across the mid-forehead, approximately 2 to 3 cm above the eyebrows. The use of excessive doses or placement of injections too close to the brow can result in inhibition of facial expression and brow ptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080962\">",
"    <span class=\"h2\">",
"     Lateral canthal rhytides (crow's feet)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orbicularis oculi muscle complex plays an important role in eyelid closure. Contraction of the lateral fibers of the orbicularis oculi muscle also produces lines (also known as crow&rsquo;s feet) that radiate from the lateral canthus and are exacerbated during smiling (",
"    <a class=\"graphic graphic_picture graphicRef59956 \" href=\"UTD.htm?3/52/3908\">",
"     picture 5A",
"    </a>",
"    ). Botulinum toxin injection into this area can reduce the appearance of these rhytides (",
"    <a class=\"graphic graphic_picture graphicRef50135 \" href=\"UTD.htm?16/58/17312\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/1,9-11\">",
"     1,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dose-dependent effect of treatment has been reported. In one randomized trial in which 157 patients with moderate to severe lateral canthal rhytides were treated with varying doses of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA or placebo, the rates of treatment response remained significantly greater than placebo for longer periods of time with higher doses than with lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients treated with 12 or 18 units per side maintained significant improvement at maximal smile for at least 150 days after treatment, while the difference between placebo and treatment groups was no longer statistically significant in patients treated with 3 or 6 units at 60 or 150 days, respectively. The authors also commented that the magnitude of effect appeared to be higher in patients treated with the higher doses of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA.",
"   </p>",
"   <p>",
"    Because the orbicularis oculi muscle is diffusely innervated, multiple injections are required to weaken the muscle effectively. We typically inject 12 to 15 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per periocular region divided into two to four injection sites (",
"    <a class=\"graphic graphic_picture graphicRef54110 \" href=\"UTD.htm?12/42/12966\">",
"     picture 5B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A separate randomized trial of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA injections for lateral canthal rhytides found that doses of 15, 30, and 45 units per side were all effective, but detected a trend towards increased response rates with doses of 30 and 45 units [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/1\">",
"     1",
"    </a>",
"    ]. Use of a total dose of 30 units, divided into three injection points per side, has been suggested by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Inco",
"    </strong>",
"    botulinumtoxinA has also been used successfully for the treatment of periocular rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to minimize the risk for complications, all injections should be placed laterally to the lateral orbital rim and should be performed while the face is at rest (",
"    <a class=\"graphic graphic_picture graphicRef54110 \" href=\"UTD.htm?12/42/12966\">",
"     picture 5B",
"    </a>",
"    ). Medial injections or injections performed while the patient is smiling can result in eyelid droop and lip ptosis, respectively. Additionally, bruising is easily induced in the periorbital area; performing only a few superficial injections may reduce this risk. The application of manual pressure immediately after needle withdrawal may also reduce the occurrence of bruising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080969\">",
"    <span class=\"h2\">",
"     Brow lift",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brow ptosis (",
"    <a class=\"graphic graphic_picture graphicRef71706 \" href=\"UTD.htm?31/11/31920\">",
"     picture 7",
"    </a>",
"    ), a common feature of aging, can result in facial features at rest that mimic angry or scowling facial expressions. Because the shape and height of the eyebrow are controlled by the opposing action of the frontalis muscle, which elevates the brow, and the muscles that depress the brow, botulinum toxin can be used to improve brow ptosis.",
"   </p>",
"   <p>",
"    The nonsurgical brow lift with botulinum toxin was discovered serendipitously during treatment of glabellar frown lines, as it became evident that treated patients exhibited central and medial brow elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Elevation of the brow was initially thought to be due to inactivation of the medial depressor muscles. However, weakening of the lower medial frontalis muscle due to local diffusion of botulinum toxin may be responsible for improved resting tone in the rest of the frontalis musculature and subsequent brow elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, brow elevation is best seen when the glabellar area is treated without concurrent injection of frontalis muscle for horizontal forehead lines [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/14\">",
"     14",
"    </a>",
"    ]. Additionally, lateral eyebrow elevation has been reported after injections limited to the superolateral orbicularis oculi muscle (tail of the eyebrow) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080976\">",
"    <span class=\"h2\">",
"     Hypertrophic orbicularis oculi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin can be used to widen the ocular aperture by weakening the orbicularis oculi muscle complex, resulting in the appearance of a wider, rounder eye during smiling and at rest.",
"   </p>",
"   <p>",
"    We evaluated the use of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA for this indication in a randomized, split-face trial of 15 women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/17\">",
"     17",
"    </a>",
"    ]. Injection of 2 units of botulinum toxin subdermally into the lower eyelid, 3 mm below the ciliary margin, increased palpebral aperture in 40 percent of patients (average increase in palpebral aperture was 0.5 mm at rest and 1.3 mm at maximum smile). Similar injections on the contralateral side given in combination with 12 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA into the lateral orbital area enhanced the effect; increases in palpebral aperture occurred in 86 percent of patients (mean increase in palpebral aperture of 1.8 mm at rest and 2.9 mm at full smile). Both treatment regimens were well tolerated.",
"   </p>",
"   <p>",
"    Doses of more than 4 units of botulinum toxin in the lower eyelid are not recommended, due to an increased risk for adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/18\">",
"     18",
"    </a>",
"    ]. Poor candidates for this procedure include patients who respond poorly to a preinjection snap test (lower eyelid does not return quickly to the globe after abrupt release from manual downward retraction), patients who are susceptible to lower lid puffiness, patients who have had ablative laser resurfacing of the lower eyelid, or patients who have had lower lid blepharoplasty without concomitant canthopexy to support the normal eyelid position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080990\">",
"    <span class=\"h1\">",
"     MID-FACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin injection is useful for the treatment of several cosmetic concerns in the mid-facial area (",
"    <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"     figure 1",
"    </a>",
"    ). Injection into the upper nasalis muscle can soften wrinkling on the dorsal or lateral nose (also known as &ldquo;bunny lines&rdquo;) (",
"    <a class=\"graphic graphic_picture graphicRef52791 graphicRef64576 \" href=\"UTD.htm?7/12/7364\">",
"     picture 8A-B",
"    </a>",
"    ). We typically utilize 2 to 4 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per side (",
"    <a class=\"graphic graphic_picture graphicRef67933 \" href=\"UTD.htm?11/25/11665\">",
"     picture 9",
"    </a>",
"    ); doses of 10 to 20 units of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA have also been used for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we have found that injection of 5 to 10 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA into the lower nasalis is useful for reducing nostril flare. A small amount of",
"    <strong>",
"     ona",
"    </strong>",
"    butlinumtoxinA (2 to 3 units) into the depressor septi nasi muscle can also be used to slightly elevate the nasal tip.",
"   </p>",
"   <p>",
"    Prominent nasolabial folds, which extend from the lateral nasal alae to the skin lateral to the mouth (",
"    <a class=\"graphic graphic_picture graphicRef77905 \" href=\"UTD.htm?40/43/41648\">",
"     picture 10",
"    </a>",
"    ), are common cosmetic concerns that are often managed with injectable soft tissue fillers and laser resurfacing. Very small amounts of botulinum toxin (eg, 1 unit of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA) into each lip elevator complex above the nasofacial groove can collapse the upper nasolabial fold. However, this procedure may also vertically lengthen the upper lip, a feature associated with aging. Thus, we only consider this procedure in patients with naturally short upper lips. Treatment may be most effective when combined with soft tissue fillers or laser resurfacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link\">",
"     \"Ablative laser resurfacing for skin rejuvenation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be taken to select patients who are most likely to benefit cosmetically from this procedure and to avoid overtreatment; in our experience, the effects of botulinum toxin injection in this site can last for up to six months. Injections should not be placed directly into the nasolabial fold, as this may result in an asymmetrical smile or lip ptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1727944\">",
"    <span class=\"h1\">",
"     LOWER FACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin injection in the lower face is commonly performed (",
"    <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, injections must be given with caution. Improper injection in the perioral area may result in a flaccid cheek, an incompetent mouth, or an asymmetrical smile. In addition, perioral injections generally are not recommended for singers or musicians who play wind instruments, or others who require intense use of the perioral musculature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4080997\">",
"    <span class=\"h2\">",
"     Perioral lip rhytides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical perioral rhytides (",
"    <a class=\"graphic graphic_picture graphicRef50746 \" href=\"UTD.htm?29/48/30465\">",
"     picture 11A",
"    </a>",
"    ) are common cosmetic concerns that may be induced by repetitive contraction of the orbicularis oris muscle, volume loss, photodamage, and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/21\">",
"     21",
"    </a>",
"    ]. Cosmetic fillers or laser resurfacing are often used to treat perioral rhytides. However, the results of these procedures are temporary, and normal perioral animation likely contributes to the fairly rapid recurrence of rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The muscular contribution to perioral rhytides can be treated with the injection of small doses of botulinum toxin adjacent to the vermillion border in the areas of rhytides lateral to the Cupid&rsquo;s bow area of the lip. In a series of 18 patients treated with varying doses of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA, smoothing of perioral rhytides and favorable eversion of the upper lip were detected after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We often inject 2 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per lip quadrant, divided into two injection sites within each quadrant (",
"    <a class=\"graphic graphic_picture graphicRef62503 \" href=\"UTD.htm?40/63/41969\">",
"     picture 11B",
"    </a>",
"    ). Doses of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA suggested by other authors include 8 units divided into four injection points for the upper lip and 4 units divided into two injection points in the lower lip [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ]. Combination treatment with soft tissue fillers may result in improved efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant lip weakening is a risk of this procedure; when performed appropriately, some patients may have altered lip proprioception after treatment, but functions such as eating, drinking, and singing should not be affected. Placing injections superficially and utilizing conservative dosing may help to minimize the risks of treatment. However, avoidance of this procedure should be considered in patients who require intense use of the perioral musculature, such as professional singers and orators or musicians who play wind instruments.",
"   </p>",
"   <p>",
"    Injection of the oral commissures (corners of the lip) and the midline area should be avoided, as it may result in a drooping lateral lip and flattening of the Cupid&rsquo;s bow, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081004\">",
"    <span class=\"h2\">",
"     Mouth frown and melomental folds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The depressor anguli oris (DAO) muscle pulls the corner of the mouth downward in opposition to the action of the zygomaticus major and zygomaticus minor muscles. When the lateral corners of the mouth angle downward, the mouth takes on a frowning, unpleasant expression (",
"    <a class=\"graphic graphic_picture graphicRef76339 \" href=\"UTD.htm?33/8/33921\">",
"     picture 12",
"    </a>",
"    ). Botulinum toxin can be used to weaken the DAO and subtly reset muscular balance, allowing the zygomaticus to elevate the corners of the mouth and return them to a horizontal position. As with perioral lip rhytides, treatment of this area is not recommended in patients in whom intense use of the perioral musculature is essential (eg, professional singers and wind instrument musicians).",
"   </p>",
"   <p>",
"    In order to avoid unintentional weakening of the nearby depressor labii inferioris muscle during the treatment of mouth frown, we inject at the posterior margin of the DAO muscle, close to the anterior margin of the masseter. We usually utilize 2 to 3 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per side. Because the upward pull of the mentalis muscle also contributes to mouth frown, we perform additional 3 unit injections into each insertion point of the mentalis muscle (",
"    <a class=\"graphic graphic_picture graphicRef69123 \" href=\"UTD.htm?42/17/43281\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Contraction of the DAO muscle also exacerbates the melomental folds (also known as marionette lines) (",
"    <a class=\"graphic graphic_picture graphicRef55290 \" href=\"UTD.htm?33/55/34673\">",
"     picture 14",
"    </a>",
"    ). Melomental folds have traditionally been corrected with soft tissue filling agents, but the benefit from treatment is generally short-lived. Treatment with botulinum toxin may potentiate the results of soft tissue filler injections by reducing the mobility of the underlying musculature. In one split-face randomized trial of 22 patients with melomental folds, photographic assessments revealed longer durations of effect after combination therapy than after treatment with a filling agent alone (median time to return to baseline of 39 weeks versus 32.5 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the difference in the rate of relapse was not significant on live physician assessment. Additional studies are necessary to explore the value of combination therapy in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the treatment of melomental folds, we inject small amounts (2 to 5 units) of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA into the posterior margin of each DAO immediately above the mandible. Injections placed too anterior or too high can cause ipsilateral weakness of the depressor labii inferioris muscle, flattening of the lower lip contour, mouth incompetence, and reduced oral sphincter function.",
"   </p>",
"   <p>",
"    When using",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA for mouth frown or melomental folds, injections of 2.5 to 10 units per side into the lower one-third of the DAO have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081011\">",
"    <span class=\"h2\">",
"     Mental crease and peau d'orange chin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraction of the mentalis muscle produces a horizontal crease between the lower lip and the prominence of the chin (",
"    <a class=\"graphic graphic_picture graphicRef80633 \" href=\"UTD.htm?33/21/34128\">",
"     picture 15",
"    </a>",
"    ). In our experience, small doses of botulinum toxin injected into the mentalis muscle just anterior to the bony mentum on each side of the midline soften the indentation. We often use 3 to 5 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per side. Injection at the level of the mental crease should be avoided, as this can weaken the orbicularis oris muscle, creating mouth incompetence that can last for up to six months.",
"   </p>",
"   <p>",
"    In patients with local loss of dermal collagen and subcutaneous fat on the chin due to aging, contraction of the mentalis muscle can contribute to the appearance of multiple dimpled areas on the chin (peau d&rsquo;orange chin) (",
"    <a class=\"graphic graphic_picture graphicRef76750 \" href=\"UTD.htm?36/0/36864\">",
"     picture 16",
"    </a>",
"    ). Peau d&rsquo;orange chin can also occur during or after recovery from Bell&rsquo;s palsy. Botulinum toxin injection into the mentalis muscle at the prominence of the chin (distal to the orbicularis oris) with or without soft tissue fillers can ameliorate the peau d'orange chin (",
"    <a class=\"graphic graphic_picture graphicRef75756 \" href=\"UTD.htm?16/51/17215\">",
"     picture 17",
"    </a>",
"    ). We typically use 5 to 10 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA as one or two injections (",
"    <a class=\"graphic graphic_picture graphicRef57846 \" href=\"UTD.htm?39/36/40512\">",
"     picture 18",
"    </a>",
"    ). Doses of 5 to 20 units of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA divided into two injections into the mentalis muscle also have been used for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081018\">",
"    <span class=\"h2\">",
"     Masseteric hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive hypertrophy of the masseter muscle, caused by bruxism (teeth grinding), temporomandibular joint disorders, misaligned jaws, or genetic background, leads to a square appearance to the jaw that may or may not be asymmetrical. Historically, persistent masseteric hypertrophy was treated surgically.",
"   </p>",
"   <p>",
"    The efficacy of botulinum toxin injection for facial sculpting in patients with masseteric hypertrophy is supported by case reports and uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Botulinum injected into each masseter effectively sculpts the jawline, reducing muscle thickness by up to 50 percent for three to six months or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/30-33\">",
"     30-33",
"    </a>",
"    ] and easing symptoms of bruxism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Mean muscle size decreases over repeated treatments, allowing for smaller doses as treatment progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/35\">",
"     35",
"    </a>",
"    ]. The potential adverse effects of treatment include temporarily reduced bite strength, speech disturbances, muscle pain, facial asymmetry, and prominent zygoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H485525\">",
"    <span class=\"h2\">",
"     Gingival (gummy) smile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients find display of a significant portion of the upper gum during smiling undesirable. The terms &ldquo;gingival smile&rdquo; or &ldquo;gummy smile&rdquo; are used to describe exposure of more than 3 mm of the gum during smiling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/37\">",
"     37",
"    </a>",
"    ]. Surgical and orthodontic interventions have been used to manage this condition; botulinum toxin offers a nonsurgical treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injections of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxinA into the levator labii superioris alaeque nasi muscles, zygomaticus muscles, or both areas (dependent upon smile characteristics) resulted in a decrease in gum display in all 16 patients in one uncontrolled study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/37\">",
"     37",
"    </a>",
"    ]. Adverse effects of treatment were mild and included smile abnormalities in two patients that were corrected with subsequent injections. In a separate uncontrolled study of 30 patients, injection of 2.5 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA into overlapping points of the levator labii superioris alaeque nasi and levator labii superioris muscles and the overlapping points of the levator labii superioris and zygomaticus minor muscles (total of four injections) was effective for the treatment of gummy smile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/38\">",
"     38",
"    </a>",
"    ]. Treatment was generally well tolerated; reported adverse effects included pain at injection sites (four patients), headache (one patient), and dizziness (one patient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081025\">",
"    <span class=\"h1\">",
"     NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited on the use of botulinum toxin for cosmetic concerns in the neck, botulinum toxin appears to be beneficial for vertical platysmal bands in patients who do not desire or who are poor candidates for surgical intervention (platysmaplasty), or in whom residual platysmal bands remain after neck rejuvenation surgery. We have also used botulinum toxin for the treatment of patients with horizontal lines on the neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475150\">",
"    <span class=\"h2\">",
"     Platysmal bands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platysmal bands are vertical linear bands on the anterior neck that result from the separation and protrusion of the anterior edges of the platysma (",
"    <a class=\"graphic graphic_picture graphicRef56880 \" href=\"UTD.htm?28/58/29600\">",
"     picture 19A",
"    </a>",
"    ). Increased prominence of platysmal bands is associated with aging and is most evident during neck animation.",
"   </p>",
"   <p>",
"    Data on the efficacy of botulinum toxin for platysmal bands are limited to case series and reports of clinical experience (",
"    <a class=\"graphic graphic_picture graphicRef64533 \" href=\"UTD.htm?31/16/32015\">",
"     picture 19B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. In a series of 1500 patients treated with varying doses of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA for platysmal bands, the majority of patients achieved good to excellent results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/40\">",
"     40",
"    </a>",
"    ]. The greatest benefit appeared to occur in patients with platysma muscle flaccidity, horizontal neck rhytides, and skin laxity that were graded as mild to moderate; 99 percent of patients with mild versions of these features achieved good to excellent results.",
"   </p>",
"   <p>",
"    The most common adverse effect associated with the injection of platysmal bands is bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/40\">",
"     40",
"    </a>",
"    ]. Edema, erythema, muscle soreness, and neck discomfort may also occur. Neck weakness and dysphagia are rare adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a wide range of doses of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA has been utilized for the treatment of platysmal bands, we typically do not exceed 30 to 40 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA in the neck per session, due to our concern for the induction of neck weakness or dysphagia with higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/45\">",
"     45",
"    </a>",
"    ]. We often use 15 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per platysmal band, divided into three injection sites separated by 1 to 1.5 cm. Doses of 30 units of",
"    <strong>",
"     abo",
"    </strong>",
"    botulinumtoxin per platysmal band have been successfully utilized by some clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475157\">",
"    <span class=\"h2\">",
"     Horizontal neck lines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horizontal neck lines (",
"    <a class=\"graphic graphic_picture graphicRef69540 \" href=\"UTD.htm?7/12/7360\">",
"     picture 20A",
"    </a>",
"    ) are caused by the attachments of superficial musculoaponeurotic system, a fibromuscular layer that envelops and connects muscles face and neck. We have had some success with softening the appearance of horizontal neck bands with botulinum toxin injection. We typically inject 10 to 20 units of",
"    <strong>",
"     ona",
"    </strong>",
"    botulinumtoxinA per session divided into multiple intradermal injections of 1 to 2 units spaced at 2 to 3 cm intervals (",
"    <a class=\"graphic graphic_picture graphicRef81469 \" href=\"UTD.htm?35/41/36511\">",
"     picture 20B",
"    </a>",
"    ). Injection beneath the dermis should be avoided to prevent bleeding from perforating veins and weakening of the underlying musculature utilized for swallowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475164\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botulinum toxin is a neuromodulator that temporarily weakens muscles through inhibition of neurotransmission between peripheral nerves and muscle tissue. Botulinum toxin type A injections have been used extensively for the treatment of cosmetic concerns that are exacerbated by muscular activity. (See",
"      <a class=\"local\" href=\"#H1727983\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1727991\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thorough knowledge of muscular anatomy and function is crucial for the effective and safe administration of botulinum toxin (",
"      <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"       figure 1",
"      </a>",
"      ). Improper administration can result in cosmetic disfigurement and functional deficits that persist for months. Dosing of botulinum toxin is not interchangeable among the different formulations. (See",
"      <a class=\"local\" href=\"#H1727991\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulinum toxin injection into the muscles that depress the brow results in improvements in glabellar rhytides (",
"      <a class=\"graphic graphic_picture graphicRef64007 graphicRef65462 \" href=\"UTD.htm?13/55/14197\">",
"       picture 2A-B",
"      </a>",
"      ). Males typically require higher doses of botulinum toxin due to greater muscle mass in this area. All injections should be placed above the supraorbital rim to reduce the risk of upper eyelid ptosis. (See",
"      <a class=\"local\" href=\"#H4080948\">",
"       'Glabellar rhytides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful treatment of horizontal forehead rhytides requires simultaneous treatment of the frontalis muscle and the brow depressors (",
"      <a class=\"graphic graphic_picture graphicRef50165 graphicRef75187 \" href=\"UTD.htm?14/49/15129\">",
"       picture 3A-B",
"      </a>",
"      ). Injections placed too low in the frontalis muscle may result in brow ptosis. (See",
"      <a class=\"local\" href=\"#H4080955\">",
"       'Horizontal forehead rhytides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lateral canthal rhytides (crow&rsquo;s feet) can be successfully treated with multiple injections into the lateral orbicularis oculi muscle (",
"      <a class=\"graphic graphic_picture graphicRef59956 graphicRef54110 \" href=\"UTD.htm?30/9/30873\">",
"       picture 5A-B",
"      </a>",
"      ). Injections should be placed lateral to the orbital rim and should be performed while the facial musculature is at rest. (See",
"      <a class=\"local\" href=\"#H4080962\">",
"       'Lateral canthal rhytides (crow's feet)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulinum toxin injection can lead to improvement in perioral rhytides and melomental folds (marionette lines), particularly when used in combination with other rejuvenation procedures (",
"      <a class=\"graphic graphic_picture graphicRef50746 graphicRef62503 \" href=\"UTD.htm?5/32/5639\">",
"       picture 11A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef55290 \" href=\"UTD.htm?33/55/34673\">",
"       picture 14",
"      </a>",
"      ). Lip weakening is a risk of injection into the perioral area; avoidance of injection in this location should be considered in musicians who play wind instruments and others who require intense use of the perioral musculature. (See",
"      <a class=\"local\" href=\"#H4080997\">",
"       'Perioral lip rhytides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to facial treatment, botulinum toxin can be used to improve the appearance of the neck. Patients with platysmal bands or horizontal neck lines may benefit from treatment (",
"      <a class=\"graphic graphic_picture graphicRef56880 graphicRef64533 \" href=\"UTD.htm?32/52/33604\">",
"       picture 19A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69540 graphicRef81469 \" href=\"UTD.htm?12/63/13300\">",
"       picture 20A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4081025\">",
"       'Neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/1\">",
"      Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/2\">",
"      Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/3\">",
"      Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/4\">",
"      Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/5\">",
"      Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/6\">",
"      Carruthers JD, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies--consensus recommendations. Plast Reconstr Surg 2008; 121:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/7\">",
"      Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010; 9:s7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/8\">",
"      Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/9\">",
"      Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/10\">",
"      Prager W, Wissm&uuml;ller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg 2010; 36 Suppl 4:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/11\">",
"      Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/12\">",
"      Frankel AS, Kamer FM. Chemical browlift. Arch Otolaryngol Head Neck Surg 1998; 124:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/13\">",
"      Huilgol SC, Carruthers A, Carruthers JD. Raising eyebrows with botulinum toxin. Dermatol Surg 1999; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/14\">",
"      Carruthers A, Carruthers J. Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 2007; 33:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/15\">",
"      Maas CS, Kim EJ. Temporal brow lift using botulinum toxin A: an update. Plast Reconstr Surg 2003; 112:109S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/16\">",
"      Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg 2000; 105:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/17\">",
"      Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/18\">",
"      Flynn TC, Carruthers JA, Carruthers JA, Clark RE 2nd. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg 2003; 29:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/19\">",
"      Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003; 29:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/20\">",
"      Carruthers J, Carruthers A. BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg 2001; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/21\">",
"      Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/22\">",
"      Fagien S. Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping. Plast Reconstr Surg 2003; 112:6S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/23\">",
"      Semchyshyn N, Sengelmann RD. Botulinum toxin A treatment of perioral rhytides. Dermatol Surg 2003; 29:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/24\">",
"      Carruthers A, Carruthers J, Monheit GD, et al. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg 2010; 36 Suppl 4:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/25\">",
"      Carruthers J, Carruthers A, Monheit GD, Davis PG. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes. Dermatol Surg 2010; 36 Suppl 4:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/26\">",
"      Custis T, Beynet D, Carranza D, et al. Comparison of treatment of melomental fold rhytides with cross-linked hyaluronic acid combined with onabotulinumtoxina and cross-linked hyaluronic acid alone. Dermatol Surg 2010; 36 Suppl 3:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/27\">",
"      Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plast Surg 2007; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/28\">",
"      Ba�� B, Ozan B, Mu��lali M, Celebi N. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases. Med Oral Patol Oral Cir Bucal 2010; 15:e649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/29\">",
"      Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, et al. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2009; :CD007510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/30\">",
"      To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001; 54:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/31\">",
"      von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001; 107:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/32\">",
"      Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003; 29:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/33\">",
"      Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J 2008; 28:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/34\">",
"      Chikhani L, Dichamp J. [Bruxism, temporo-mandibular dysfunction and botulinum toxin]. Ann Readapt Med Phys 2003; 46:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/35\">",
"      Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg 2010; 125:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/36\">",
"      Kim KS, Byun YS, Kim YJ, Kim ST. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle. Dermatol Surg 2009; 35:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/37\">",
"      Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol 2010; 63:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/38\">",
"      Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J Orthod Dentofacial Orthop 2008; 133:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/39\">",
"      Polo M. Botulinum toxin type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop 2005; 127:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/40\">",
"      Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999; 103:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/41\">",
"      Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 1999; 103:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/42\">",
"      Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998; 24:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/43\">",
"      Brandt FS, Boker A. Botulinum toxin for the treatment of neck lines and neck bands. Dermatol Clin 2004; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/44\">",
"      Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14665/abstract/45\">",
"      Carruthers J, Carruthers A. Practical cosmetic Botox techniques. J Cutan Med Surg 1999; 3 Suppl 4:S49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16222 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14665=[""].join("\n");
var outline_f14_20_14665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H475164\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1727983\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1727991\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4080941\">",
"      UPPER FACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080948\">",
"      Glabellar rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080955\">",
"      Horizontal forehead rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080962\">",
"      Lateral canthal rhytides (crow's feet)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080969\">",
"      Brow lift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080976\">",
"      Hypertrophic orbicularis oculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4080990\">",
"      MID-FACE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1727944\">",
"      LOWER FACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4080997\">",
"      Perioral lip rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081004\">",
"      Mouth frown and melomental folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081011\">",
"      Mental crease and peau d'orange chin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081018\">",
"      Masseteric hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H485525\">",
"      Gingival (gummy) smile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4081025\">",
"      NECK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H475150\">",
"      Platysmal bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H475157\">",
"      Horizontal neck lines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475164\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16222|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/46/3815\" title=\"figure 1\">",
"      Muscles of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16222|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4149\" title=\"picture 1\">",
"      Glabellar rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/28/2497\" title=\"picture 2A\">",
"      Botulinum toxin injection - glabellar rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/39/39551\" title=\"picture 2B\">",
"      Glabellar line botulinum toxin injection sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/4/11334\" title=\"picture 3A\">",
"      Horizontal forehead rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/8/35970\" title=\"picture 3B\">",
"      Forehead rhytides botulinum toxin injection sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/60/27584\" title=\"picture 4\">",
"      Botulinum toxin injection forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/52/3908\" title=\"picture 5A\">",
"      Lateral canthal rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/42/12966\" title=\"picture 5B\">",
"      Lateral canthal rhytides botulinum toxin injection sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/58/17312\" title=\"picture 6\">",
"      Botulinum toxin injection - lateral canthal rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/11/31920\" title=\"picture 7\">",
"      Brow ptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/18/8481\" title=\"picture 8A\">",
"      Bunny lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/22/39278\" title=\"picture 8B\">",
"      Bunny lines lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/25/11665\" title=\"picture 9\">",
"      Bunny line botulinum toxin injection sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/43/41648\" title=\"picture 10\">",
"      Nasolabial folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/48/30465\" title=\"picture 11A\">",
"      Perioral rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/63/41969\" title=\"picture 11B\">",
"      Botulinum toxin injection sites for perioral rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/8/33921\" title=\"picture 12\">",
"      Mouth frown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/17/43281\" title=\"picture 13\">",
"      Botulinum toxin injection sites for mouth frown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/55/34673\" title=\"picture 14\">",
"      Melomental folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/21/34128\" title=\"picture 15\">",
"      Mental crease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/0/36864\" title=\"picture 16\">",
"      Peau d orange chin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/51/17215\" title=\"picture 17\">",
"      Botulinum toxin injection - chin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/36/40512\" title=\"picture 18\">",
"      Botulinum toxin injection sites for peau d orange chin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/58/29600\" title=\"picture 19A\">",
"      Botulinum toxin - platysmal bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/16/32015\" title=\"picture 19B\">",
"      Botulinum toxin injection sites for platysmal bands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/12/7360\" title=\"picture 20A\">",
"      Horizontal neck lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/41/36511\" title=\"picture 20B\">",
"      Botulinum toxin injection sites for horizontal neck lines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=related_link\">",
"      Ablative laser resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=related_link\">",
"      Injectable soft tissue fillers: Overview of clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=related_link\">",
"      Injectable soft tissue fillers: Permanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=related_link\">",
"      Injectable soft tissue fillers: Semipermanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=related_link\">",
"      Overview of botulinum toxin for cosmetic indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14666="Prostate biopsy";
var content_f14_20_14666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prostate biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Brian M Benway, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Gerald L Andriole, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/20/14666/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/20/14666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate biopsy is a minimally invasive procedure in which tissue samples are obtained from the prostate gland for the purpose of detecting the presence of cancer. The procedure is typically performed by an urologist in the office setting.",
"   </p>",
"   <p>",
"    Prostate biopsy techniques and periprocedural management will be reviewed here. Screening for prostate cancer and the clinical presentation, diagnosis, and staging of prostate cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although generally considered safe, prostate biopsy is an invasive procedure and recommendations for its use are limited to a defined subset of patients. However, the definition of this subset continues to evolve. Screening the general population for prostate cancer remains a controversial issue, since improved patient outcomes have not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. When screening is warranted, it is accomplished with digital rectal examination and measurement of serum prostate specific antigen (PSA) levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on digital rectal examination that may indicate a need for prostate biopsy include the presence of nodules, induration, or asymmetry. Repeat biopsies may be indicated for inadequate initial sampling or continued high clinical suspicion for prostate cancer after initial negative biopsy based upon rising PSA levels or a variety of other PSA-based parameters (eg, PSA velocity, PSA density). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H38#H38\">",
"     \"Screening for prostate cancer\", section on 'Repeat biopsies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for prostate cancer\", section on 'Improving the accuracy of PSA'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2924776\">",
"     'Need for repeat biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROSTATE ANATOMY AND IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prostate gland is a firm walnut-shaped structure located at the base of the urinary bladder; the apex is caudal and the base cranial. The prostate is composed of both glandular and muscular tissue. Secretions from the prostate, vas deferens, and seminal vesicle empty into the prostatic urethra (ie, section of the urethra that traverses the prostate); each of these structures contributes to the composition of the semen (",
"    <a class=\"graphic graphic_figure graphicRef54803 \" href=\"UTD.htm?19/35/20023\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Zones of the prostate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prostate gland is divided into three general zones (",
"    <a class=\"graphic graphic_figure graphicRef57801 \" href=\"UTD.htm?30/9/30866\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral &ndash; Approximately 70 percent of the prostate gland is contained within the peripheral zone, and the majority of prostate cancers originate within this zone.",
"     </li>",
"     <li>",
"      Central &ndash; The central zone comprises 25 percent of the volume of the normal prostate. The stroma of the prostate gland is the densest in this zone. Approximately 5 percent of prostate cancers originate within the central zone.",
"     </li>",
"     <li>",
"      Transition &ndash; The transition zone comprises 5 percent of the normal volume of the prostate and is the site of benign prostatic hyperplasia. Approximately 10 percent of cancers originate within the transition zone",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although prostate biopsy can be performed with digital guidance, the accuracy of prostate biopsy is greatly improved with transrectal ultrasound (TRUS) guidance, which is easy to perform and generally well-tolerated (",
"    <a class=\"graphic graphic_picture graphicRef66789 \" href=\"UTD.htm?21/26/21921\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Two-dimensional TRUS is typically used for measuring prostate volume. Prostate height and width are measured in a longitudinal plane, and then the probe orientation is switched on the machine to measure length and width in the transverse plane. The software contains an algorithm that reliably computes prostate volume based upon these measurements. Three-dimensional TRUS can provide additional information about the location and extent of prostate cancer (eg, seminal vesicle invasion, extension through the prostatic capsule); however, three-dimensional imaging devices are not widely available in the office setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultrasonographic characteristics of the prostate and its surrounding tissues correlate with underlying prostate histology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/10\">",
"     10",
"    </a>",
"    ]. The normal prostate has a uniform echotexture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76064 \" href=\"UTD.htm?12/45/13008\">",
"     image 1",
"    </a>",
"    ). The prostate should be visualized in both the sagittal and longitudinal planes and the overall echotexture of the prostate and seminal vesicles are assessed and correlated with the findings of digital rectal exam. Hypoechoic lesions and those that correlate with an abnormality on digital rectal ultrasound have a higher likelihood of harboring cancer; however, up to one-third of prostate cancers are isoechoic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Hyperechoic areas represent areas of prostatic calcification (ie, stones).",
"   </p>",
"   <p>",
"    Prostate measurements are recorded. Prostate volume and PSA density (PSA",
"    <span class=\"nowrap\">",
"     level/prostate",
"    </span>",
"    volume) are easily determined and may aid in determining the sample size on prostate biopsy. Patients with larger prostates (eg, those with benign prostatic hypertrophy) may have higher than normal PSA levels due to increased prostate volume [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link&amp;anchor=H10#H10\">",
"     \"Measurement of prostate specific antigen\", section on 'Benign prostatic hyperplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link&amp;anchor=H16#H16\">",
"     \"Measurement of prostate specific antigen\", section on 'PSA density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is the primary modality used to image the prostate gland and guide biopsy, but other imaging modalities, including computed tomography (CT) and magnetic resonance imaging (MRI), may be needed in selected circumstances. As examples, transrectal ultrasonography (TRUS) of the prostate gland may not be possible for patients with prior rectal resection or those with severe anal stenosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Anatomic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) can be used in guiding prostate biopsy through a transperineal approach, although the technique is still undergoing standardization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Guided biopsy under endorectal coil MRI has been advocated as an alternative for men with persistently elevated serum PSA and negative TRUS-guided biopsies. Endorectal coil MRI provides superior resolution of prostate anatomy and potential targets for biopsy (especially anterior tumors) compared with other noninvasive imaging procedures. However, one trial found that needle placement may subject to error [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnosis of prostate cancer\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANATOMIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main anatomic approaches to prostate biopsy are transrectal and transperineal. The transurethral approach can also be used to resect the prostate for pathologic analysis. Transrectal ultrasound-guided approaches are typically performed in the office setting, while CT or MRI-guided transperineal procedures are most often performed in an outpatient hospital setting by a radiologist alone or in conjunction with an urologist. Staging biopsy can be performed with any approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/8,9,21,22\">",
"     8,9,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transrectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transrectal ultrasound (TRUS)-guided biopsy is the most common approach for prostate sampling and is described in detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'TRUS Biopsy procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To improve the diagnostic accuracy of TRUS-guided biopsy, a template-guided TRUS technique (TargetScan&reg;) has been introduced to ensure more uniformly distributed sampling of the prostate. This technique, which is not widely available, is highly accurate in providing localizing information that correlates highly with abnormal pathologic findings identified in radical prostatectomy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transperineal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transperineal approach to the prostate gland can be used to perform a prostate biopsy in men who cannot undergo a transrectal procedure (eg, those with a prior abdominoperineal resection or severe anal stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Transperineal biopsy can be performed with ultrasound, CT, or MR guidance and the overall diagnostic accuracy appears to be equivalent to that of TRUS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stereotactic prostate biopsy using a standard brachytherapy plate can be performed via a transperineal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/25\">",
"     25",
"    </a>",
"    ]. This enhanced localization augments the biopsy technique and may prove especially beneficial for repeat biopsy when premalignant pathology is found on initial biopsy. (See",
"    <a class=\"local\" href=\"#H2924776\">",
"     'Need for repeat biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240595\">",
"    <span class=\"h2\">",
"     Transurethral resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom suspicion for prostate cancer remains high in spite of aggressive negative sampling, transurethral resection of the prostate (TURP) can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a retrospective review, TURP detected cancer in 35 of 375 patients (9.3 percent) with one prior negative biopsy and in 6 of 35 patients with two prior negative biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are understandably anxious and may benefit from administration of an anxiolytic prior to undergoing prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of bacteriuria or an indwelling catheter at the time of biopsy increases the risk of postbiopsy urinary tract infection and other infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Thus, a urinalysis should be performed prior to biopsy. If the urinary findings are suspicious for urinary tract infection (eg, pyuria with or without bacteriuria), the biopsy is postponed, urine cultures obtained, and a short course (five to seven days) of culture-appropriate antibiotics is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Genitourinary surgery'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics are recommended prior to prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The main effect of antibiotic prophylaxis is a lowered incidence of postbiopsy bacteriuria. Although not all patients with bacteriuria are symptomatic, all patients who develop infectious complications following rectal biopsy are bacteriuric.",
"   </p>",
"   <p>",
"    Prostate biopsy performed without antibiotic prophylaxis is associated with increased rates of bacteriuria (8 to 44 percent) and bacteremia (16 to 70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/29,30,36-44\">",
"     29,30,36-44",
"    </a>",
"    ]. Major infectious complications, such as sepsis, Fournier gangrene, and urinary tract infection requiring hospital admission have been reported in patients who did not receive prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/40\">",
"     40",
"    </a>",
"    ]. A metaanalysis of nine trials found that antibiotic administration prior to prostate biopsy significantly reduces the risk of bacteriuria (risk ratio [RR] 0.25, 95% CI, 0.15-0.42), bacteremia (RR 0.67, 95% CI 0.49-0.92), fever (RR 0.39, 95% CI 0.23-0.64), urinary tract infection (RR 0.37, 95% CI 0.22-0.62), and the need for hospitalization (RR 0.13, 95% CI 0.03-0.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selection of antibiotics is based upon coverage of skin and urinary tract flora which includes both gram-positive and gram-negative organisms. In the metaanalysis, there were no significant differences between several classes of antibiotics for the outcomes tested (bacteriuria, bacteremia, fever and the need for hospitalization). No differences were identified for oral versus systemic (intravenous or intramuscular) antibiotics. Seven trials reported a one-day versus a three-day course of antibiotics. A single day of antibiotics was associated with an increased risk of bacteriuria (RR 1.98, 95% CI 1.18-3.33) but there were no significant differences in the incidences of more important clinical outcomes. The data were insufficient to recommend multiple doses or a longer course of treatment.",
"   </p>",
"   <p>",
"    We prefer to use a single dose of an oral fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 to 750 mg) one hour prior to prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Other antibiotic classes that are equally effective include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam,",
"    </span>",
"    cephalosporins and aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/37,47\">",
"     37,47",
"    </a>",
"    ]. The development of resistant organisms is becoming an increasing problem and may lead to a need to alter the antibiotic regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The increase in the incidence of antibiotic-resistant infections following prostate biopsy is felt to be responsible for the increasing need for hospitalization after prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For procedures in which ultrasonography is performed, sterile ultrasound transmission gel should be used. Outbreaks of infection due to resistant organisms have been traced to contaminated gel from multiple-use tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rectal cleansing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal cleansing with enemas, suppositories, or iodine lavage is not necessary as long as appropriate antibiotic prophylaxis is provided [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/52\">",
"     52",
"    </a>",
"    ]. The potential benefit of enema administration or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    lavage prior to prostate biopsy is based upon the supposition that these measures will reduce infectious complication due to transmission of bacteria from the rectal vault [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/53\">",
"     53",
"    </a>",
"    ]. In patients who have received antibiotic prophylaxis, a clinically significant benefit from rectal cleansing has not been found. In addition to lack of benefit, improper or incomplete enema technique may hinder visualization and increase patient discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review identified four trials evaluating rectal preparation and found no significant differences for any outcome (bacteriuria, bacteremia, fever, urinary tract infection, the need for hospitalization) for prophylactic antibiotics versus enema [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/35\">",
"     35",
"    </a>",
"    ]. A decreased risk of bacteremia, however, was found for the use of &lsquo;antibiotic plus enema&rsquo; versus &lsquo;antibiotic&rsquo; (relative risk 0.25, 95% CI 0.08-0.75). However, the authors noted that the quality of the evidence for these comparisons was overall poor because of the limited number of studies, patients and events. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy/anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men undergoing prostate biopsy are middle-aged or elderly with significant cardiovascular risk factors. Many of these patients are being treated with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and some with an anticoagulant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The decision to withhold or continue these agents requires clinical judgment weighing the risk of a significant cardiovascular event to the risk of bleeding. The general principles of perioperative",
"    <span class=\"nowrap\">",
"     antiplatelet/anticoagulation",
"    </span>",
"    management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H25#H25\">",
"     \"Perioperative medication management\", section on 'Medications affecting hemostasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The continued use of",
"    <span class=\"nowrap\">",
"     antiplatelet/anticoagulation",
"    </span>",
"    therapy at the time of prostate biopsy may not be associated with an increase in risk for local bleeding complications that are sufficiently severe to require further intervention (ie, endoscopy, surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. For patients on low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , two trials did not identify an increased risk of clinically significant hemorrhage in patients who remained on aspirin in the periprocedural period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In the larger of these trials, 200 men on low-dose aspirin were randomly assigned to continue low-dose aspirin, discontinue low-dose aspirin, or replace low-dose aspirin with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH); systematic 10-core prostate biopsy was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/56\">",
"     56",
"    </a>",
"    ]. No severe bleeding complications occurred in any of the patients, although the duration of minor bleeding was significantly longer in the patients on low-dose aspirin or LMWH.",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, a prospective observational study evaluating the risk of bleeding in patients undergoing sextant biopsy identified no significant differences in the incidence or severity of rectal bleeding, hematuria, or hematospermia in the patients who remained on warfarin compared with those who were not anticoagulated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients undergoing extended core or saturation prostate biopsy, the risk of bleeding for patients on low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has not been established. In addition, the risk of bleeding with other antiplatelet medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , has not been extensively evaluated. In the absence of sufficient evidence, these agents are typically withheld. In a survey that included 297 respondents, greater than 90 percent of urologists discontinued clopidogrel prior to prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TRUS BIOPSY PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transrectal ultrasound-guided (TRUS) biopsy is most often performed in the office setting with local analgesia on a patient who is awake. A preprocedure transrectal ultrasound and digital rectal examination are performed to confirm previous findings. The patient is placed in a lateral decubitus position, with the knees and hips flexed 90-degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/5\">",
"     5",
"    </a>",
"    ]. With appropriate lubrication, the ultrasound probe (",
"    <a class=\"graphic graphic_figure graphicRef75517 \" href=\"UTD.htm?43/11/44208\">",
"     figure 3",
"    </a>",
"    ) is gently inserted into the rectum. The application of a topical perianal or intrarectal anesthetic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    gel, glyceryl trinitrate ointment) may reduce pain related to probe insertion, but does not provide adequate analgesia for prostate biopsy. The prostate is imaged and prostate volume determined. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some clinicians feel that prostate biopsy is generally well-tolerated without analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/60\">",
"     60",
"    </a>",
"    ], multiple randomized trials have found that local anesthetic administration significantly reduces patient discomfort during prostate biopsy, especially in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/61-67\">",
"     61-67",
"    </a>",
"    ]. In addition, the administration of local analgesia does not appear to increase the rate of complications following prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/65,68\">",
"     65,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, pain control with local anesthesia has been achieved with the administration of plain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (1% or 2%) injected at the junction between the seminal vesicle and the prostate (peri-prostatic nerve block), which is easily seen with ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/69\">",
"     69",
"    </a>",
"    ]. Some investigators have found that the addition of intraprostatic lidocaine administration may provide better analgesia than peri-prostatic blockade alone, despite the risk of increased pain at the time of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Randomized trials have found that topical anesthetic agents alone are not sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/62-65,73\">",
"     62-65,73",
"    </a>",
"    ]. Among the available topical anesthetics, no significant differences regarding pain of probe insertion have been found. Glyceryl trinitrate ointment may be useful in some patients due to its ability to relax the anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sampling methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sampling schemes have been developed in an effort to improve the accuracy of prostate biopsy in the detection of cancer. Systematic prostate sampling is performed and is augmented by additional sampling of any abnormal areas (eg, hypoechoic) found on ultrasound or rectal examination [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Prostate anatomy and imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Six core",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early era of transrectal ultrasound (TRUS)-guided biopsy, a six-core, or sextant biopsy technique, was commonly employed taking one sample each from the apex, base, and mid-prostate on each side [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/76\">",
"     76",
"    </a>",
"    ]. However, this method misses about 30 percent of clinically significant cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. Because of these data, sextant biopsy has been largely replaced by extended core biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18433713\">",
"    <span class=\"h3\">",
"     Extended core",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extended core biopsy is performed by obtaining five to seven evenly-distributed specimens from each side, sampling more extensively from the lateral aspects of the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/79,81-83\">",
"     79,81-83",
"    </a>",
"    ]. A systematic review of 87 studies found that an increasing number of cores were significantly associated with increased detection of prostate cancer. Schemes with 12 core samples that took additional laterally directed cores detected 31 percent more cancers (95% CI 25-37) compared to a six-core approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another method extends initial biopsy to include 18 cores. This approach may be more effective in detecting premalignant pathology, but the overall success in diagnosing true cancer appears to be equivalent to a 12 core biopsy, except for those patients with prostate volume exceeding 55 cm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with six core biopsy, extended core biopsy is not associated with an increased risk of infection, abdominal or rectal pain, or voiding difficulties. However, rectal bleeding and hematospermia may be more frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The number of cores taken at biopsy may be tailored to prostate volume. In a study of 500 men, for example, an eight core prostate biopsy was sufficient for the detection of cancer in men whose prostate volume was less than 35 cm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/86\">",
"     86",
"    </a>",
"    ]. Age may also play an important role in guiding the number of core samples obtained. The Vienna nomogram, developed from a large European cohort of men with a serum PSA between 2 to 10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    suggested that at a given prostate volume, fewer cores are needed as age increases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to repeat prostate biopsy are discussed below. (See",
"    <a class=\"local\" href=\"#H2924776\">",
"     'Need for repeat biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Saturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saturation biopsy involves extensive sampling of the prostate, obtaining up to 24 core samples. Saturation techniques do not provide increased cancer detection when utilized for first-time biopsy, but may provide increased sensitivity when repeat biopsies are performed and should be considered after two negative TRUS-biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2924776\">",
"     'Need for repeat biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Saturation biopsy is typically performed in the outpatient setting under regional or general anesthesia due to concerns for pain control, and because it is associated with a 12 percent incidence of morbidity (eg, severe hematuria) requiring hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106424\">",
"    <span class=\"h3\">",
"     Limited value of FNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) smears lack architectural detail and are",
"    <strong>",
"     not",
"    </strong>",
"    considered sufficiently accurate to definitively diagnose prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/91\">",
"     91",
"    </a>",
"    ]. As a result, some premalignant histology cannot be adequately distinguished from prostate cancer, even by an experienced pathologist. FNA of the prostate gland is particularly unreliable in men who have undergone hormonal or radiation therapy. However, FNA may have a role in confirming advanced prostate cancer or metastatic disease in men with a prior history of localized cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Procedure and specimen handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 18 gauge spring-loaded core biopsy needle is advanced into the rectum adjacent to the ultrasound probe and guided into the prostate to obtain core samples, one at a time. Extended core biopsy is indicated for most patients, although a smaller number of cores may be adequate for patients with low prostate volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18433713\">",
"     'Extended core'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The specimen is removed from the biopsy gun and examined. The core should measure 0.1 cm in diameter and 1.0 to 1.5 cm in length. Inadequate cores require resampling from the same region. The specimens are labeled according to location before being sent for pathologic analysis.",
"   </p>",
"   <p>",
"    For stereotactic biopsy, the cores are coded to a grid pinpointing both their &ldquo;x&rdquo; and &ldquo;y&rdquo; location and their depth. Using newer systematic transrectal biopsy approaches (ie, TargetScan&reg; biopsy), a machine that controls the ultrasound probe records the precise position of the probe for each biopsy site, allowing precise localization of prostate cancer and reproducible positioning on repeat biopsy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Postprocedure instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postprocedural pain is not common and generally responds to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Nonsteroidal antiinflammatory drugs (NSAIDs) are not commonly used because of the concern for bleeding. However, this concern may not be warranted. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Antiplatelet therapy/anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients may resume their normal activities, including sexual intercourse, following the procedure. Routine use of stool softeners after uncomplicated TRUS-guided biopsy is not necessary, although patients who develop prostatitis or urinary tract obstruction may benefit from their use. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Infection'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H30\">",
"     'Urinary obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients are alerted to seek medical attention if they develop fever, or difficulty voiding. A small amount of bright red blood per rectum is expected, but persistent rectal bleeding warrants immediate evaluation. Similar considerations apply to moderate hematuria, which should also be self-limited. Hematospermia is common after prostate biopsy, and discoloration of the semen may persist for weeks. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under most circumstances (providing the patient does not experience any complications), initial follow-up to discuss the pathology results will be over the phone. The results of the biopsy may be positive or negative for cancer, or equivocal with respect to adequacy or histology. The interpretation of prostate biopsy histology is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H5#H5\">",
"     \"Interpretation of prostate biopsy\", section on 'Histologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men with adequate and negative extended biopsies should resume follow-up with their primary care clinician. In contrast, face-to-face consultation with an appropriate specialist is warranted in patients with positive or suspicious pathology. Patients with a diagnosis of prostate cancer will require additional staging prior to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2924776\">",
"    <span class=\"h2\">",
"     Need for repeat biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the acceptable diagnostic yield of prostate biopsy, it remains a sampling technique with a substantial potential for misdiagnosis. When interpreting the pathology report, it should be determined whether an appropriate number of core samples were of adequate quality; a core sample is not adequate if prostatic glands or stroma are not visualized. Patients with a negative biopsy who have undergone inadequate (ie, low number of quality cores) or prior limited (ie, sextant) biopsy are at increased risk for a missed diagnosis of prostate cancer and should be considered for repeat biopsy. Another indication for repeat biopsy is the finding of abnormal but nonmalignant pathology (eg, small acinar proliferation).",
"   </p>",
"   <p>",
"    The potential yield of a repeat biopsy was illustrated by a series of 10,400 men undergoing prostate biopsy in the linked Surveillance, Epidemiology and End Results (SEER) and Medicare database [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/92\">",
"     92",
"    </a>",
"    ]. The overall proportion of repeat biopsies found to contain prostate cancer was 32 percent and increased with age: 26 percent at 65 to 69 years; 31 percent at 70 to 74 years; 35 percent at 75 to 79 years; and 41 percent at &ge;80 years. Among men whose first recorded biopsy did not detect prostate cancer, the need to have a subsequent biopsy was 12 percent at one year and 38 percent at five years.",
"   </p>",
"   <p>",
"    Similar findings were noted in other studies as prostate cancer was detected in up to 39 percent of patients at second biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/93-97\">",
"     93-97",
"    </a>",
"    ]. Further biopsies were not likely to be helpful since the likelihood of detecting cancer was only to 10 to 17 percent on a third biopsy and 4 to 14 percent on a fourth biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/93,95\">",
"     93,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2921326\">",
"    <span class=\"h3\">",
"     Abnormal histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of abnormal nonmalignant histology (ie, atypical small acinar proliferation or high grade prostate intraepithelial neoplasia) in the initial biopsy specimen warrants repeat prostate biopsy in many patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89085844\">",
"    <span class=\"h4\">",
"     Atypical small acinar proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical small acinar proliferation (ASAP) is defined as highly suspicious glandular architecture that is insufficient for the diagnosis of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/98\">",
"     98",
"    </a>",
"    ]. ASAP is detected in approximately 1 to 5 percent of extended core biopsies, and is associated with a 40 to 59 percent risk of cancer detection on repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. The number of cores positive for ASAP, serum PSA levels, and PSA density do not appear to influence the subsequent detection of prostate cancer in patients with ASAP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/98,100\">",
"     98,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although prostatic inflammation may be confused with ASAP, the independently predictive value of ASAP indicates that all patients with this diagnosis at the time of initial biopsy should undergo repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/98,100\">",
"     98,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89085851\">",
"    <span class=\"h4\">",
"     Prostatic intraepithelial neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic intraepithelial neoplasia (PIN) is defined pathologically as abnormal cellular change within the prostatic ductal cells consistent with prostate cancer, but without invasion of the basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/101\">",
"     101",
"    </a>",
"    ]. PIN is divided into low-grade and high-grade subtypes. When discovered, high-grade PIN is often multifocal (defined as high-grade PIN found on at least four biopsy cores), and typically located within the peripheral zone of the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. A majority of pathologists will not comment on findings of low-grade PIN, as evidence suggests that this histologic pattern is not premalignant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-grade PIN is a premalignant condition and is noted in 2 to 22 percent of extended core prostate biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/99,104,106\">",
"     99,104,106",
"    </a>",
"    ]. However, it is commonly overdiagnosed. In a prospective study, for example, high-grade PIN was confused with benign pathology in nearly 25 percent of biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/107\">",
"     107",
"    </a>",
"    ]. Thus, the diagnosis of PIN should be confirmed by an experienced urologic pathologist. A more detailed discussion of the histology of high-grade PIN is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26937?source=see_link&amp;anchor=H2#H2\">",
"     \"Precancerous lesions of the prostate: Pathology and clinical implications\", section on 'Prostatic intraepithelial neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need to perform a repeat biopsy in patients with high-grade PIN is controversial. Although many studies have suggested a strong correlation between high-grade PIN and the detection of prostate cancer on subsequent biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/104,108,109\">",
"     104,108,109",
"    </a>",
"    ], other studies have found that the rate of cancer detection after a diagnosis of high-grade PIN does not differ significantly from those with benign pathology at the time of initial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/99,100,110\">",
"     99,100,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multifocal high-grade PIN is associated with a 50 to 80 percent rate of cancer detection on repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/104,111,112\">",
"     104,111,112",
"    </a>",
"    ]. Thus, patients with multifocal high-grade PIN should undergo early repeat biopsy, whereas patients with focal high grade PIN may not require repeat biopsy unless PSA velocity is elevated or there are changes in the digital rectal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H38#H38\">",
"     \"Screening for prostate cancer\", section on 'Repeat biopsies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2921333\">",
"    <span class=\"h3\">",
"     Rising PSA after biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat biopsy may be considered in patients with a rising serum PSA after negative initial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/108\">",
"     108",
"    </a>",
"    ]. In these patients, PSA velocity, free-to-total PSA, and urinary prostate cancer gene-3 (PCA3) have shown promise in guiding clinical decision-making regarding repeat prostate biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H38#H38\">",
"     \"Screening for prostate cancer\", section on 'Repeat biopsies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2921348\">",
"    <span class=\"h3\">",
"     Sampling considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performing a repeat biopsy, an extended core sampling technique should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/94,95,108,113,114\">",
"     94,95,108,113,114",
"    </a>",
"    ]. The lateral peripheral zone should be thoroughly sampled preferentially over the anterior aspect or transition zone because the anterior regions have a lower yield [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/96,97,115-117\">",
"     96,97,115-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Saturation biopsy is not appropriate for initial screening but may be performed after a second negative TRUS-biopsy in the patient for whom clinical suspicion for prostate cancer remains high. Saturation biopsy detects prostate cancer in 22 to 33 percent of patients undergoing repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], but is associated with a higher incidence of complications (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Saturation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate biopsy is generally uncomplicated and well-tolerated. With the administration of proper antibiotic prophylaxis, the rate of serious infectious complications (eg, urosepsis, prostatitis) is low [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a study of the Surveillance, Epidemiology and End Results (SEER) database, the rate of hospitalization within 30 days of undergoing a prostate biopsy was 6.9 percent compared with 2.7 in a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/50\">",
"     50",
"    </a>",
"    ]. The need for hospitalization was primarily due to infectious complications. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor urinary or rectal bleeding is to be expected after prostate biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/118\">",
"     118",
"    </a>",
"    ]. Bleeding is generally self-limited and requires no intervention. Blood streaks on the ultrasound probe are noted in 17 to 27 percent of patients undergoing the procedure. In a retrospective review of 5802 transurethral ultrasound-guided sextant biopsies, hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematospermia occurred in about 50 percent of patients and lasted more than three days in 23 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/119\">",
"     119",
"    </a>",
"    ]. The risk of rectal bleeding increases with an increasing numbers of sample cores [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/85,120\">",
"     85,120",
"    </a>",
"    ], but severe rectal bleeding requiring intervention occurs in less than 1 percent of procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Management of rectal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hemodynamically stable patient who is experiencing brisk rectal bleeding, manual digital compression of the prostate is the first line strategy; rectal packing with gauze can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/122\">",
"     122",
"    </a>",
"    ]. As direct pressure is being applied, the patient's vital signs are monitored and coagulation parameters checked and corrected, as needed. In the event that bleeding continues or the patient becomes hemodynamically unstable, consultation for endoscopic (eg, epinephrine injection, Endoclip&trade;) or surgical (ie, ligation) intervention should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial of 275 patients evaluated the efficacy of placement of a rectal Foley catheter inflated to 50 mL in an attempt to prevent rectal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/124\">",
"     124",
"    </a>",
"    ]. Placement of the catheter was associated with a significantly reduced incidence of any amount of rectal bleeding compared to controls (1.5 versus 17.7 percent). We do not advocate the routine use of this technique for prevention, since it may cause undue discomfort for a marginal benefit. However, it may be useful for temporary control of significant rectal bleeding while awaiting consultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection is the most common infectious complication of prostate biopsy, occurring in 1 to 11 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/30,52,125\">",
"     30,52,125",
"    </a>",
"    ]. Antibiotic prophylaxis before biopsy decreases the rate of urinary tract infection, but some patients are at risk for serious infectious complications independent of prophylaxis. In an observational study of 2023 patients who received antibiotics prior to prostate biopsy, 3 percent became septic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/126\">",
"     126",
"    </a>",
"    ]. Predictive risk factors for sepsis included presence of an indwelling urethral catheter, diabetes mellitus, or biopsy with more than ten cores.",
"   </p>",
"   <p>",
"    Treatment of urinary infection following prostate biopsy with oral antibiotics (eg, fluoroquinolone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) is generally sufficient, though hospitalization and intravenous antibiotics may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/36,120\">",
"     36,120",
"    </a>",
"    ]. Antibiotic treatment may be altered based upon the clinical response and the results of urine culture and antibiotic sensitivity testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute postbiopsy prostatitis is a relatively uncommon, but potentially life-threatening complication that warrants immediate evaluation and intervention. Issues related to acute prostatitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Urinary obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients may develop a degree of urinary obstruction due to acute postbiopsy prostatic inflammation, assessment of postvoid residual with a bladder scan should be performed for symptomatic patients. Alpha-blocker therapy can be initiated for patients with residual urine volumes of less than 100 mL, while insertion of a small-caliber (12 to 16 Fr) urethral catheter (or suprapubic catheter) is warranted in patients with higher residual volumes. The patient should also be placed on stool softeners to ease mechanical strain on the prostate during bowel movements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240755\">",
"    <span class=\"h2\">",
"     Rare tumor seeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common patient concern is the possibility of spreading cancer cells with prostate. Although isolated cases of tumor seeding the needle tract have been reported, these are rare and more often associated with the transperineal compared with a transrectal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/20/14666/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. The very low risk of tumor seeding should not preclude an indicated biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate biopsy is a safe and effective sampling technique in which tissue is obtained in a minimally-invasive fashion from the prostate gland for the purpose of detecting cancer. Prostate biopsy is performed on patients with abnormal prostate specific antigen levels or abnormal digital rectal examination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transrectal ultrasound (TRUS)-guided prostate biopsy is the preferred approach for most patients. This procedure is usually performed in an office setting with local anesthesia. Other approaches, including transperineal prostate biopsy, are used under special circumstances with ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) guidance. Transurethral resection of the prostate (TURP) may occasionally be used to obtain a tissue specimen. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Anatomic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antibiotic prophylaxis prior to prostate biopsy with a single dose of a fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). With antibiotic prophylaxis, the rate of serious infectious complications (eg, urosepsis) is low. Cleansing enemas are unnecessary provided patients have received appropriate antibiotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Rectal cleansing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For first-time prostate biopsy, we suggest extended-core biopsy rather than sextant biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Extended core biopsy as a means to sample the prostate increases the detection of prostate pathology; however, it remains unclear whether the benefits of increased detection outweigh the risks for over diagnosis and subsequent treatment complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H42#H42\">",
"       \"Screening for prostate cancer\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a small prostate volume, a smaller number of core samples may be appropriate. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sampling methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2924776\">",
"       'Need for repeat biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a histologic diagnosis of atypical small acinar proliferation (ASAP), we suggest repeat biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The need to perform repeat biopsy in patients with other premalignant pathology is individualized. A larger number of core samples should be obtained during repeat biopsy. (See",
"      <a class=\"local\" href=\"#H2924776\">",
"       'Need for repeat biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor urinary or rectal bleeding is common after prostate biopsy, is generally self-limited and only on rare occasion requires some form of intervention. The risk of rectal bleeding increases with an increasing numbers of sample cores. The continued use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in the periprocedural period has not been associated with an increased risk of clinically significant hemorrhage. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Antiplatelet therapy/anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/1\">",
"      Schr&ouml;der FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/2\">",
"      Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310.",
"     </a>",
"    </li>",
"    <li>",
"     Carroll, PR, Albertsen, PC, Greene, K, et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. In: AUA Best Practice Guidelines, 2009. www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf (Accessed on June 18, 2010).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines are available online at www.nccn.org/index.asp (Accessed on June 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/5\">",
"      Boczko J, Messing E, Dogra V. Transrectal sonography in prostate evaluation. Radiol Clin North Am 2006; 44:679.",
"     </a>",
"    </li>",
"    <li>",
"     Ramey J, Halpern E, Gomella L. Ultrasonography and biopsy of the prostate. In: Campbell-Walsh Urology, Wein, A, Kavoussi, K, Novick, A, et al (Eds), Saunders, Philadelphia 2006. p.2889.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/7\">",
"      Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27:4321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/8\">",
"      Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. Urology 2007; 70:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/9\">",
"      Mitterberger M, Pinggera GM, Pallwein L, et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 2007; 100:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/10\">",
"      Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995; 195:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/11\">",
"      Shinohara K, Scardino PT, Carter SS, Wheeler TM. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am 1989; 16:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/12\">",
"      Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 1989; 142:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/13\">",
"      Newton MR, Phillips S, Chang SS, et al. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol 2010; 184:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/14\">",
"      Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/15\">",
"      D'Amico AV, Tempany CM, Cormack R, et al. Transperineal magnetic resonance image guided prostate biopsy. J Urol 2000; 164:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/16\">",
"      Yakar D, Hambrock T, Hoeks C, et al. Magnetic resonance-guided biopsy of the prostate: feasibility, technique, and clinical applications. Top Magn Reson Imaging 2008; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/17\">",
"      Adusumilli S, Pretorius ES. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 2002; 20:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/18\">",
"      Blumenfeld P, Hata N, DiMaio S, et al. Transperineal prostate biopsy under magnetic resonance image guidance: a needle placement accuracy study. J Magn Reson Imaging 2007; 26:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/19\">",
"      Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/20\">",
"      Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/21\">",
"      Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/22\">",
"      Takenaka A, Hara R, Ishimura T, et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis 2008; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/23\">",
"      Andriole GL, Bullock TL, Belani JS, et al. Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach. Urology 2007; 70:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/24\">",
"      Kawakami S, Yamamoto S, Numao N, et al. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol 2007; 14:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/25\">",
"      Moran BJ, Braccioforte MH. Stereotactic transperineal prostate biopsy. Urology 2009; 73:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/26\">",
"      Lin CC, Huang WJ, Wu LJ, et al. Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection. J Chin Med Assoc 2008; 71:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/27\">",
"      Coplen DE, Andriole GL, Yuan JJ, Catalona WJ. The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. J Urol 1991; 146:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/28\">",
"      Galetti TP, Dal Moro F, Milani C, et al. Patient's preparation in order to reduce pain, anxiety, and complications of TRUS prostatic biopsies. Eur Urol 2002; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/29\">",
"      Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982; 127:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/30\">",
"      Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/31\">",
"      Lindstedt S, Lindstr&ouml;m U, Ljunggren E, et al. Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol 2006; 50:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/32\">",
"      Aus G, Ahlgren G, Bergdahl S, Hugosson J. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. Br J Urol 1996; 77:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/33\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2009; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/34\">",
"      Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/35\">",
"      Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011; :CD006576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/36\">",
"      Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000; 164:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/37\">",
"      Ruebush TK 2nd, McConville JH, Calia FM. A double-blind study of trimethoprim-sulfamethoxazole prophylaxis in patients having transrectal needle biopsy of the prostate. J Urol 1979; 122:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/38\">",
"      Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/39\">",
"      Isen K, K&uuml;peli B, Sinik Z, et al. Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. Int Urol Nephrol 1999; 31:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/40\">",
"      Puig J, Darnell A, Berm&uacute;dez P, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol 2006; 16:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/41\">",
"      Yang L, Hu J, Wei H, et al. [Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy]. Zhonghua Wai Ke Za Zhi 2001; 39:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/42\">",
"      Argyropoulos AN, Doumas K, Farmakis A, et al. Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy. Int Urol Nephrol 2007; 39:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/43\">",
"      Sabbagh R, McCormack M, P&eacute;loquin F, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol 2004; 11:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/44\">",
"      Hori S, Sengupta A, Joannides A, et al. Changing antibiotic prophylaxis for transrectal ultrasound-guided prostate biopsies: are we putting our patients at risk? BJU Int 2010; 106:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/45\">",
"      Shigemura K, Tanaka K, Yasuda M, et al. Efficacy of 1-day prophylaxis medication with fluoroquinolone for prostate biopsy. World J Urol 2005; 23:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/46\">",
"      Shandera KC, Thibault GP, Deshon GE Jr. Efficacy of one dose fluoroquinolone before prostate biopsy. Urology 1998; 52:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/47\">",
"      Cormio L, Berardi B, Callea A, et al. Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. BJU Int 2002; 90:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/48\">",
"      Steensels D, Slabbaert K, De Wever L, et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012; 18:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/49\">",
"      Zaytoun OM, Vargo EH, Rajan R, et al. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/50\">",
"      Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/51\">",
"      Hadway P, Barrett LK, Waghorn DJ, et al. Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy. BJU Int 2009; 104:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/52\">",
"      Zaytoun OM, Anil T, Moussa AS, et al. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011; 77:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/53\">",
"      Davis M, Sofer M, Kim SS, Soloway MS. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol 2002; 167:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/54\">",
"      Han KS, Lee KH, Korean Urologic Oncology Society Prostate Cancer Study Group. Factors influencing pain during transrectal ultrasonography-guided prostate biopsy. Prostate Cancer Prostatic Dis 2008; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/55\">",
"      Ihezue CU, Smart J, Dewbury KC, et al. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol 2005; 60:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/56\">",
"      Giannarini G, Mogorovich A, Valent F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007; 70:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/57\">",
"      Maan Z, Cutting CW, Patel U, et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int 2003; 91:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/58\">",
"      Ghani KR, Rockall AG, Nargund VH, Chinegwundoh FI. Prostate biopsy: to stop anticoagulation or not? BJU Int 2006; 97:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/59\">",
"      Mukerji G, Munasinghe I, Raza A. A survey of the peri-operative management of urological patients on clopidogrel. Ann R Coll Surg Engl 2009; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/60\">",
"      Ingber MS, Ibrahim I, Turzewski C, et al. Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study. Int Urol Nephrol 2010; 42:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/61\">",
"      Cantiello F, Imperatore V, Iannuzzo M, et al. Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study. BJU Int 2009; 103:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/62\">",
"      Yurdakul T, Taspinar B, Kilic O, et al. Topical and long-acting local anesthetic for prostate biopsy: a prospective randomized placebo-controlled study. Urol Int 2009; 83:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/63\">",
"      Song SH, Kim JK, Song K, et al. Effectiveness of local anaesthesia techniques in patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective randomized study. Int J Urol 2006; 13:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/64\">",
"      Szlauer R, Gotschl R, Gnad A, et al. Comparison of lidocaine suppositories and periprostatic nerve block during transrectal prostate biopsy. Urol Int 2008; 80:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/65\">",
"      Giannarini G, Autorino R, Valent F, et al. Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. J Urol 2009; 181:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/66\">",
"      Irani J, Fournier F, Bon D, et al. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br J Urol 1997; 79:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/67\">",
"      Matlaga BR, Lovato JF, Hall MC. Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy. Urology 2003; 61:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/68\">",
"      Turgut AT, Ol&ccedil;&uuml;c&uuml;o��lu E, Ko��ar P, et al. Complications and limitations related to periprostatic local anesthesia before TRUS-guided prostate biopsy. J Clin Ultrasound 2008; 36:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/69\">",
"      Kubo Y, Kawakami S, Numao N, et al. Simple and effective local anesthesia for transperineal extended prostate biopsy: application to three-dimensional 26-core biopsy. Int J Urol 2009; 16:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/70\">",
"      Bingqian L, Peihuan L, Yudong W, et al. Intraprostatic local anesthesia with periprostatic nerve block for transrectal ultrasound guided prostate biopsy. J Urol 2009; 182:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/71\">",
"      Ashley RA, Inman BA, Routh JC, et al. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer 2007; 110:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/72\">",
"      Kuppusamy S, Faizal N, Quek KF, et al. The efficacy of periprostatic local anaesthetic infiltration in transrectal ultrasound biopsy of prostate: a prospective randomised control study. World J Urol 2010; 28:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/73\">",
"      Akay AF, Akay H, Aflay U, et al. Prevention of pain and infective complications after transrectal prostate biopsy: a prospective study. Int Urol Nephrol 2006; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/74\">",
"      Skriapas K, Konstantinidis C, Samarinas M, et al. Comparison between lidocaine and glyceryl trinitrate ointment for perianal-intrarectal local anesthesia before transrectal ultrasonography-guided prostate biopsy: a placebo-controlled trial. Urology 2011; 77:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/75\">",
"      Gosselaar C, Roobol MJ, Roemeling S, et al. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int 2008; 101:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/76\">",
"      Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/77\">",
"      Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/78\">",
"      Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997; 158:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/79\">",
"      Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/80\">",
"      Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/81\">",
"      Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/82\">",
"      Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. Urology 2008; 71:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/83\">",
"      Scattoni V, Roscigno M, Raber M, et al. Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores? J Urol 2008; 179:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/84\">",
"      Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/85\">",
"      Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004; 94:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/86\">",
"      Eskicorapci SY, Guliyev F, Akdogan B, et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/87\">",
"      Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/88\">",
"      Sajadi KP, Kim T, Terris MK, et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 2007; 70:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/89\">",
"      Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/90\">",
"      Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/91\">",
"      B&ouml;cking A. [Cytopathology of the prostate]. Pathologe 1998; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/92\">",
"      Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007; 99:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/93\">",
"      Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/94\">",
"      Eskicorapci SY, Guliyev F, Islamoglu E, et al. The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique. Int Urol Nephrol 2007; 39:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/95\">",
"      Campos-Fernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/96\">",
"      Chon CH, Lai FC, McNeal JE, Presti JC Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002; 167:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/97\">",
"      Hong YM, Lai FC, Chon CH, et al. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/98\">",
"      Abouassaly R, Tan N, Moussa A, Jones JS. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol 2008; 180:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/99\">",
"      Ploussard G, Plennevaux G, Allory Y, et al. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol 2009; 27:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/100\">",
"      Amin MM, Jeyaganth S, Fahmy N, et al. Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J 2007; 1:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/101\">",
"      Bostwick DG, Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Pract 1995; 191:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/102\">",
"      H&auml;ggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997; 158:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/103\">",
"      Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004; 28:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/104\">",
"      De Nunzio C, Trucchi A, Miano R, et al. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 2009; 181:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/105\">",
"      Egevad L, Allsbrook WC Jr, Epstein JI. Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum Pathol 2006; 37:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/106\">",
"      Singh PB, Nicholson CM, Ragavan N, et al. Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. BMC Urol 2009; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/107\">",
"      Bostwick DG, Ma J. Over-diagnosis of high-grade prostatic intraepithelial neoplasia: a prospective study of 251 cases. BJU Int 2007; 100:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/108\">",
"      Djavan B, Remzi M, Schulman CC, et al. Repeat prostate biopsy: who, how and when?. a review. Eur Urol 2002; 42:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/109\">",
"      Zlotta AR, Raviv G, Schulman CC. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Eur Urol 1996; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/110\">",
"      Gallo F, Chiono L, Gastaldi E, et al. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies. Urology 2008; 72:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/111\">",
"      Schoenfield L, Jones JS, Zippe CD, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 2007; 99:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/112\">",
"      Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/113\">",
"      Rabbani F, Stroumbakis N, Kava BR, et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/114\">",
"      Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/115\">",
"      Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol 2008; 10:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/116\">",
"      Presti JC Jr. Repeat prostate biopsy--when, where, and how. Urol Oncol 2009; 27:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/117\">",
"      Abd TT, Goodman M, Hall J, et al. Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans. Urology 2011; 77:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/118\">",
"      Halliwell OT, Yadegafar G, Lane C, Dewbury KC. Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008; 63:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/119\">",
"      Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/120\">",
"      Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/121\">",
"      Chiang IN, Chang SJ, Pu YS, et al. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan. J Formos Med Assoc 2007; 106:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/122\">",
"      Braun KP, May M, Helke C, et al. Endoscopic therapy of a massive rectal bleeding after prostate biopsy. Int Urol Nephrol 2007; 39:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/123\">",
"      Katsinelos P, Kountouras J, Dimitriadis G, et al. Endoclipping treatment of life-threatening rectal bleeding after prostate biopsy. World J Gastroenterol 2009; 15:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/124\">",
"      Kilciler M, Erdemir F, Demir E, et al. The effect of rectal Foley catheterization on rectal bleeding rates after transrectal ultrasound-guided prostate biopsy. J Vasc Interv Radiol 2008; 19:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/125\">",
"      Kanjanawongdeengam P, Viseshsindh W, Santanirand P, et al. Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial. J Med Assoc Thai 2009; 92:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/126\">",
"      Simsir A, Kismali E, Mammadov R, et al. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/127\">",
"      Vaghefi H, Magi-Galluzzi C, Klein EA. Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. Urology 2005; 66:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/20/14666/abstract/128\">",
"      Moul JW, Bauer JJ, Srivastava S, et al. Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. Urology 1998; 51:158.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8097 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14666=[""].join("\n");
var outline_f14_20_14666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROSTATE ANATOMY AND IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Zones of the prostate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANATOMIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transrectal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transperineal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1240595\">",
"      Transurethral resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rectal cleansing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antiplatelet therapy/anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TRUS BIOPSY PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sampling methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Six core",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18433713\">",
"      - Extended core",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Saturation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6106424\">",
"      - Limited value of FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Procedure and specimen handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Postprocedure instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATIENT FOLLOW-UP AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2924776\">",
"      Need for repeat biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2921326\">",
"      - Abnormal histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89085844\">",
"      Atypical small acinar proliferation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89085851\">",
"      Prostatic intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2921333\">",
"      - Rising PSA after biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2921348\">",
"      - Sampling considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Management of rectal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Urinary obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1240755\">",
"      Rare tumor seeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8097\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8097|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/45/13008\" title=\"diagnostic image 1\">",
"      Normal prostate on ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8097|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20023\" title=\"figure 1\">",
"      Prostate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/9/30866\" title=\"figure 2\">",
"      Zones of the prostate gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/11/44208\" title=\"figure 3\">",
"      Rectal ultrasound transducer with needle guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8097|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/26/21921\" title=\"picture 1\">",
"      Ultrasound guided biopsy machine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=related_link\">",
"      Acute bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=related_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26937?source=related_link\">",
"      Precancerous lesions of the prostate: Pathology and clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_20_14667="Long term outcomes in infantile spasms";
var content_f14_20_14667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key Key outcome parameters in West syndrome/Infantile spasms (irrespective of cause)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Suppression of spasms (in response to treatment)",
"       </td>",
"       <td>",
"        50 to 90 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Development of other seizure types",
"       </td>",
"       <td>",
"        50 to 70 percent (intractable in 40 to 50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evolution into the Lennox-Gastaut syndrome",
"       </td>",
"       <td>",
"        20 to 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Learning difficulties (usually moderate or severe)",
"       </td>",
"       <td>",
"        70 to 90 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric (including autistic) dysfunction",
"       </td>",
"       <td>",
"        20 to 40 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality",
"       </td>",
"       <td>",
"        5 to 30 percent (of which 50 percent are disease, and 50 percent treatment-related)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Appleton, RE. West syndrome: long-term prognosis and social aspects. Brian and Development 2001; 23:688. Copyright &copy; 2001 Elsevier Science",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14667=[""].join("\n");
var outline_f14_20_14667=null;
var title_f14_20_14668="Somatization";
var content_f14_20_14668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Somatization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A. Somatoform disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        1. Somatoform disorders common to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) and World Health Organization's International Classification of Diseases-10th Revision (ICD-10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Somatization disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Undifferentiated somatoform disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Pain disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        d. Hypochondriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        e. Somatoform disorder not otherwise specified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        2. Somatoform disorders unique to DSM-IV-TR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Conversion disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Body dysmorphic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        3. Somatoform disorders unique to ICD-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Somatoform autonomic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Other somatoform disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        B. Other specific types of somatization common to DSM-IV-TR and ICD-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        1. Factitious disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        2. Malingering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional categories have been proposed that are not recognized by DSM-IV-TR or ICD-10, to address dissatisfaction with existing diagnoses. These categories are:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        1. Abridged somatization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        2. Multisomatoform disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.",
"      <br>",
"       2. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. file://www.who.int/classifications/apps/icd/icd10online/ (Accessed on November 22, 2009).",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14668=[""].join("\n");
var outline_f14_20_14668=null;
var title_f14_20_14669="Use of SCOOP system III";
var content_f14_20_14669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient management tips for the SCOOP transtracheal oxygen system - III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management Strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"13\">",
"        III",
"       </td>",
"       <td>",
"        Assure patient compliance",
"       </td>",
"       <td>",
"        Spend sufficient time teaching to prevent later problems. Teach the patient to wear a nasal cannula when cleaning the catheter. Demonstrate correct technique for cleaning with normal saline instillation and use of the cleaning rod. Watch a return demonstration. Provide written teaching materials and phone access to health care providers for problem solving, concerns.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teach signs and symptoms of mucus ball formation",
"       </td>",
"       <td>",
"        Teach the patient to promptly report signs and symptoms that suggest formation of mucus balls: (1) whistling or \"pop-off\" of the humidifier from back pressure; (2) persistent, severe cough or change in cough; (3) unexplained dyspnea, wheezing or hoarseness; (4) hemoptysis; and (5) perception that the catheter is \"fixed in place\" in the tract.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Teach cough techniques which assist in preventing mucus ball formation",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Use cough techniques to maximize airflow during expiration, increase force of the \"glottic blast\" and help loosen mucus from the catheter:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sit in chair, feet on floor, pillow against abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Take 3 to 4 slow deep breaths in through mouth, out nose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inhale deeply&nbsp;and cough forcefully while exhaling and bending forward with pillow pressed against abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Titrate care and followup based on risk of mucus ball formation",
"       </td>",
"       <td>",
"        Monitor progress with phone calls. Periodic phone calls allow closer patient monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         LOW RISK:",
"        </strong>",
"        (TTO flow &lt;1 L/min, no secretion problem, good cough.) Call third day and as needed. After TTO hookup, advise&nbsp;twice daily&nbsp;cleaning. Use a humidifier on the stationary oxygen source. Schedule return visit&nbsp;one week after hookup. Strip catheter and adjust future visits and cleaning protocol based on clinical course.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         MODERATE RISK:",
"        </strong>",
"        (TTO flow 2 to 4 L/min, some mucus, good cough.) Call third day and as needed. After TTO hookup, advise cleaning two to three times daily. Use a humidifier on the stationary oxygen source. Schedule return visits&nbsp;one and&nbsp;two weeks after hookup. Strip catheter at this visit and adjust future visits and cleaning protocol based on clinical course.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         HIGH RISK:",
"        </strong>",
"        (TTO flow &gt;5 L/min, large amounts of secretions, poor cough.) Call third day and as needed. After TTO hookup, advise cleaning four times daily. Use a servo-controlled heated humidifier to provide 100 percent humidity. Schedule return visits&nbsp;three days and&nbsp;one week after hookup in the office or via a home care nurse. Strip catheter and adjust future visits and cleaning protocol based on clinical course.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prevent catheter displacement",
"       </td>",
"       <td>",
"        Place a small strip of OpSite",
"        <sup>",
"         &reg;",
"        </sup>",
"        or other clear tape over the chain on each side of the flange for the first&nbsp;two weeks of catheter use. Teach the patient to keep the oxygen delivery tubing under upper body clothing at all times. At night, place the tubing under a t-shirt or cloth belt. This helps to prevent accidental displacement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reinsert displaced catherter into the tract",
"       </td>",
"       <td>",
"        Instruct the patient to keep a tube of water-soluble lubricant available. If displacement occurs, the patient may be able to clean and replace the catheter If unsuccessful after two attempts, instruct the patient to call the clinic and return for assistance. The longer the catheter is out of the tract, the more difficult it will be to replace.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintain O",
"        <sub>",
"         2",
"        </sub>",
"        delivery if problems develop",
"       </td>",
"       <td>",
"        Teach the patient to keep a carrying kit for supplies (nasal cannula, normal saline, mirror, etc) available at all times. The patient can use the nasal cannula if there is any doubt about correct function. Instruct the patient to call if the problem cannot be resolved.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hoffman LA, Wesmiller SW. Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14669=[""].join("\n");
var outline_f14_20_14669=null;
var title_f14_20_14670="Acute seasonal conjunctivitis";
var content_f14_20_14670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute seasonal conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 201px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute seasonal conjunctivitis classically presents with eyelid and conjunctival erythema and swelling. It is almost always bilateral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14670=[""].join("\n");
var outline_f14_20_14670=null;
var title_f14_20_14671="Cancer incidence in males in more and less developed countries";
var content_f14_20_14671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Cancer incidence in males in more and less developed countries*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Comparison of the most common cancers in more and less developed countries in 2000.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stewart B, Kleihues P. World Cancer Report, IARC Press, Lyon 2003.&nbsp;Copyright &copy; 2003 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_20_14671=[""].join("\n");
var outline_f14_20_14671=null;
